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While there has been an opulence of data and studies surrounding the study of 
the developing pancreas in mammals and other vertebrates, the focus has largely 
been in mice. The paucity of research in the development of the human pancreas has 
led to diminished knowledge in the area, compared to other species. Recent 
discoveries provide growing evidence for discrepancies between mouse and human 
pancreatic development and diseases and highlight the fact that developmental 
studies of the pancreas in humans are imperative. The need to develop therapies for 
diabetes, a growing and one of the leading health problems worldwide, further 
compels more exploration in this area to deepen our understanding in the different 
aspects of diabetes in humans and its underlying causes. 
 
Research involving modelling human diseases in vitro enables the investigation 
of the cellular and molecular mechanisms underlying these diseases as well as the 
development of therapies for treating them. The availability of hPSCs brings with it the 
advantage of overcoming the limitations of animal models for certain disorders such as 
pancreatic agenesis, the focus of my project. The use of site-specific nucleases such as 
TALENs for such a purpose represents a paradigm shift in disease modelling, where 
TALENs are capable of directly correcting disease-causing mutations, therefore 
permanently eliminating the symptoms with precise genome modifications. 
Alternatively, TALENs can also be used to inactivate specific genes by inducing site-
specific mutations.  
 
Using these tools, I found that GATA6 is required for the formation of the 
definitive endoderm and pancreas in humans; hPSCs harbouring homozygous GATA6 
mutations fail to form the definitive endoderm, and consequently the pancreas, 
whereas hPSCs harbouring heterozygous GATA6 mutations exhibited impairment in 
definitive endoderm development, although it remains unclear if this is a protocol-
dependent defect. At the pancreatic stage, heterozygous GATA6 mutations 
consistently compromised pancreas formation regardless of protocol used. I also 
found that GATA6 transcriptionally activates the development of the definitive 
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endoderm and pancreatic endoderm, and possibly represses the development of 
mesoderm. Furthermore, I also established that GATA6 directly interacts with key 
definitive endoderm markers CXCR4 and SOX17, and pancreatic marker PDX1.  
 
Taken together, the work herein demonstrates the successful use of hPSCs 
coupled with the TALEN genome editing technology as a unique in vitro system for 
disease modelling. These findings also establish two developmental windows, the DE 
and pancreatic progenitor stages, where GATA6 haploinsufficiency can result in the 
impairment of pancreatic development leading to pancreatic hypoplasia observed in 
human GATA6 heterozygous patients. Lastly, my work also provides the molecular 
mechanism by which GATA6 regulates pancreatic development. 
 
Overall, this study provided new insights in the role of GATA6 during 
development of the human pancreas. These results will be important in developing 
new methods of differentiation for hPSCs and understanding the interconnection 
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CHAPTER 1  INTRODUCTION 
 
1.1. Overview of the pancreas 
The pancreas is a glandular organ originating from two separate primordia, 
the dorsal and ventral buds that arise from either side of the distal foregut 
endoderm. The organ is made up of a variety of distinct cell types and has a mix of 
both exocrine and endocrine functions.  
 
The exocrine gland serves as a digestive organ with its acinar cells performing 
gastrointestinal functions by secreting digestive enzymes and a duct system that 
allows these digestive enzymes to drain into the intestine.  
 
The endocrine gland is arranged as cell clusters known as islets of Langerhans 
which functions in regulating blood glucose homeostasis and other hormone 
secretions. Each cluster comprises of multiple distinct cell types, each secreting 
unique hormones into the body’s circulation (α-cells, glucagon to increase blood 
glucose; β-cells, insulin to decrease blood glucose; δ-cells, somatostatin which 
regulates α-cells and β-cells; ε-cells, ghrelin which stimulates hunger and functions 
as a neuropeptide in the central nervous system; and γ or pancreatic polypeptide 
(Rashid et al.)-cells, pancreatic polypeptide which regulates pancreatic secretions, 
hepatic glycogen levels and gastrointestinal secretions). (Figure 1, adapted from 
(Shih et al., 2013)). 
 
 






Figure 1. The pancreas as a mixed exocrine and endocrine organ. The mature 
pancreas lies behind the stomach and is adjacent to the duodenum. Acinar cells form 
the exocrine pancreas. The endocrine pancreas consists of small cell clusters, called 
islets of Langerhans, containing five endocrine cell types. Adapted from (Shih et al., 
2013). 
  




1.1.1. Development of the human pancreas 
Human embryogenesis spans from fertilisation to approximately 8 weeks 
post-conception. After which, the embryo is referred to as a foetus. During the 
development of the embryo, specification of the three germ layers: ectoderm, 
mesoderm and endoderm occur, from which all adult tissues are formed. A recent 
publication by O’Rahilly and Müller has proposed a staging classification covering 
embryonic development (O'Rahilly and Müller, 2010). Based on a morphological 
scheme and staged by extension of time i.e. days post-conception (dpc), human 
embryonic development was divided into 23 different Carnegie Stages (CS). The key 
developmental stages of the pancreas during human embryogenesis, along with the 
approximate equivalent stage of mouse development, are mapped onto the 23 





Table 1. Stages of human pancreas development and their respective Carnegie 
Stages (CS). CS stages are shown together with their estimates of corresponding 
days post-conception (dpc). Key events in human embryonic pancreas development 
along with the approximate equivalent stage of mouse development are mapped to 





















Pancreas organogenesis is a highly complex and orchestrated process, 
comprising of coordinated signalling events that occur in a step-wise manner, as well 
as transcriptional networks that result in a cascade of transcription factors driving 
pancreatic specification (Figure 2 adapted from (Jennings et al., 2015)).  
 
Pancreas induction occurs at CS9, where the definitive endoderm (DE) 
maintains communication with the visceral endoderm of the yolk sac (Jennings et al., 
2013), and ventral and dorsal thickenings of the epithelial cells in the distal foregut 
occurs (Piper et al., 2002, Piper et al., 2004).  
 
At CS10, endodermal folding gives rise to the foregut and hindgut, thus 
restricting the opening of the yolk sac to the intervening midgut (Jennings et al., 
2013). The anterior end of this opening, known as the anterior intestinal portal (AIP), 
constitutes the foregut-midgut boundary and is the site of pancreatic specification. 
In other species, early specification of the pancreas within the gut endoderm occurs 
in the absence of sonic hedgehog (Shh) signalling (Apelqvist et al., 1997, Kim and 
Melton, 1998, Hebrok et al., 2000). In chick embryos, Activin secreted from the 
notochord and the close proximity of the resulting dorsal foregut endoderm to it 
causes exclusion of Shh expression, allowing for the expression of key transcription 
factor pancreatic and duodenal homeobox factor 1 (Pdx1) (Kim and Melton, 1998, 
Hebrok et al., 1998). In humans, patterning was similarly observed where PDX1 was 
first detected at CS12, even though SHH could still be detected at CS10, which 
suggests a slightly later timing for the exclusion of SHH in humans (Jennings et al., 
2013). The dorsal foregut endoderm subsequently develops into the dorsal 
pancreatic bud. One difference worth noting that was observed between human 
embryos and mouse or chick embryos is that in humans, there has been no detection 
of early pancreatic endocrine differentiation (Villasenor et al., 2008, Jennings et al., 
2013), whereas early pro-endocrine patterning has been observed in mouse and 
chick (Lammert et al., 2001, Bonal and Herrera, 2008). This observation could 
possibly be explained by the lack of proximity of the paired dorsal aortae to the early 
pancreatic endoderm, thus reducing the opportunity for early pro-endocrine 
patterning.  






Figure 2. Developmental stages of human pancreas development and its respective 
transcription factor network. Illustration of transcription factors and key markers 
that identify the various key stages of early pancreas specification in the dorsal 
pancreas and commitment to subsequent lineages.  
 
At CS13, the dorsal and ventral pancreatic buds are clearly defined and are 
marked by the transcription factors SRY (sex-determining region Y)-box 9 (SOX9), 
PDX1, GATA binding protein 4 (GATA4) and GATA6 (Piper et al., 2004, Jennings et al., 
2013), all of which play a pivotal role in promoting human pancreatic growth 
(Stoffers et al., 1997, Piper et al., 2002, Allen et al., 2012, Shaw-Smith et al., 2014). 
The human pancreas continues its expansion of proliferative progenitor cells for the 
remainder of the embryonic period. Another notable difference between the human 
and mouse pancreatic development is that transcription factor Nirenberg and Kim 
homeobox factor (NKX) 2.2 (Nkx2-2) is detected in these progenitor cells of the 
mouse but not human (Jennings et al., 2013). 




At CS19, divergence into “tip” or “trunk” progenitor cells is marked by the 
expression levels of GATA4 (Jennings et al., 2013). “Trunk” cells, which commit to 
central duct-like structures, express lower levels of GATA4 as compared to the more 
peripheral clustered pro-acinar “tip” cells, even though both progenitor cell types 
express several common pancreatic markers such as PDX1, SOX9 and NKX6-1 (Figure 
2). A similar separation of acinar cells was also observed in the mouse (Esni et al., 
2004, Solar et al., 2009, Schaffer et al., 2010), although Sox9 is lost more promptly in 
these peripheral tip cells in mouse (Schaffer et al., 2010) than in humans, where the 
loss of SOX9 is delayed to between 10 and 14 weeks post-conception (wpc) (Jennings 
et al., 2013). 
 
The commencement of endocrine specification is marked by the transient 
expression of transcription factor neurogenin 3 (NGN3) (Figure 2). In the mouse, 
Ngn3 is transiently expressed to enable progenitor cells within the central duct-like 
structures to commit into the endocrine lineage (Gradwohl et al., 2000, Schwitzgebel 
et al., 2000, Gu et al., 2002). In humans, NGN3 expression is detected at CS21 (8 
wpc) around the end of the first trimester of human pregnancy upon the formation 
of foetal β-cells, which function as true endocrine cells by this time (Piper et al., 
2004, Lyttle et al., 2008). The peak expression level of NGN3 occurs at 10 to 14 wpc 
and declines at and after 18 wpc, and diminishes in human foetuses after 35 wpc 
(Salisbury et al., 2014). By contrast, SOX9 is absent in cells robustly expressing NGN3 
and continues to be absent in subsequent endocrine cells, but is present in 
pancreatic duct cells (Jennings et al., 2013). By 10 wpc, β-cells are well vascularised 
and at 12-13 wpc, islets containing α-cells, β-cells, δ-cells and γ-cells are apparent 
(Piper et al., 2004, Jennings et al., 2013). 
 
  




1.1.2. Diabetes Mellitus as a pancreatic disease 
Diabetes Mellitus (‘diabetes’) represents a family of metabolic disease caused 
primarily by dysfunction in the pancreas. Diabetes is a growing health problem 
worldwide. The global prevalence of diabetes has nearly doubled since 1980, rising 
from 4.7% to 8.5% in the adult population and causing 1.5 million deaths in 2012 
(World Health Organisation, 2016). It is estimated that 366 million people were 
diagnosed with diabetes in 2011; by 2030 this would have risen to 552 million 
(International Diabetes Federation, 2011). The need to understand human pancreas 
development is, therefore, critical because of its relevance to the different types of 
diabetes and therapies for this disease. There are multiple forms of diabetes, such as 
polygenic forms Type 1 diabetes (T1D), Type 2 diabetes (T2D), and monogenic forms 
maturity onset diabetes of the young (MODY), and neonatal diabetes mellitus 
(NDM). Polygenic forms of diabetes i.e. T1D and T2D make up an overwhelming 
majority (98%) of diabetic cases and its risk is related to multiple genes. Rare, 
monogenic forms of diabetes such as MODY and NDM result from mutations in a 
single gene and account for about 1 to 5% of all cases of diabetes in young people. 
Gene mutations in monogenic diabetes can either be inherited or spontaneous (de 
novo). 
 
T1D, or juvenile-onset diabetes, accounts for approximately 5-10% of diabetic 
patients and is caused by the chronic autoimmune destruction of insulin-secreting β-
cells, usually leading to complete insulin deficiency or hyperglycaemia (Anderson and 
Bluestone, 2005). Hyperglycaemia occurs when blood glucose levels are high, and 
this can lead to serious health conditions such as ketoacidosis, kidney failure, heart 
disease, stroke, and blindness. Despite being able to affect children and adult with 
normal weight, the childhood onset is most prevalent. Although the main effector 
mechanism of T1D is clearly an autoimmune reaction, T1D is also suggested to result 
from genetic susceptibility and/or environmental triggers (reviewed in (Atkinson and 
Eisenbarth, 2001, Van Belle et al., 2011)). T1D can be fatal if not treated with 
exogenous insulin to compensate for the lack of insulin production by the body.  
 




T2D, or adult-onset diabetes, on the other hand, accounts for approximately 
90% of diabetic patients and is usually associated with obesity or older age. T2D is 
characterised by insulin resistance, where insulin-sensitive target tissues such as the 
pancreatic β-cells, liver, muscle or adipose cells do not respond adequately to 
normal levels of insulin produced by intact β-cells. Consequently, this leads to 
disruption of the pancreatic β-cell function and decreased β-cell mass. Although T2D 
is most prevalent in adults, there has been increasing evidence of this form of 
diabetes affecting younger individuals (Fajans et al., 2001). T2D is a polygenic disease 
influenced by many environmental and behavioural risk factors. Thus, it has not only 
been challenging to identify the underlying genetic causes for this disease, but also 
to devise universal therapeutic strategies. No cure has yet been found for the 
disease. Several forms of treatment that currently exist, especially for obese 
patients; include lifestyle modifications, treatment of obesity, oral hypoglycaemic 
drugs, and insulin sensitizers such as metformin that reduces insulin resistance. 
 
MODY was first recognised by Tattersall (Tattersall, 1974, Tattersall and Fajans, 
1975) and is characterised by autosomal dominant inheritance, onset typically 
before 25 years of age and β-cell dysfunction leading to hyperglycaemia. The 
prevalence of MODY is higher than NDM, accounting for about 1% of people with 
diabetes in Europe (Frayling et al., 2001, Ledermann, 1995). Many MODY genes are 
pancreatic development transcription factors with the exception of glucokinase 
(GCK), acinar cell carboxyl ester lipase (CEL) and insulin (INS). Common MODY genes 
include MODY1 (Hepatic Nuclear Factor 4 Alpha; HNF4A-MODY), MODY2 (GCK-
MODY), MODY3 (Hepatic Nuclear Factor 1 Alpha; HNF1A-MODY) which account for 
70% of MODY cases, and MODY5 (Hepatic Nuclear Factor 1 Beta; HNF1B-MODY). 
 
NDM is a rare, genetically heterogeneous monogenic form of diabetes 
occurring in approximately 1 in 200,000 live births (Stanik et al., 2007, Kanakatti 
Shankar et al., 2013). It presents in the days and weeks after birth, and almost always 
before 6 months of age (Iafusco et al., 2002, Edghill et al., 2006). NDM may be 
transient or permanent. In transient NDM (TNDM), the condition remits during 
infancy but may reappear later in life whereas in permanent NDM (PNDM), 




hyperglycaemia persists during life. Approximately 50% of NDM patients have 
heterozygous activating mutations in the potassium inwardly-rectifying channel, 
subfamily J, member 11 (KCNJ11) and ATP-binding cassette, sub-family C, member 8 
(ABCC8) genes encoding the adenosine triphosphate-sensitive potassium channel 
subunits (De Franco et al., 2015). Failure of the potassium channels to close 
appropriately in response to rising glucose, thus inhibiting the release of insulin from 
β-cells, leads to diabetes. Sulfonylurea therapy permits insulin secretion through 
closure of the channel (Pearson et al., 2006, Rafiq et al., 2008). 
Other rare gene mutations leading to monogenic NDM include eukaryotic 
translation initiation factor 2 alpha kinase 3 (EIF2AK3), forkhead box P3 (FOXP3), 
GATA6, GLIS family zinc finger 3 (GLIS3), neuronal differentiation 1 (NEUROD1), 
NGN3, PDX1, pancreas specific transcription factor 1a (PTF1A), regulatory factor X6 
(RFX6) and methylation defects at chromosome 6q24. 
  
Studies of rare monogenic diseases provide an invaluable opportunity to 
learn about underlying molecular mechanisms, thereby contributing significantly to 
our understanding of the molecular genetic basis of common, complex diseases 
(Antonarakis and Beckmann, 2006). 




1.1.3. Pancreatic agenesis 
Congenital pancreatic agenesis is an extremely rare cause of NDM with a 
prevalence of less than 1/1 000 000 and around 50 cases being reported in the 
literature so far. It is caused by an impaired formation of the pancreas during 
embryonic development. Morphologically, the pancreas can either be totally absent 
or extremely reduced in size (pancreatic hypoplasia).  
 
Clinically, pancreatic agenesis is defined as insulin dependent neonatal 
diabetes diagnosed before 6 months of age and pancreatic exocrine insufficiency 
requiring enzyme replacement therapy. Patients affected by pancreatic agenesis 
usually present with intrauterine growth retardation (IUGR) as a result of reduced 
insulin secretion in utero and are diagnosed with hyperglycaemia in the first days of 
life. Patients with pancreatic agenesis usually require insulin treatment.  
 
Diagnosis of pancreatic agenesis can be made by imaging (MRI or ultrasound) 
showing reduction or absence of pancreatic tissue, measurement of fecal elastase 
which is often undetectable in patients with pancreatic agenesis as a result of 
exocrine dysfunction, or clinically by the presence of insulin-dependent neonatal 
diabetes and exocrine insufficiency requiring enzyme replacement therapy. 
 
A genetic diagnosis is also possible for over 80% of patients with pancreatic 
agenesis and transcription factor GATA6 has recently been identified to be a major 
cause of pancreatic agenesis (Lango Allen et al., 2012). In these patients, pancreatic 
agenesis is commonly associated with other extrapancreatic malformations such as 
cardiac malformation, neurocognitive defects, hypothyroidism, gut abnormalities 
and gallbladder agenesis/biliary atresia (De Franco et al., 2013). These defects affect 
organs of endodermal origin, suggesting a defect in early embryonic differentiation.  
 
  




1.2. Human pluripotent stem cells as an in vitro system to model the 
development of the human pancreas 
Stem cells are cells with unique properties such as the capacity to self-renew 
indefinitely and the ability to differentiate into many diverse cell types. Being 
pluripotent, these cells are able to differentiate into all derivatives of the three 
primary germ layers, namely endoderm, mesoderm and ectoderm (Evans and 
Kaufman, 1981). This is in contrast to adult stem cells which are multipotent and 
more restrictive in their differentiation to various cell types (Suda et al., 1987, Zwaka 
and Thomson, 2005). With advances in pluripotent stem cell (PSC) technology, a 
large number of stem cells can now be expanded and maintained in vitro whilst 
retaining their unique properties (Suda et al., 1987, Solter, 2006). This allows for 
studies that were once difficult using primary tissues or biopsies to progress. In the 
clinical setting, human PSCs (hPSCs) bring vast potential in providing opportunities 
for treating and curing diseases.  
 
hPSCs can be broadly categorised into two categories; embryonic stem cells 
(ESCs) and induced pluripotent stem cells (iPSCs). ESCs were first derived from the 
inner cell mass (ICM) of the mouse embryo at the early post-implantation blastocyst 
stage by Evans and Kaufman, and Martin in 1981 (Evans and Kaufman, 1981, Martin, 
1981). The ICM in the blastocyst is a transient pluripotent pool of cells that rapidly 
differentiates during gastrulation into the primary germ layers. They can be 
maintained indefinitely in vitro in their pluripotent state in the presence of cytokine 
leukaemia inhibitory factor (LIF) on a layer of mitotically inactivated mouse 
embryonic fibroblasts (MEF) feeder cells (Smith et al., 1988, Williams et al., 1988).  
  




There was a significant lag before the first human ESC (hESC) line was 
successfully isolated from human blastocysts in 1998 (Thomson et al., 1998). This 
was largely due to the fact that human embryos were much more difficult to obtain 
than mouse embryos and the ethical dilemmas that accompanied it. Prior to this, the 
first primate ESC line from the blastocyst of a rhesus monkey was also isolated and 
successfully derived (Thomson et al., 1995). The derivation of hESCs paved the way 
to an accelerated expansion on stem cell research. 
 
Approximately a decade later, pioneering studies describing human iPSCs 
(hiPSCs) emerged (Takahashi and Yamanaka, 2006, Takahashi et al., 2007, Gurdon 
and Melton, 2008). These studies showed that by introducing a cocktail of four 
specific transcription factors (SOX2, KLF4, c-MYC and OCT4) ex-vivo, differentiated 
fibroblasts could be converted to a pluripotent state resembling ESCs derived from 
the blastocyst ICM. Like ESCs, iPSCs also had the ability to form teratomas in mice 
(Wernig et al., 2007). iPSC technology has the advantage over ESCs in that it was able 
to circumvent the ethical issues associated with human embryos. Furthermore, since 
iPSCs can be derived from patients’ cells, it brings with it the potential application of 
excluding immunosuppression treatments that are required in conventional cell 
replacement or transplantation therapies to prevent tissue rejection when cells are 
transferred between genetically different individuals. iPSC is therefore a robust and 
ethical way of re-programming differentiated cells to a pluripotent state. Similarly to 
ESCs, the iPSCs can then be directed, by growth factors important and specific for 
development and differentiation, to form functional differentiated cells of a variety 
of lineages. It has been suggested that hiPSCs and hESCs are functionally equivalent 
since they both utilise similar signalling pathways to maintain pluripotency and drive 
differentiation, and the mechanisms controlling the early cell fate decision of these 
pluripotent stem cells are similar (Vallier et al., 2009a). 
  




Since their discovery, both hESCs and hiPSCs have proven to be powerful 
tools in biomedical research, overcoming ethical limitations in human embryonic 
development studies where access to human embryos is scarce. hPSCs have the 
potential to be used in disease models for studying the molecular basis of diseases, 
including genetically inherited human diseases (Yusa et al., 2011). It brings 
tremendous potential not only in disease modelling, but also in regenerative 
medicine, cell replacement therapy, drug testing and targeted gene-repair strategies, 
such as homologous recombination to repair genetic defects (Figure 3). Thus, they 
serve as ideal model systems for human developmental scientific studies. This 
dissertation focuses on using hPSCs to model the development of the human 




Figure 3. Applications of hiPSCs. hiPSCs have the potential to be used to model and 
treat human disease, in this case, via drug testing or targeted gene-repair strategies. 
Patient-specific hiPSCs are derived from co-transfection of pluripotency-inducing 
transcription factors in cells isolated from a skin biopsy. The hiPSCs are differentiated 
in vitro into the affected cell type where they could be used in a drug screen to test 
for suitable drugs for treatment of the disease. Alternatively, the disease-causing 
mutation is corrected and repaired hiPSCs are differentiated in vitro into healthy 
cells of the affected cell type, and the genetically matched cells are subsequently 
transplanted into the patient. Adapted from (Robinton and Daley, 2012). 




1.2.1 Pancreatic specification protocols to date 
Pancreatic differentiation was first published by Soria et al. in a landmark 
study reporting the successful differentiation of ESCs into insulin-producing cells 
(Soria et al., 2000). In this study, mouse ESCs constructed to contain a neomycin 
resistance gene under the control of the human insulin promoter were able to 
correct hyperglycaemia a week upon implantation into streptozotocin-induced 
diabetic mice. A subsequent study described the specification of mouse ESCs into the 
definitive endoderm (DE) in the presence of activin A and absence of fetal bovine 
serum, establishing the first stepping stone for directed differentiation to many 
organ systems (Kubo et al., 2004), namely the digestive and respiratory tracts, 
thyroid, liver, and pancreas. The high levels of activin A mimics the action of Nodal, a 
ligand for transforming growth factor-β (TGF-β) superfamily, which activates 
downstream signalling pathways and transcriptional networks that regulates the 
formation of the DE (Lowe et al., 2001, Champeris Tsaniras and Jones, 2010). Later, 
hESCs were also efficiently differentiated into DE using elevated concentration of 
activin A (D'Amour et al., 2005). 
 
Shortly after, a comprehensive stepwise pancreatic specification protocol 
was introduced, describing the differentiation of hESCs to endocrine cells capable of 
synthesising pancreatic hormones such as insulin, glucagon, somatostatin, pancreatic 
polypeptide and ghrelin with the use of specific growth factors and chemical 
compounds (D'Amour et al., 2006). With this in vitro differentiation protocol, the 
cells mimic in vivo pancreas organogenesis by being directed through stages 
resembling DE, gut-tube endoderm, pancreatic endoderm and endocrine precursor, 
thus recapitulating the major stages of normal pancreatic endocrine development. 
Each stage is recognised by the expression of specific markers. One striking 
difference between in vitro differentiation protocols and in vivo pancreas 
organogenesis is the duration, which are 2-3 weeks and 12-13 weeks respectively.  
The cells produced from this protocol have an insulin content almost mimicking that 
of adult islets, and released C-peptide in response to various secretagogues, but only 
minimally to glucose. The presence of immature polyhormonal cells e.g. insulin and 




glucagon, or insulin and somatostatin double-positive cells, however, suggested a 
lack of precision in the endocrine specification, as mature β-cells solely secrete 
insulin. 
 
The publication of an improved serum-free protocol by Jiang et al. which 
involved activin A, retinoic acid (RA), basic fibroblast growth factor (bFGF) and 
nicotinamide to promote pancreatic differentiation resulted in islet-like structures 
with distinct insulin-, glucagon-, and somatostatin-positive mono-hormonal cells 
(Jiang et al., 2007b). The protocol, composed of four stages (definitive endoderm 
induction, pancreatic endoderm formation, endocrine induction, islet-like cluster 
maturation) generated about 24% PDX1-positive cells and 4% C-peptide-positive 
cells. These cells were insulin-producing and responsive to fluctuations in glucose 
levels in a suspension cell culture system but showed low levels of response when 
cultured in adherence.  
 
These studies were succeeded by numerous modified variations of pancreatic 
differentiation protocols (Jiang et al., 2007a, Kroon et al., 2008, Zhang et al., 2009, 
Cai et al., 2010, Nostro et al., 2011, Loh et al., 2014, Pagliuca et al., 2014, Rezania et 
al., 2014, Russ et al., 2015, Cho et al., 2012). With the introduction of such a wide 
variety of different protocols coupled with the ability to generate hPSC lines from 
healthy individuals or patients with different genetic backgrounds, it is not 
unexpected that reports on variations in differentiation efficiencies due to the use of 
different protocols cell lines have arisen (Osafune et al., 2008, Chin et al., 2009). A 
recent study that closely compared protocol variations at both the DE (Table 2) and 
pancreatic progenitor (Table 3) stages, and variation in lineage propensity among 
hPSC lines reported varying differentiation efficiencies between the tested hiPSC and 
hESC (H9) lines (Rostovskaya et al., 2015). Interestingly, the different protocols 
specifying pancreatic progenitors yielded no significant difference between the hPSC 
lines. Furthermore, it was also reported that certain protocols displayed higher 
endodermal and pancreatic differentiation efficiencies than others (Rostovskaya et 
al., 2015); two protocols that were the most recently published fared the best for 




pancreatic specification, generating over 90% PDX1-positive cells (Rezania et al., 
2014, Pagliuca et al., 2014). 
 
Although there have been substantial improvements in pancreatic 
differentiation protocols over the years, several challenges hindering the complete 
generation of functional β-cells that fully mimics those in vivo still remains. 
Transplantation of these hPSC-derived pancreatic progenitors into 
immunocompromised mice often resulted in the formation of teratomas, indicating 
the presence of pluripotent cells and incomplete differentiation. Efficient and 
consistently reproducible generation of pure pancreatic lineages derivatives is, 
therefore, key toward driving research in human β-cell biology, drug testing, disease 
modelling, development of cell replacement therapy and other applications. 
Understanding the molecular mechanisms promoting β-cell specification, including 
the studying the transcriptional regulatory networks of β-cell specification, will 
greatly contribute to the advancement of this field of research. 
 
 
Table 2. Comparison of definitive endoderm differentiation protocols for hPSCs. 
Table adapted from Rostovskaya et al., 2015 showing the different conditions of 
various protocols that were developed and published by independent groups.  





Table 3. Comparison of pancreatic progenitor differentiation protocols for hPSCs. 
Table adapted from Rostovskaya et al., 2015 showing the different conditions of 
various pancreatic progenitor differentiation protocols that were developed and 
published by independent groups. 
  




1.2.2 Transcription factors associated with pancreas development 
Most biological processes are regulated on a transcriptional level. In 
mammalian cells, the transcription of genes is regulated by several regulatory 
proteins known as transcription factors (TFs). TFs recognise specific DNA sequences 
near the target gene, often in regulatory promoter regions that are located upstream 
of the transcriptional start site (TSS), and can either activate or repress these 
promoter regions. During islet cell development, TFs play an integral role in directing 
cell fates by regulating the transcriptional network controlling pancreatic 
specification and ultimately mature function (Figure 4). Some of the TFs that play a 





Figure 4. Key transcription factors controlling lineage specification during 
pancreatic development. Highlighted in this diagram are the key transcription 
factors known to have an integral role at each stage of pancreatic development. 
Adapted from (Cano et al., 2014). 
  




SRY (sex determining region Y)-box 17 (SOX17) 
The Sox family of TFs has a conserved DNA-binding HMG (high mobility 
group) domain (Bowles et al., 2000), and its early expression is necessary for 
endoderm formation. In Xenopus, Xsox17 plays important roles in endoderm 
formation (Hudson et al., 1997, Clements and Woodland, 2000). It has also been 
shown to be a direct regulator of FoxA1 and FoxA2 (Sinner et al., 2004). β-catenin, an 
intracellular signal transducer in the Wnt signalling pathway, physically interacts with 
Sox17 and promotes transcriptional activation of its target genes (Sinner et al., 
2004). 
 
Sox17/SOX17 expression in the mouse and human is similar; it is expressed as 
an early endoderm marker immediately before 4 weeks post conception in human 
and e6.0 in mouse, then excluded from pancreatic cells 1 week or 2.5 days later in 
human and mouse respectively (Kanai-Azuma et al., 2002, Piper et al., 2004, Jennings 
et al., 2013). Sox17 is required for the induction of Pdx1 expression and Sox17-/- mice 
are deficient in the formation of the DE, although they form some foregut but not 
midgut or hindgut (Kanai-Azuma et al., 2002). Furthermore, constitutive expression 
of SOX17 in hESCs produced stable definitive endoderm progenitors, while absence 
of SOX17 blocked endoderm differentiation (Seguin et al., 2008). 
 
Forkhead Box A2 (FOXA2) 
Winged helix/forkhead transcription factors such as FoxA2 have been 
reported to be necessary for DE formation (Dufort et al., 1998). In early human 
development, FOXA2 is consistently expressed from week 4 (Lyttle et al., 2008, Jeon 
et al., 2009, Jennings et al., 2013). This is similar in the mouse where FoxA2 is 
expressed throughout pancreatic development, and remains expressed in all mature 
pancreatic cell types of both mice and humans (reviewed in (Pan and Wright, 2011, 
Cano et al., 2014)). FoxA1 and FoxA2 both regulate the expression of key pancreatic 
gene Pdx1 by co-occupying multiple regulatory domains in the PDX1 gene, although 
this has not been verified in human (Gao et al., 2008, Pan and Wright, 2011). 
Compound conditional ablation of both FoxA1 and FoxA2 in mice resulted in 




complete loss of Pdx1 expression and severe pancreatic hypoplasia (Gao et al., 
2008). Forkhead genes of the FOXA class have also been proposed to interact with 
GATA factors during DE formation (Bossard and Zaret, 1998, Cirillo et al., 2002). 
FoxA2 is also strongly expressed in DE derivatives such as the liver (Ang et al., 1993). 
In contrast to Sox17-/- mice, FoxA2-/- mice can form the hindgut but not the foregut 
and midgut (Dufort et al., 1998).  
 
Hepatocyte nuclear factor 1 homeobox beta (HNF1B) 
 HNF1B is highly expressed in humans around 7 weeks post conception and 
remains expressed throughout pancreatic development (Jeon et al., 2009). In the 
mouse, Hnf1B is expressed in the foregut endoderm prior to the onset of Pdx1 
expression (e8), and later restricted to the epithelial trunk domain and exocrine 
ducts (Coffinier et al., 1999, Maestro et al., 2003, Haumaitre et al., 2005). Hnf1B-/- 
mice die before gastrulation due to defective visceral endoderm formation, but 
when the embryonic lethality was rescued by tetraploid aggregation, Hnf1B-/- mice 
displayed absence of the ventral pancreatic bud and an extremely reduced and 
transient dorsal bud that leads to pancreas agenesis by e13.5 (Haumaitre et al., 
2005). In humans, heterozygous mutations in the HNF1B gene are associated with 
MODY5 (Nishigori et al., 1998, Lindner et al., 1999, Bingham et al., 2000, Horikawa et 
al., 1997). This is in contrast to the mouse where only homozygous mutations 
produced diabetes in mice. 
 
PDX1 
 PDX1 is expressed in all pancreatic precursor cells and has been shown to be 
critically important for early pancreatic development (Bernardo et al., 2009). In 
humans, PDX1 is broadly expressed at around 4 weeks post conception, peaking at a 
later stage when its expression becomes restricted to β-cells (Lyttle et al., 2008, 
Jennings et al., 2013). In mice, Pdx1 is first expressed in the primitive gut tube at 
e8.5, marking the pre-pancreatic endoderm. Pdx1 is not expressed exclusively in the 
pancreas and by e10.5, its expression has been reported in parts of the posterior 
foregut including the stomach, duodenum and bile duct (Guz et al., 1995, Offield et 




al., 1996). Pdx1 high expression then becomes restricted mostly to endocrine cells in 
the pancreas just before birth (Guz et al., 1995, Offield et al., 1996, Stoffers et al., 
1999). Growth of the pancreatic epithelium in Pdx1-/- mice is arrested around e10.5 
despite the presence of initial budding (Jonsson et al., 1994, Offield et al., 1996, 
Ahlgren et al., 1996). Microarray analyses performed on e10.5 Pdx1-/- mutant mice 
embryos found downregulation of several TFs including Nkx6-1 and Ptf1A, 
supporting its critical role in the pancreatic transcriptional network (Svensson et al., 
2007). However, the direct regulation of Pdx1 to Nkx6-1 and Ptf1A has yet to be 
established, though this has been shown for other TFs such as Gata4, FoxA2 and 
Hnf1B (Rojas et al., 2009, Oliver-Krasinski et al., 2009). In humans, homozygous 
inactivating mutations of the PDX1 gene result in pancreatic agenesis, known as 
MODY4 (Stoffers et al., 1997). 
 
PTF1A 
 PTF1A expression in the human foetal pancreas is only detectable by 
quantitative real time polymerase chain reaction (qRT-PCR) around mid-gestation, 
when acinar cells are formed (Jeon et al., 2009). From studies in mice, the separation 
process of pro-acinar tip cells and trunk cells is established by an antagonistic 
relationship between TFs Nkx6-1 and Ptf1A (Schaffer et al., 2010). Thus, Nkx6-1 and 
Ptf1A have important roles in specifying progenitors toward an endocrine or acinar 
fate, respectively. From being broadly expressed in the dorsal and ventral pancreatic 
buds, PTF1A is progressively restricted to the pro-acinar tip cells, while NKX6-1 and 
other TFs such as SOX9, and HNF1B are localised to the trunk (Obata et al., 2001, 
Jeon et al., 2009, Schaffer et al., 2010). In mice, Ptf1A is first expressed in the 
pancreatic epithelium at e9.5. By e13.5, its expression is restricted to acinar 
precursor cells as the tip and trunk domains become segregated. In contrast to Pdx1, 
Ptf1A expression is expressed only in the pancreas during development (Kawaguchi 
et al., 2002). Ptf1A-/- mice died shortly after birth and displayed a complete absence 
of exocrine pancreatic tissue (Krapp et al., 1998). In humans, mutations in the PTF1A 
enhancer may lead to pancreatic agenesis (Sellick et al., 2004, Weedon et al., 2014). 
 





The GATA family identified in vertebrates is composed of six zinc-finger TFs, 
each playing important roles in the specification and differentiation of multiple cell 
types (Arceci et al., 1993, Molkentin, 2000, Patient and McGhee, 2002). All members 
of the GATA family contains a highly conserved DNA binding domain consisting of 
two zinc fingers that recognise and bind to the motif WGATAR, in which W indicates 
A/T and R indicates A/G, in the regulatory sequences of target genes (Ko and Engel, 
1993). The six GATA members are known as Gata1 (Evans and Felsenfeld, 1989, Tsai 
et al., 1989), Gata2 (Yamamoto et al., 1990, Lee et al., 1991, Dorfman et al., 1992), 
Gata3 (Yamamoto et al., 1990, Ho et al., 1991, Joulin et al., 1991, Ko et al., 1991), 
Gata4 (Arceci et al., 1993, Kelley et al., 1993), Gata5 (Laverriere et al., 1994), and 
Gata6 (Laverriere et al., 1994). Based on their expression patterns in restricted 
tissues, the GATA members have been divided into two subfamilies: GATA1-3 and 
GATA4-6 (Molkentin, 2000). Gata1-3 are prominently expressed in hematopoietic 
stem cells where they regulate lineage-specific gene expression in T-lymphocytes, 
erythroid cells, and megakaryocytes (reviewed in (Orkin, 1998)). Gata4 -6 are 
expressed in various mesoderm- and endoderm-derived tissues such as the heart, 
liver, lung, pancreas and gut where they play critical roles in regulating tissue-specific 
gene expression (Arceci et al., 1993, Kelley et al., 1993, Laverriere et al., 1994, 
Morrisey et al., 1996a, Suzuki et al., 1996, Morrisey et al., 1997). Of these GATA 
family members, only Gata4 and Gata6 have been shown to be expressed in the 
pancreas and have a role in pancreatic development (Decker et al., 2006, Carrasco et 
al., 2012). In the mouse embryo, Gata4 and Gata6 overlap in the foregut endoderm 
at e9.5, including the pre-pancreatic endoderm (Molkentin, 2000). As embryonic 
development proceeds, Gata4 and Gata6 expression diverges to be expressed in 
acinar cells at e16.5, and endocrine islets at e14.5 respectively (Ketola et al., 2004). 
 
Gata4 null mice display severe developmental abnormalities, resulting in 
embryonic lethality between e7.0 and e9.5 (Molkentin et al., 1997). Tetraploid 
embryo complementation experiments were able to rescue these defects, enabling 
the generation of clonal embryonic e9.5 Gata4 –/– embryos directly from embryonic 




stem cells (Watt et al., 2004). Similarly, Gata6 null mice die after implantation 
because of defects in visceral endoderm function and extraembryonic development 
(Morrisey et al., 1998). This early embryonic deficiency associated with Gata6 null 
mice could also be rescued with tetraploid embryo complementation by providing 
Gata6-null embryos with a wild-type extraembryonic endoderm (Zhao et al., 2005). 
Thus, although the early embryonic lethality associated with the Gata4–/– and Gata6–
/– mice has precluded loss-of-function analyses in the pancreas, in vivo mouse 
studies using tetraploid complementation and a transgenic Gata-engrailed fusion 
protein have suggested that Gata4 and/or Gata6 contribute to the regulation of 
pancreas development (Decker et al., 2006, Watt et al., 2007). 
 
 As mentioned earlier, GATA4 is expressed during early human pancreatic 
budding between 4 to 5 weeks post conception, then becomes reduced in pancreatic 
progenitors, remaining mainly in mature acinar cells, an expression pattern similar to 
that of mice. In humans, the precise expression pattern of GATA6 during pancreatic 
development from has not been closely studied. Recently, studies established a 
critical regulatory role for GATA4 and GATA6 in human pancreas formation, and 
reported that heterozygous mutations in GATA4 or GATA6 can lead to pancreatic 
agenesis (Lango Allen et al., 2012, Shaw-Smith et al., 2014, Bonnefond et al., 2012). 
Heterozygous mutations in GATA4 and GATA6 have also been associated with 
congenital heart defects (Garg et al., 2003, Lango Allen et al., 2012, Bonnefond et al., 
2012). Strikingly, this is not the case in mice. Heterozygous or homozygous 
inactivation of either Gata4 or Gata6 does not impair pancreas formation, but 
simultaneously inactivation of both three or four Gata4 and Gata6 alleles in the 
pancreatic progenitor domain leads to pancreatic agenesis and loss of Pdx1 
expression, indicating a functional redundancy for these TFs during pancreas 
development in mice (Carrasco et al., 2012, Xuan et al., 2012). 
 
SOX9 
 SOX9, a member of the SRY/HMG box family, is found in PDX1-positive cells 
in early human pancreas by about 4 weeks post conception and in the mouse is 




expressed in the Pdx1 domain from e9.5 (Seymour et al., 2007, Lynn et al., 2007, 
McDonald et al., 2012, Jennings et al., 2013). Although SOX9 expression is absent in 
subsequent endocrine cells and restricted to pancreatic duct cells (Jennings et al., 
2013), it plays integral roles in maintaining the pancreatic progenitor pool, 
supporting endocrine cell differentiation, and co-localising with and regulating the 
expression of other important TFs such as FOXA2 and NGN3 (Seymour et al., 2007, 
McDonald et al., 2012). In mice, conditional inactivation of Sox9 in the Pdx1 domain 
results in severe pancreatic hypoplasia (Seymour et al., 2007). In addition, the Sox9+/- 
mice display a similar phenotype to SOX9 haploinsufficiency in humans, where failed 
maintenance of endocrine progenitors result in islet hypoplasia (Sosa-Pineda et al., 
1997, Piper et al., 2002, Seymour et al., 2008). 
 
NKX6-1 
 As mentioned earlier, NKX6-1 expression in humans is detected after 4 weeks 
post conception, once SOX17 is excluded from the pancreatic buds. Its expression 
then becomes restricted to β-cells by 14-16 weeks (Brissova et al., 2005, Jennings et 
al., 2013). Similarly in rodent, Nkx6.1 expression is broadly expressed in the early 
stages of pancreatic development, then gradually becomes restricted to β-cells 
(Sosa-Pineda et al., 1997). NKX6-1-/- mice exhibit a severe reduction in β-cells, and 
failure of conditional Nkx6.1 mutants to express Pdx1 reveal its role in specifying 
endocrine precursors toward β-cell lineage (Sander et al., 2000, Henseleit et al., 
2005, Schaffer et al., 2013). In human T2D islets, there is a reduced expression of 
NKX6-1 (Guo et al., 2013). 
 
NGN3 
 The expression pattern of NGN3 in human has been described in an earlier 
section (1.1.1 Development of the human pancreas). NGN3-/- mice fail to generate 
pancreatic endocrine cells and die postnatally from severe hyperglycemia (Gradwohl 
et al., 2000). In humans, it has been reported that a rare biallelic NGN3 null mutation 
resulted in PNDM with no histologically detectable islets, but detectable C-peptide 
levels suggest the presence of some β-cells (Rubio-Cabezas et al., 2011). 




1.2.3 Transcription factor GATA6 
The human (Suzuki et al., 1996) and mouse (Narita et al., 1996, Morrisey et 
al., 1996a) GATA6/Gata6 gene was first described in 1996. In humans, the GATA6 
gene is located on human chromosome 18 q11.1–q11.2 (Suzuki et al., 1996). Initially, 
the GATA6 cDNA was reported to have an open reading frame (ORF) from nucleotide 
residues 348 to 1697 extending from an initiator methionine codon at 716 bp, 
encoding a predicted protein size of 45.3 kDa composed of 449 amino acids (MYQ-
ORF, Figure 5) (Suzuki et al., 1996, Huggon et al., 1997). It was subsequently 
discovered that translation of the GATA6 gene can initiate from two alternative 
initiator methionine codons, giving rise to two protein isoforms (Brewer et al., 1999). 
In this study, a longer potential ORF encoding a protein of 595 amino acids, which 
commences at a more upstream, “in-frame” putative initiator methionine codon at 
278 bp was revealed (MALT-ORF, Figure 5) (Brewer et al., 1999). Both methionine 
codons are within a theoretically favourable context for translation initiation (Kozak, 
1981, Cavener and Ray, 1991, Kozak, 1997) and are located within exon 2, out of the 
7 exons of the GATA6 gene (Figure 5). Both isoforms possess an N-terminal 
transactivation domain and two zinc finger domains, both of which are essential for 
activity (Takeda et al., 2004). It has been reported that the two isoforms differ in 
their transactivation potential; full length GATA6 which expresses both isoforms and 
an altered GATA6 which only produces the longer isoform had the highest 
transactivation potentials (Brewer et al., 1999). However, deletion of the extended 
N-terminal 146 amino acids reduced transactivation potential by approximately 50%, 
and deletion of the region proximal to the zinc finger domains resulted in very little 
transactivation activity (Brewer et al., 1999).  
 
          
Figure 5. Corresponding cDNA transcript and protein product of GATA6. Top row 
represents cDNA, noncoding (grey) and coding (blue regions) of exons 1-7. Two 
initiator methionine codons (MALT and MYQ) are indicated in exon 2. Bottom row 
represents the full length isoform of the GATA6 protein, including locations of the 
two zinc finger DNA binding domains (red boxes, ZF1 and ZF2). 




The distribution of GATA6 transcripts in embryonic tissue appeared to be 
high in the heart and lungs, and absent in brain, liver, or kidney (Suzuki et al., 1996). 
In adult tissues, GATA6 transcripts were expressed at high levels in the heart, ovary, 
lung, and pancreas, low levels in the liver and spleen, and absent in the brain, 
placenta, skeletal muscle, thymus, prostate, testes, small intestine, colon, or 
leukocytes. Distribution of GATA4 differed slightly as was not detected in either adult 
or embryonic lung or in adult spleen, but present in testes. Of note, GATA6 and 
GATA4 expression overlapped in the adult pancreas and heart (Suzuki et al., 1996). 
 
In mice, the Gata6 gene maps to a region of chromosome 18 that shows 
homology to human chromosome 18 (Narita et al., 1996). The Gata6 cDNA was 
initially reported to include a 1332 bp ORF encoding a 444 amino acid polypeptide 
with a predicted protein size of 45 kDa (Morrisey et al., 1996a). Similarly to human, 
the mouse Gata6 gene encodes a longer polypeptide in addition to the one 
described earlier, with both methionine initiator codons located within exon 2, 
resulting in two protein isoforms (Brewer et al., 1999). The extended N-terminal 
sequence comprises 147 amino acid residues. Gata6 distribution overlaps with 
Gata4 in the adult mouse, and is abundant in the heart, lung, stomach, small 
intestine, large intestine and ovary, has lower levels in the liver and is absent in the 
brain, kidney, or skeletal muscle (Narita et al., 1996). Importantly, during mouse 
development, Gata4 and Gata6, but not Gata5, are expressed in overlapping 
domains within the primitive and foregut endoderm, including the regions that give 
rise to liver and pancreas (Bossard and Zaret, 1998, Decker et al., 2006). 
 
The recent genome sequencing of 27 neonatal diabetic patients with 
pancreatic agenesis or severe pancreas hypoplasia that revealed 56% of the patients 
had spontaneous heterozygous mutations in the GATA6 gene sparked a potential 
interest in the GATA6 gene (Lango Allen et al., 2012). This study associated GATA6, 
on top of previously identified genes such as PDX1 and PTF1A whose inactivation 
causes pancreatic agenesis in humans, to a potential role in pancreas 
morphogenesis.  
 




1.3. Disease modelling of pancreatic agenesis 
hPSC technology is a ground-breaking step toward modelling human disease 
in a controlled laboratory setting. hiPSCs can be derived from healthy volunteers or 
patients, thus hiPSC technology allows cellular models of disease to be formed from 
differentiated human pluripotent stem cells. Although animal models have proven 
invaluable in uncovering fundamental biology, inherent differences between human 
and rodent biology lead to limitations in the ability of animal systems to recapitulate 
human disease. Several such examples are human islets comprise a lower proportion 
of β-cells, and a higher proportion of α- and δ- cells compared to mouse islets 
(Brissova et al., 2005), and a different islet architecture between the two species, 
with human β-cells being dispersed among α- and δ- cells, while mouse β-cell 
maintaining a core surrounded by the four other endocrine cell types (Figure 6) 
(Cabrera et al., 2006). In rodents, insulin is encoded by two genes (INS1 and INS2), 
whereas in humans, insulin is only encoded by one gene (INS) (Melloul et al., 2002). 
Indeed, discordant phenotypes in the mouse compared to human caused by GATA6 
mutations have been noted as discussed in an earlier section (1.2.2). As such, this 
precludes the use of animal models in modelling the disease.  
 
The advancement of hPSC technology coupled with the availability of genome 
editing tools (discussed in the next section) provide a valuable opportunity to 
accurately model pancreatic agenesis as a disease and investigate the role of TF 
GATA6 in pancreatic development and elucidate how GATA6 mutations can impair 
the formation of the human pancreas. 
 






Figure 6. Confocal microscopy images of α-, β- and δ- cells within Islets of 
Langerhans show striking interspecies differences. (A, B) In human and monkey 
islets, insulin-immunoreactive β-cells (red), glucagon-immunoreactive α-cells (green), 
and somatostatin-immunoreactive δ-cells (blue) cells were all found randomly 
distributed. (C) In mouse islets, insulin-containing cells were located in the core, and 
glucagon- and somatostatin-containing cells in the circumference. (D) In pig islets, α-, 
β- and δ- cell distributions are similar to that of the mouse but appear to be formed 
in smaller units. Scale bar, 50 μm. Adapted from (Cabrera et al., 2006). 
 
  




1.3.1 Genome editing tools 
The concept of genetic engineering was first introduced in 1972 by Paul 
Berg’s lab in the form of recombinant DNA, where scientists successfully combined 
genes from different species (Jackson et al., 1972). Over the years, there has been 
tremendous progress in the development of methods not only to manipulate DNA, 
but also to generate vector systems and optimise their delivery into cells. The 
success of the Human Genome Project opened up many doors toward a deeper 
understanding of how the nucleotide sequence of human nuclear DNA relates to 
pathology of hereditary as well as multifactorial diseases. It also enabled the study of 
functional elements within the human genome, such as transcription factors. In 
order to establish relationships between gene function and disease, two strategies 
are often used: repression by switching off a gene i.e. knockdown or knockout and 
activation by overexpressing a gene. 
 
In 1996, a study reporting precise genome editing using a zinc finger protein 
domain coupled with the FokI endonuclease domain was published (Kim et al., 
1996). For the first time, it was possible to perform site-specific nuclease cutting of 
DNA at strictly defined sites in vitro. Zinc finger nuclease (ZFN) thus became the basis 
for editing cultured cells including pluripotent stem cells, plants and animals 
(Bibikova et al., 2002, Townsend et al., 2009, Zhang et al., 2010, Lombardo et al., 
2011, Provasi et al., 2012, Torikai et al., 2012). However, the technology brought 
several disadvantages such as the high complexity and cost of assembling the DNA-
binding protein domains, low efficiency and potential off-target effects. This drove 
the discovery of two more genome editing tool which succeeded the ZFN: 
transcription activator-like effector nuclease (TALEN) from Xanthomonas bacteria 
(Boch et al., 2009, Moscou and Bogdanove, 2009, Christian et al., 2010, Miller et al., 
2011) and RNA-guided DNA endonuclease Cas9 from the type II bacterial adaptive 
immune system clustered regulatory interspaced short palindromic repeats 
(CRISPR/Cas) (Cong et al., 2013, Mali et al., 2013). As CRISPR technology was only 
just emerging when the project started, TALEN was the genome editing tool that was 
used in this project, and will be described in detail below. 




1.3.2 Transcription activator-like effector nuclease (TALEN) 
The TALEN system was developed based on the study of the bacteria 
Xanthomonas genus, which act as pathogens to crop plants by secreting naturally 
occurring effector proteins (transcription activator-like effectors, TALEs) that support 
bacterial virulence, proliferation, and dissemination (Boch and Bonas, 2010). The 
TALE proteins bind to genomic DNA to alter transcription in host cells, thereby 
facilitating pathogenic bacterial colonisation.  
 
TALEN proteins contain a DNA-binding TALE repeat domains composed of a 
series of 33 to 35 amino acid repeat domains each recognising a single nucleotide 
base (Figure 7d), flanked by an amino (N)-terminal domain and a carboxy (C)-
terminal domain that is fused to a FokI restriction endonuclease domain (Figure 7a). 
In order for the TALEN to recognise a specific sequence on the double-stranded DNA, 
two TALEN proteins are required, commonly called the left and right TALEN arms, 
and they each recognise a particular sequence on the forward or reverse strand of 
the DNA (Figure 7b).  
 
Each TALE repeat domain has an almost identical amino acid sequence, 
except for two hypervariable residues typically found at positions 12 and 13 of the 
repeat domain, which determines which nucleotide base the individual TALE repeat 
domain will recognise (Figure 7c) (Boch et al., 2009). These hypervariable residues 
are also known as the repeat variable di-residues (RVDs). The RVDs NN, NI, HD and 
NG code for the recognition of nucleotide base guanine, adenine, cytosine and 
thymine, respectively (Figure 7d). The last repeat that binds a nucleotide at the 3’-
end of the recognition site consists only of 20 amino acid residues, and is therefore 
called a half-repeat. Subsequent improvements were made to increase binding and 
specificity of these residues to their respective nucleotide. For example, the RVDs NK 
was reported to be more specific for guanine than NN, although it also recognises 
adenine (Moscou and Bogdanove, 2009, Miller et al., 2011) and displayed less 
activity as compared to NN (Streubel et al., 2012). The RVDs NH were suggested to 
be more specific than the NN repeat but with lower activity (Streubel et al., 2012, 




Cong et al., 2012). It was also reported that RVDs HD and NH bind their preferred 
nucleotides strongly, while NI and NG bind to their preferred nucleotides relatively 
weaker (Streubel et al., 2012). Furthermore, a second generation scaffold greatly 




Figure 7. Overview of TALEN proteins. (a) Schematic of one arm of a fully 
constructed TALEN protein comprising of an amino (N)-terminal and carboxy (C)-
terminal domain that are required for DNA-binding, a non-specific FokI endonuclease 
domain and TALE repeat domains forming an array ending with a truncated half 
repeat. (b) A pair of TALEN arms, namely the left and right TALEN arm, binds and 
cleaves as dimers on a specific target site of the double-stranded DNA, resulting in a 
double-stranded break of the DNA. Cleavage by the FokI nuclease domains occurs 
within a spacer region that lies between binding sites of the left and right TALEN 
arms. (c) The amino acid sequence of a single TALE repeat domain is highly 
conserved and is similar in all the various domains except for the 12th and 13th amino 
acid known as the hypervariable residues or repeat variable di-residues (RVDs) 
(highlighted in orange and bold text). (d) Each RVD confers specificity to a single 
nucleotide and is arranged in the order of its target sequence during construction of 
the TALEN protein. The TALE array is responsible for binding to DNA at a specific site. 
Preceding the first base bound by a TALE repeat at the 5’ end is a thymine. Adapted 
from (Joung and Sander, 2013). 




TALEN construction can be challenging due to the nature of the nearly 
identical repeat sequences of the TALE repeat domains, and the assembly of 
numerous domains. Many groups have devised platforms for TALEN assembly to 
facilitate a simple and efficient construction process and these can be broadly 
grouped into three categories: standard restriction enzyme and ligation-based 
cloning (Sander et al., 2011, Huang et al., 2011), ‘Golden Gate’ cloning (Engler et al., 
2008, Engler et al., 2009), and solid-phase assembly (Reyon et al., 2012). In this 
project, the standard restriction enzyme and ligation-based cloning platform was 
used. This method utilises an archive of plasmids encoding single or multiple TALE 
repeat domains and join them in a parallel hierarchical fashion via restriction 
digestion and ligation reactions. The ‘Golden Gate’ cloning platform is a multi-
fragment ligation strategy and allows for 3 to 10 TALE repeat domains to be 
simultaneously ligated in a particular linear order into a plasmid vector (Weber et al., 
2011). Solid-phase assemblies such as Fast Ligation-based Automatable Solid-phase 
High-throughput (FLASH) assembly, Iterative Capped Assembly (ICA) are automated, 
high-throughput methods for assembling numerous TALE repeat arrays (Reyon et al., 










1.3.3 Nuclease-mediated mutations 
 Simultaneous introduction of the left and right TALEN arms into cells often 
lead to site-specific DNA double-stranded breaks (DSB). The FokI endonuclease 
domain is crucial for the successful cleavage of the double-stranded DNA by 
recognising a non-palindromic DNA sequence and making a double-stranded cut 
outside of that sequence, commonly within a region known as a spacer, resulting in a 
5′ overhang (Hiroyuki and Susumu, 1981). The spacer must be an appropriate length 
of around 16 nucleotides to permit dimer formation. In order to cleave the DNA, 
each of the FokI domain within the left or right TALEN arm must dimerise during 
adjacent and independent binding events of each arm onto the site-specific DNA in 
the correct orientation (Vanamee et al., 2001). The need for two DNA binding events 
to occur and for the FokI domains to form a heterodimer pair prior to DNA cleavage 
improves specificity and reduces off-target effects via the elimination of unwanted 
homodimers (Miller et al., 2007, Szczepek et al., 2007). 
 
Numerous studies have established that normal cellular repair of DSB occur 
through two pathways; non-homologous end-joining (NHEJ) or homologous 
recombination (HR) (Rudin et al., 1989, Plessis et al., 1992, Rouet et al., 1994, 
Choulika et al., 1995, Lieber, 2008, Jackson and Bartek, 2009). It was subsequently 
realised that these two highly conserved cell repair pathways can be exploited to 
introduce targeted mutations in a wide variety of cell types and species after 
nuclease-induced DSBs have taken place (Figure 8) (Bibikova et al., 2001, Bibikova et 
al., 2002, Bibikova et al., 2003). The NHEJ repair pathway is error-prone and often 
lead to mutations containing insertions and/or deletions (indel) of variable length 
originating from the site of the DSB, thus resulting in frameshift mutations that can 
lead to the knockout of gene function (Bibikova et al., 2002). Alternatively, if a 
double-stranded DNA 'donor template' is supplied in combination with the pair of 
TALEN arms, HR of a nuclease-induced DSB can be used to introduce precise 
nucleotide substitutions or insertions by repairing the DSB with the information 
encoded on this template (Moehle et al., 2007).   
 






Figure 8. TALEN-mediated genome editing. After a TALEN-induced double-stranded 
break in the DNA occurs, the cell may undergo one of two highly conserved repair 
pathways, NHEJ or HR, to repair the cleaved DNA. In the absence of a donor 
template, the cell undergoes the error-prone NHEJ pathway by ligating the DNA. 
Nucleotide insertions and/or deletions (asterisk) will commonly be introduced, 
disrupting the open reading frame and possibly resulting in a premature stop codon. 
In the presence of a donor template, the cell undergoes the HR pathway which can 
be used to either correct a mutation (asterisk) in the genome or to target integration 
of a transgene into a specific site. Adapted from (Mussolino and Cathomen, 2012). 
 
  




Genome editing tools such as the TALEN technology provide tremendous 
potential for experimental, biotechnological and therapeutic purposes. Such 
applications include gene disruptions in model organisms, cell-based disease 
modelling such as in hPSCs, and gene corrections (allele editing).  In cell-based 
disease modelling, the impact of a specific gene disruption and of specific sequence 
variants on gene function can be studied closely and be directly associated with 
diseases. This enables the generation of isogenic cell lines so any possible effects on 
the disease phenotype under investigation that may be caused by genetic 





Figure 9. hPSC-based disease modelling. Wild-type hPSCs are targeted by genome 
editing tools such as TALEN to generate isogenic cell lines. Wild-type and mutated 
hPSCs are then differentiated into disease-relevant cell types followed by phenotypic 
comparison and pathophysiological studies to determine the direct association of 
the gene to the disease phenotype. Adapted from (Yu and Cowan, 2016). 
  




1.4. Objectives of the project 
Advancement in genome sequencing technologies in the recent years has 
provided a major unexpected discovery in this field. The recent study published by 
Allen et al. where 15/27 (56%) patients with pancreatic agenesis and exocrine 
pancreatic insufficiency requiring enzyme replacement therapy, born to non-diabetic 
parents harboured de novo heterozygous inactivating mutations in GATA6 
established a key role for the transcription factor GATA6 in human pancreatic 
development (Lango Allen et al., 2012). This study is the basis for my project. Human 
genetics, therefore, has established that GATA6 is an essential regulator of human 
pancreas development, but it does not shed light on the underlying molecular 
mechanism, nor does it define the precise cell types or developmental stages in 
which the essential role takes place. The role of GATA6 in the development of the 
pancreas has been well studied in the mouse, but this is not the case in humans. 
From mouse studies, it is known that GATA6 is expressed in the developing pancreas 
and is an important regulator of pancreas development. Thus, the overall objective 
of my project is to elucidate the role GATA6 in the development of the human 
pancreas. Knowledge gained from this project could potentially contribute to 
therapies for neonatal diabetes. 
 
The first objective of this study is to perform directed differentiation of hPSCs 
into the pancreatic lineage using a fully defined culture system. The second objective 
is to obtain GATA6 patient lines, reprogram them to obtain patient-derived GATA6 
mutant lines, and perform directed differentiation into the pancreatic lineage to 
assay the effect of GATA6 mutations on the development of the pancreas. The third 
objective is to perform disease modelling of pancreatic agenesis by generating 
GATA6 heterozygous and homozygous mutations in hPSC lines via TALEN as a 
genome editing tool. The fourth objective is to perform phenotypic comparisons 
between these TALEN-generated GATA6 mutant hPSCs and their respective isogenic 
control hPSC lines. The final objective is to define the molecular mechanisms of 
GATA6 by investigating the transcriptional networks controlled by GATA6 through 
RNA-sequencing and identifying its interacting partners through ChIP-sequencing.
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CHAPTER 2  MATERIALS AND METHODS 
 
2.1. Tissue culture 
2.1.1. Human pluripotent stem cell lines 
H9 hESCs were purchased from WiCell (WA09). FSPS13.B hiPSCs were derived 
by a colleague from peripheral blood mononuclear cells (PBMCs) using Sendai virus 
as described previously (Yusa et al., 2011) by the Human induced pluripotent stem 
cell initiative (HIPSCI). The resulting cells are available for distribution through 
European Collection of Authenticated Cell Cultures (ECACC). Further information is 
available at http://www.hipsci.org/lines/#/lines/HPSI0813i-fpdm_2.  
 
The generation of GATA6 patient-derived hiPSCs was approved by the Great 
Ormond Street Hospital and Institute of Child Health Research Ethics Committee 
(ethics reference number: 08/H0713/82), and informed consent was obtained from 
all patients. Skin fibroblasts from GATA6 patients were obtained with the help of Dr 
Ranna El Khairi. Skin punch biopsy samples were collected from volunteering 
patients and all hiPSC lines used were derived and validated by the Cambridge 
Biomedical Research Centre hiPSC Core Facility.  
 
Reprogramming of the GATA6 patient fibroblasts to derive GATA6-patient 
iPSCs was done with the help of the hiPSC core facility at the Anne McLaren 
Laboratory for Regenerative Medicine using sendai virus reprogramming as 
described previously (Yusa et al., 2011). 
 
  




2.1.2. Growth conditions 
hPSCs were routinely cultured in feeder-free conditions on vitronectin-coated 
(Stemcell Technologies #07180) sterile plates (Corning, Costar) with Essential 8 (E8) 
media (Life Technologies #A1517001). Subculture was performed every 4-6 days by 
aspirating the cell culture media, washing the cells once with D-PBS, incubating them 
in 0.5 mM EDTA (Invitrogen, #15575020) for 5 min at room temperature, aspirating 
the EDTA and adding appropriate volumes of fresh E8 media (Table 4) to the cells. 
hPSCs were further physically detached from the plates by gentle pipetting, collected 
in a 15 ml Falcon tube (BD Falcon) and allowed to settle for 10 min. The supernatant 
was aspirated and hPSCs were re-suspended in fresh E8 media, and then dissociated 
into smaller clumps by gentle pipetting. The cells were split and plated onto fresh 
vitronectin-coated plates (Table 5) containing appropriate volumes of media (Table 
4). Cells were maintained by refreshing E8 media on a daily basis. 
 
Prior to differentiation into any lineages, culture plates were pre-coated with 
0.1% Gelatin (Millipore, #ES-006-B) for at least 20 min at room temperature. The 
gelatin solution was then aspirated and replaced with MEF media (Table 6 and Table 
7). The MEF-coated plates were allowed to incubate at 37°C overnight, up to 1 week, 
and used when required. 
 
Table 4. Volume of E8 used in splitting and maintenance of cells 
Culture vessel During splitting prior to physical detachment Maintenance 
10 cm dish 3 ml 7 ml 
1 well of 6wp 1 ml per well 1.5 ml 
1 well of 12wp 0.5 ml per well 1 ml 
1 well of 24wp 0.3 ml per well 0.5 ml 
 
 
Table 5. Splitting ratio of cells 
Initial growth area Final growth area 
1 x 10 cm dish 4 x 10 cm dishes 
1 well of 6wp 1 full 6wp, 12wp or 24wp 
 




Table 6. MEF media formulation 
Component Volume 
Advanced DMEM/F-12 (Gibco, #12634028) 450 ml 
FBS (Biosera, #S04253S181S) 50 ml 
L-Glutamine (Gibco, #25030024) 5 ml 
+/- Penicillin-Streptomycin (Gibco, #15140122) 5 ml 
β-Mercaptoethanol (Sigma-Aldrich, #M6250) 3.5 µl 
 
 
Table 7. Volume of MEF media used for coating 
Culture vessel Volume 
10 cm dish 8 ml 
1 well of 6wp 2 ml 
1 well of 12wp 1.5 ml 
1 well of 24wp 1 ml 
 
  




2.1.3. Definitive endoderm (DE) differentiation 
To plate hPSCs for differentiation, hPSCs were grown to about 80% 
confluency and then passaged as described in the previous section. The cells were 
broken into clumps smaller than routine passaging by doubling the number of times 
they pass through the pipette tip. They were then filtered through a 70 µm cell 
strainer (BD Falcon, #352350) to obtain a uniformly-sized cell suspension, re-
suspended in fresh E8 media containing ROCK inhibitor Y-27632 (Sigma-Aldrich, 
#Y0503) and plated onto the appropriate MEF-coated culture plates. Prior to plating, 
the MEF media was aspirated and plates were washed once with D-PBS (Life 
Technologies, #14190094). Cells were plated at a density such that they were about 
60 - 70% confluent at the start of DE differentiation. 24 hours after plating, the 
culture media was replaced with fresh E8 media without ROCK inhibitor Y-27632. DE 
differentiation commenced 48 hours after plating. 
 
Using the lab’s established DE differentiation protocol, the E8 media was 
aspirated and cells were washed once with D-PBS to remove any residual E8 media. 
Chemically defined medium-poly vinyl alcohol (CDM-PVA; Table 8) media of 
appropriate volume (Table 9) supplemented with 100 ng/ml Activin A (produced in-
house), 20 ng/ml basic FGF (bFGF/FGF2; produced in-house), 10 ng/ml BMP4 (R&D 
Systems, #314-BP-010), 10 μM LY294002 (Promega, #V1201) and 3 μM CHIR99201 
(Stratech Scientific, #CT99021) was added to the cells on Day 1 (Table 10). On Day 2, 
media from Day 1 was aspirated and CDM-PVA media containing 100 ng/ml Activin 
A, 20 ng/ml FGF2, 10 ng/ml BMP4, and 10 µM LY294002 was added to the cells. On 
Day 3, media from Day 2 was aspirated and RPMI-B27 media (Table 11) 
supplemented with 100 ng/ml Activin A and 20 ng/ml FGF2 was added to the cells. 









For DE differentiation using a commercial kit PSC Definitive Endoderm 
Induction Kit (Gibco, #A27654SA), cells were initially passaged and plated similarly to 
the lab’s established protocol. Volumes of media used are indicated in Table 9.       
On Day 1, Medium A of the kit was added and on Day 2, Medium A was replaced 
with Medium B. Cells were harvested on Day 3 for downstream analyses of the DE. 
 
Table 8. CDM-PVA formulation 
Component Volume 
Ham’s F-12+ GlutaMAX-1 (Gibco, #31765068) 250 ml 
Iscove's Modified Dulbecco's Medium (Gibco, #21980065) 250 ml 
Chemically Defined Lipid Concentrate (Gibco, #11905031) 5 ml 
1-Thioglycerol (Sigma-Aldrich, #M6145) 20 µl 
Transferrin (30 mg/ml; Roche #652202) 250 µl 
Insulin (10 mg/ml; Roche #1376497) 350 µl 
Poly vinly alcohol (Sigma-Aldrich, #P8136) 0.5 g 
+/- Penicillin-Streptomycin (Gibco, #15140122) 5 ml 
 
Table 9. Volume of media used for DE differentiation 
Culture vessel Volume 
10 cm dish 7 ml 
1 well of 12wp 0.5 ml 
1 well of 24wp 0.3 ml 
 
Table 10. Lab DE differentiation protocol 
Time point Media Supplements 
Day -1 (plate) E8 ROCK inhibitor 
Day 0 E8 None 
Day 1 CDM-PVA 100 ng/ml Activin A + 20 ng/ml FGF2 + 10 ng/ml BMP4 + 
10 µM LY294002 + 3 µM CHIR99201 
Day 2 CDM-PVA 100 ng/ml Activin A + 20 ng/ml FGF2 + 10 ng/ml BMP4 + 
10 µM LY294002 
Day 3 RPMI-B27 100 ng/ml Activin A + 20 ng/ml FGF2 
 
Table 11. RPMI-B27 formulation 
Component Volume 
RPMI 1640 + GlutaMAX (Gibco, #61870-10) 500 ml 
B-27 supplement (Gibco, #17504-044) 10 ml 
MEM Non-Essential Amino Acids Solution (Gibco, #11140-050) 5 ml 
+/- Penicillin-Streptomycin (Gibco, #15140122) 5 ml 




2.1.4. Pancreatic differentiation 
Following on from DE differentiation, cells were further specified toward the 
pancreatic lineage by using a protocol that was previously established in the lab. On 
Day 4, Day 3 media was aspirated and replaced with Advanced DMEM/F-12 
containing bovine serum albumin (ADV-BSA; Table 12) supplemented with 2 µM 
retinoic acid (RA; Sigma-Aldrich, #R2625), 50 ng/ml FGF10 (Autogen Bioclear, 
#ABC144), 150 ng/ml Noggin (R&D, #33-44NG/CF) and 10 µM SB-431542 (R&D, 
#1614/10) (Table 13) using appropriate volumes indicated in Table 14. On Days 5 and 
6, media was refreshed with the same supplements as Day 4. Cells were harvested 
on Day 7 for downstream analyses of the primitive gut tube. 
 
On Day 7, Day 6 media was aspirated and replaced with ADV-BSA 
supplemented with 2 µM RA, 50 ng/ml FGF10, 150 ng/ml Noggin and 1 mg/ml KAAD-
cyclopamine (Toronto Research Chemicals Incorporated, #K171000). On Days 8 and 
9, media was refreshed with the same supplements as Day 7. Cells were harvested 
on Day 10 for downstream analyses of the posterior foregut. 
 
On Day 10, Day 9 media was aspirated and replaced with ADV-BSA 
supplemented with 2 µM RA, 50 ng/ml FGF10 and 0.25 µg/ml KAAD-cyclopamine 
(Toronto Research Chemicals Incorporated, #K171000). On Days 11 and 12, media 
was refreshed with the same supplements as Day 10. Cells were harvested on Day 13 
for downstream analyses of the pancreatic progenitors. 
 
On Day 13, Day 12 media was aspirated and replaced with ADV-BSA 
supplemented with 2 µM RA, 1% vol/vol B27 supplement, 1 µM DAPT (Sigma-
Aldrich, #D5942) and 0.1 mM 6-Bnz-cAMP sodium salt (BNZ; Sigma-Aldrich, #B4560). 
Media was left unchanged on Days 14 and 15. Cells were harvested on Day 16 for 
downstream analyses of the endocrine progenitors. 
 
 




On Days 16, 18 and 22, cells were then allowed to mature into immature β-
cells by aspirating media from Days 15, 17 and 21 respectively and adding ADV-BSA 
supplemented with 2 µM RA, 1% B27 supplement and  0.25 µg/ml KAAD-
cyclopamine. Cells were harvested on Days 19 and 25 for downstream analyses of 
immature endocrine cells and β-cells respectively. 
 
Table 12. ADV-BSA formulation 
Component Volume 
Advanced DMEM/F-12 (Gibco, #21634010) 500 ml 
Bovine Serum Albumin (Europa Bioproducts, Lot #1260) 2.5 g 
L-Glutamine (Gibco, #25030024) 5 ml 
Penicillin-Streptomycin (Gibco, #15140122) 5 ml 
 
Table 13. Pancreatic differentiation protocol 
Time point Media Supplements 
Day 4 ADV-BSA 2 µM RA + 50 ng/ml FGF10 + 150 ng/ml Noggin + 10 µM SB-
431542 
Day 5 ADV-BSA 2 µM RA + 50 ng/ml FGF10 + 150 ng/ml Noggin + 10 µM SB-
431542 
Day 6 ADV-BSA 2 µM RA + 50 ng/ml FGF10 + 150 ng/ml Noggin + 10 µM SB-
431542 
Day 7 ADV-BSA 2 µM RA + 50 ng/ml FGF10 + 150 ng/ml Noggin +  
0.25 µg/ml KAAD-cyclopamine 
Day 8 ADV-BSA 2 µM RA + 50 ng/ml FGF10 + 150 ng/ml Noggin +  
0.25 µg/ml KAAD-cyclopamine 
Day 9 ADV-BSA 2 µM RA + 50 ng/ml FGF10 + 150 ng/ml Noggin +  
0.25 µg/ml KAAD-cyclopamine 
Day 10 ADV-BSA 2 µM RA + 50 ng/ml FGF10 + 0.25 µg/ml KAAD-cyclopamine 
Day 11 ADV-BSA 2 µM RA + 50 ng/ml FGF10 + 0.25 µg/ml KAAD-cyclopamine 
Day 12 ADV-BSA 2 µM RA + 50 ng/ml FGF10 + 0.25 µg/ml KAAD-cyclopamine 
Days 13-15 ADV-BSA 2 µM RA + 1% B27 + 1 µM DAPT + 0.1 mM BNZ 
Days 16-18 ADV-BSA 2 µM RA + 1% B27 + 0.25 µg/ml KAAD-cyclopamine 
Days 18-21 ADV-BSA 2 µM RA + 1% B27 + 0.25 µg/ml KAAD-cyclopamine 
Days 22-24 ADV-BSA 2 µM RA + 1% B27 + 0.25 µg/ml KAAD-cyclopamine 
 
Table 14. Volume of media used for pancreatic differentiation 
Culture vessel Volume 
10 cm dish 7 ml each day from Days 4 to 9, 14 ml on Days 13, 16, 18 and 22 
1 well of 12wp 0.5 ml each day from Days 4 to 9, 1.5 ml on Days 13, 16, 18 and 22 
1 well of 24wp 0.3 ml each day from Days 4 to 9, 1 ml on Days 13, 16, 18 and 22 




2.1.5. Pancreatic differentiation using STEMdiff pancreatic progenitor kit 
Alternatively, cells were also differentiated into pancreatic progenitors using 
the STEMdiff pancreatic progenitor kit (Stem Cell Technologies, #05120). They were 
cultured in E8 media as described in section 2.1.1 and plated for differentiation as 
described in section 2.1.3. Cells were differentiated according to the manufacturer’s 
protocol and were harvested on Days 4 and 14 for downstream FACS analyses of the 
DE and pancreatic progenitors respectively, and Days 4, 7, 10 and 14 for downstream 




2.1.6. Glucose response assay and Enzyme linked immunosorbent assay 
(ELISA) for C-peptide 
 
hPSCs differentiated into the endocrine progenitors after Day 24 are cultured 
in differentiation medium without insulin for 24 hr prior to ELISA. Cells were washed 
thrice in D-PBS and pre-incubated in DMEM supplemented with 2.5 mM glucose 
(Invitrogen) for 60 min at 37°C. To perform glucose-induced insulin secretion, the 
buffer is replaced with 22.5 mM glucose (high glucose) alternatively with 5.5 mM 
glucose (low glucose) twice at 30 min intervals. The supernatant is collected after 
each round of incubation and stored at -80°C for determination of C-peptide release. 
For control, cells were incubated in DMEM supplemented with 2.5 mM glucose.  
 
C-peptide ELISA was measured using the Mercodia Ultrasensitive C-peptide 
ELSIA kit (Mercodia) following the manufacturer’s instructions. Absorbance was read 
at 450 nm using Tecan Infinite 200 Pro plate reader. 
 
  




2.1.7. Hepatic differentiation 
Following on from DE differentiation, cells were further specified toward the 
hepatic lineage by using a protocol that was previously established in the lab. From 
Day 4 to Day 9, cells were cultured in 0.5 ml per well of a 12 well plate of RPMI-B27 
(Table 11) and supplemented with 50 ng/ml Activin A (Table 15). Media was 
refreshed daily. 
 
From Days 10 to 26, cells were cultured in 1 ml per well of a 12 well plate of 
Hepatozyme (Table 16) and supplemented with 10ng/ml Oncostatin M (OSM; R&D, 
#295-OM) and 50ng/ml Hepatocyte growth factor (HGF; Peprotech, #100-39). Media 
was refreshed every other day. 
 
Table 15. Hepatic differentiation protocol 
Time point Media Supplements Volume 
Day 4 RPMI-B27 50 ng/ml Activin A 0.5 ml 
Day 5 RPMI-B27 50 ng/ml Activin A 0.5 ml 
Day 6 RPMI-B27 50 ng/ml Activin A 0.5 ml 
Day 7 RPMI-B27 50 ng/ml Activin A 0.5 ml 
Day 8 RPMI-B27 50 ng/ml Activin A 0.5 ml 
Day 9 RPMI-B27 50 ng/ml Activin A 0.5 ml 
Day 10-11 Hepatozyme 10 ng/ml OSM + 50 ng/ml HGF 1 ml 
Day 12-13 Hepatozyme 10 ng/ml OSM + 50 ng/ml HGF 1 ml 
Day 14-15 Hepatozyme 10 ng/ml OSM + 50 ng/ml HGF 1 ml 
Days 16-17 Hepatozyme 10 ng/ml OSM + 50 ng/ml HGF 1 ml 
Days 18-19 Hepatozyme 10 ng/ml OSM + 50 ng/ml HGF 1 ml 
Days 20-21 Hepatozyme 10 ng/ml OSM + 50 ng/ml HGF 1 ml 
Days 22-23 Hepatozyme 10 ng/ml OSM + 50 ng/ml HGF 1 ml 
Days 24-26 Hepatozyme 10 ng/ml OSM + 50 ng/ml HGF 1 ml 
 
Table 16. Hepatozyme formulation 
Component Volume 
Hepatozyme (Gibco, #17705-021  ) 500 ml 
MEM Non-Essential Amino Acids Solution (Gibco, #11140-050) 10.6 ml 
Chemically Defined Lipid Concentrate (Gibco, #11905031) 10.6 ml 
L-Glutamine (Gibco, #25030024) 5.3 ml 
Transferrin (30 mg/ml; Roche #652202) 530 µl 
Insulin (10 mg/ml; Roche #1376497) 742 µl 
+/- Penicillin-Streptomycin (Gibco, #15140122) 5.3 ml 




2.2. Cloning of plasmid DNA constructs 
2.2.1. Transformation of plasmids into Escherichia coli cells 
XL-10 Gold Ultracompetent cells (Agilent Technologies, #200314) were 
thawed on ice. The competent cells were gently mixed by gentle tapping of the tube 
then 50 µl of competent cells were aliquoted into tubes containing DNA plasmids or 
ligation reactions while keeping all tubes on ice. The tubes were gently tapped to 
mix. The cells were incubated on ice for 20 min, then heat-shocked for 45 s in a 42°C 
water bath. They were then placed back on ice for a further 2 min. 500 µl of room 
temperature S.O.C. Medium (Invitrogen) was then added to the tubes and they were 
incubated shaking at 225 rpm for 1 hr at 37°C. 200-500 µl of the reaction mix was 
then spread on LB plates containing the appropriate antibiotics and incubated 
overnight at 37°C. 
 
2.2.2. Small scale DNA plasmid purification and colony selection 
 
Plasmid DNA constructs were prepared using QIAprep Spin Miniprep kit 
(Qiagen, #27106). They were analysed by restriction digest to confirm presence of 
the insert in the correct orientation. 
 
2.2.3. Genotyping via Sanger sequencing 
 
Plasmid DNA constructs were sent to AITBiotech, Singapore and GATC 
Biotech, UK for genotype verification. 
  





For DNA plasmid constructs used in cell culture, they were prepared using 
EndoFree Plasmid Maxi Kit (Qiagen, #12362). For all other applications, DNA plasmid 
constructs were prepared using QIAprep Spin Miniprep kit (Qiagen, #27106). 
 
2.3.1. Transcription activator-like effector nuclease (TALEN) vectors 
Suitable TALEN target sites on the GATA6 gene were generated using an 
online TALEN targeter software tool (Cermak et al., 2011, Doyle et al., 2012). Two 
TALEN targets within exon 2 of the GATA6 gene were selected based on higher 
numbers of RVDs HD and NH and the presence of a restriction site in the spacer 
region; one targeting a site that is 6 base pairs downstream of the first start codon 
while the other targeting a site that is 149 base pairs downstream of the second start 
codon. They are termed TALEN 1 and TALEN 2 respectively. The sequences of the 
two selected TALEN target pairs are listed in Table 17. 
Table 17. Two selected TALEN target sites for GATA6 
TALEN pair Name Sequence (5’ → 3’) 
TALEN 1 (T1) Left arm GACTGACGGCGGCTGGT Right arm CCGCACCCGCGGCCCCG 
TALEN 2 (T2) Left arm GCTGCCCGGCCTACCGT Right arm GGCTGGCCCACTGCCC 
 
TALEN vectors were assembled using the Joung Lab REAL Assembly TALEN kit 
(Addgene, #1000000017). Modifications of the pTAL scaffold into the second 
generation GoldyTALEN scaffold and NN RVDs into NH were performed by Dr 
Norihiro Tsuneyoshi. Plasmids obtained from this kit used for the TALEN assemblies 
and their corresponding RVDs are listed in Table 18. The selected target sequences 
were entered into a ZiFiT targeter software via the REAL assembly method prior to 
TALEN assembly (Sander et al., 2007, Sander et al., 2010). Assembly of the TALE 
repeat arrays were performed in three polymerase chain reaction (PCR) steps (Table 
19 for T1 and Table 20 for T2) with the primers listed in Table 21. Primers used in the 
final PCR step included the Kozak sequence. PCR was performed using PrimeSTAR 
Max DNA polymerase (Takara, # R045B) according to the manufacturer’s protocol.  




















TAL024 NN to NH 
TAL025 NG 
 
Table 19. TALEN 1 repeat array assembly via three step PCR method 
PCR step TALEN name Primer name RVD number Plasmid 
1 T1 left arm TALEN-RVDs 1 Fwd 1 TAL009 
TALEN-RVDs 1 Rev 5 TAL009 
  9 TAL009 
  13 TAL007 
TALEN-RVDs 2 Fwd 2 TAL011 
TALEN-RVDs 2 Rev 6 TAL011 
  10 TAL012 
  14 TAL015 
TALEN-RVDs 3 Fwd 3 TAL017 
TALEN-RVDs 3 Rev 7 TAL017 
  11 TAL019 
  15 TAL019 
TALEN-RVDs 4 Fwd 4 TAL025 
TALEN-RVDs 4 Rev 8 TAL024 
  12 TAL024 
  16 TAL024 
T1 right arm TALEN-RVDs 1 Fwd 1 TAL007 
TALEN-RVDs 1 Rev 5 TAL006 
  9 TAL009 
  13 TAL007 
  





TALEN-RVDs 2 Fwd 2 TAL012 
TALEN-RVDs 2 Rev 6 TAL012 
  10 TAL012 
  14 TAL012 
TALEN-RVDs 3 Fwd 3 TAL019 
TALEN-RVDs 3 Rev 7 TAL017 
  11 TAL019 
  15 TAL017 
TALEN-RVDs 4 Fwd 4 TAL022 
TALEN-RVDs 4 Rev 8 TAL022 
  12 TAL024 
  16 TAL022 
2 T1 left arm TALEN-RVDs 1 Fwd 1 TAL009, 
TAL011 TALEN-RVDs 2 Rev 2 
TALEN-RVDs 3 Fwd 3 TAL017, 
TAL025 TALEN-RVDs 4 Rev 4 
TALEN-RVDs 1 Fwd 5 TAL009, 
TAL011 TALEN-RVDs 2 Rev 6 
TALEN-RVDs 3 Fwd 7 TAL017, 
TAL024 TALEN-RVDs 4 Rev 8 
TALEN-RVDs 1 Fwd 9 TAL009, 
TAL012 TALEN-RVDs 2 Rev 10 
TALEN-RVDs 3 Fwd 11 TAL019, 
TAL024 TALEN-RVDs 4 Rev 12 
TALEN-RVDs 1 Fwd 13 TAL007, 
TAL015 TALEN-RVDs 2 Rev 14 
TALEN-RVDs 3 Fwd 15 TAL019, 
TAL024 TALEN-RVDs 4 Rev 16 
T1 right arm TALEN-RVDs 1 Fwd 1 TAL007, 
TAL012 TALEN-RVDs 2 Rev 2 
TALEN-RVDs 3 Fwd 3 TAL019, 
TAL022 TALEN-RVDs 4 Rev 4 
TALEN-RVDs 1 Fwd 5 TAL006, 
TAL012 TALEN-RVDs 2 Rev 6 
TALEN-RVDs 3 Fwd 7 TAL017, 
TAL022 TALEN-RVDs 4 Rev 8 
TALEN-RVDs 1 Fwd 9 TAL009, 
TAL012 TALEN-RVDs 2 Rev 10 
TALEN-RVDs 3 Fwd 11 TAL019, 
TAL024 TALEN-RVDs 4 Rev 12 
TALEN-RVDs 1 Fwd 13 TAL007, 
TAL012 TALEN-RVDs 2 Rev 14 
TALEN-RVDs 3 Fwd 15 TAL017, 
TAL022 TALEN-RVDs 4 Rev 16 








TALEN-RVDs 1-4 Rev 2 
  3 
  4 




TALEN-RVDs 5-8 Rev 6 
  7 
  8 




TALEN-RVDs 9-12 Rev 10 
  11 
  12 




TALEN-RVDs 13-16 Rev 14 
  15 
  16 




TALEN-RVDs 1-4 Rev 2 
  3 
  4 




TALEN-RVDs 5-8 Rev 6 
  7 
  8 




TALEN-RVDs 9-12 Rev 10 
  11 
  12 




TALEN-RVDs 13-16 Rev 14 
  15 
  16 
 
Table 20. TALEN 2 repeat array assembly via three step PCR method 
PCR step TALEN name Primer name RVD number Plasmid 
1 T2 left arm  TALEN-RVDs 1 Fwd 1 TAL009 
TALEN-RVDs 1 Rev 5 TAL007 
  9 TAL009 
  13 TAL006 
TALEN-RVDs 2 Fwd 2 TAL012 
TALEN-RVDs 2 Rev 6 TAL012 
  10 TAL012 
  14 TAL012 




TALEN-RVDs 3 Fwd 3 TAL020 
TALEN-RVDs 3 Rev 7 TAL017 
  11 TAL017 
  15 TAL017 
TALEN-RVDs 4 Fwd 4 TAL024 
TALEN-RVDs 4 Rev 8 TAL024 
  12 TAL025 
  16 TAL024 
T2 right arm TALEN-RVDs 1 Fwd 1 TAL009 
TALEN-RVDs 1 Rev 5 TAL009 
  9 TAL007 
  13 TAL009 
TALEN-RVDs 2 Fwd 2 TAL014 
TALEN-RVDs 2 Rev 6 TAL014 
  10 TAL011 
  14 TAL012 
TALEN-RVDs 3 Fwd 3 TAL017 
TALEN-RVDs 3 Rev 7 TAL017 
  11 TAL017 
  15 TAL017 
TALEN-RVDs 4 Fwd 4 TAL025 
TALEN-RVDs 4 Rev 8 TAL022 
  12 TAL025 






















T2 left arm TALEN-RVDs 1 Fwd 1 TAL009, 
TAL012 TALEN-RVDs 2 Rev 2 
TALEN-RVDs 3 Fwd 3 TAL020, 
TAL024 TALEN-RVDs 4 Rev 4 
TALEN-RVDs 1 Fwd 5 TAL007, 
TAL012 TALEN-RVDs 2 Rev 6 
TALEN-RVDs 3 Fwd 7 TAL017, 
TAL024 TALEN-RVDs 4 Rev 8 
TALEN-RVDs 1 Fwd 9 TAL009, 
TAL012 TALEN-RVDs 2 Rev 10 
TALEN-RVDs 3 Fwd 11 TAL017, 
TAL025 TALEN-RVDs 4 Rev 12 
TALEN-RVDs 1 Fwd 13 TAL006, 
TAL012 TALEN-RVDs 2 Rev 14 
TALEN-RVDs 3 Fwd 15 TAL017, 
TAL024 TALEN-RVDs 4 Rev 16 




TALEN-RVDs 1 Fwd 1 TAL009, 
TAL014 TALEN-RVDs 2 Rev 2 
TALEN-RVDs 3 Fwd 3 TAL017, 
TAL025 TALEN-RVDs 4 Rev 4 










TALEN-RVDs 1 Fwd 5 TAL009, 
TAL014 TALEN-RVDs 2 Rev 6 
TALEN-RVDs 3 Fwd 7 TAL017, 
TAL022 TALEN-RVDs 4 Rev 8 
TALEN-RVDs 1 Fwd 9 TAL007, 
TAL011 TALEN-RVDs 2 Rev 10 
TALEN-RVDs 3 Fwd 11 TAL017, 
TAL025 TALEN-RVDs 4 Rev 12 
TALEN-RVDs 1 Fwd 13 TAL009, 
TAL012 TALEN-RVDs 2 Rev 14 
TALEN-RVDs 3 Fwd 15 TAL017  
TALEN-RVDs 4 Rev   




TALEN-RVDs 1-4 Rev 2 
  3 
  4 




TALEN-RVDs 5-8 Rev 6 
  7 
  8 




TALEN-RVDs 9-12 Rev 10 
  11 
  12 




TALEN-RVDs 13-16 Rev 14 
  15 
  16 




TALEN-RVDs 1-4 Rev 2 
  3 
  4 




TALEN-RVDs 5-8 Rev 6 
  7 
  8 




TALEN-RVDs 9-12 Rev 10 
  11 
  12 
TALEN-RVDs 13-16 Fwd 13 TAL009, 
TAL012, 
TAL017  
TALEN-RVDs 13-16 Rev 14 
  15 
    
 




Table 21. Primers used to assemble TALEN repeat arrays 
Primer name Primer sequence (5’ → 3’) 
TALEN-RVDs 1 Fwd  CTGACCCCAGACCAGGTAGTCGCA 
TALEN-RVDs 1 Rev  CACGACTTGATCCGGTGTAAGGCCGTGGTCTTGACAAAGG 
TALEN-RVDs 2 Fwd  CCTTTGTCAAGACCACGGCCTTACACCGGATCAAGTCGTG 
TALEN-RVDs 2 Rev  TACAACTTGATCGGGAGTCAGCCCGTGGTCTTGACAGAGA 
TALEN-RVDs 3 Fwd  TCTCTGTCAAGACCACGGGCTGACTCCCGATCAAGTTGTA 
TALEN-RVDs 3 Rev  GACCACTTGGTCAGGCGTCAAACCGTGATCTTGACACAAC 
TALEN-RVDs 4 Fwd  GTTGTGTCAAGATCACGGTTTGACGCCTGACCAAGTGGTC 
TALEN-RVDs 4 Rev  TCCATGATCCTGGCACAGTACAGG 
TALEN-RVDs 1-4 Fwd  tcagGGTCTCAGAACCTGACCCCAGACCAGGTAGTC 
TALEN-RVDs 1-4 Rev  tcagGGTCTCTAGTCCATGATCCTGGCACAGT 
TALEN-RVDs 5-8 Fwd  tcagGGTCTCAGACTGACCCCAGACCAGGTAGTC 
TALEN-RVDs 5-8 Rev  tcagGGTCTCTGTCAGTCCATGATCCTGGCACAGT 
TALEN-RVDs 9-12 Fwd  tcagGGTCTCATGACCCCAGACCAGGTAGTC 
TALEN-RVDs 9-12 Rev  tcagGGTCTCTCAGTCCATGATCCTGGCACAGT 
TALEN-RVDs 13-16 Fwd  tcagGGTCTCAACTGACCCCAGACCAGGTAGTC 
TALEN-RVDs 13-16 Rev  tcagGGTCTCTTCAGTCCATGATCCTGGCACAGT 
 
Plasmids derived from PCR steps 1 and 2 were purified by gel extraction using 
QIAquick Gel Extraction Kit (Qiagen, #28706) and the final TALE repeat array 
plasmids derived from PCR step 3 were purified using QIAquick PCR Purification Kit 
(Qiagen, #28106). The TALE repeat arrays were then digested with restriction 
enzyme BsaI-HF (New England Biolabs, #R3535S) for 2 hours at 37°C then purified by 
gel extraction, while the respective vector backbones for each TALE repeat array 
(Table 22) were digested with restriction enzyme BsmBI (New England Biolabs, 
#R0580S) for 3 hours at 55°C then purified by gel extraction. The TALE repeat array 
were next ligated with their respective vector backbones by using T4 DNA ligase 
(New England Biolabs, #M0202S) for 2 hours at room temperature. The success of 
the TALEN assembly was verified by Sanger sequencing (Table 23). 
 
Table 22. TALE repeat arrays and their corresponding vector backbone 
TALEN name Vector backbone 
T1 left arm JDS78 
T1 right arm JDS74 
T2 left arm JDS78 
T2 right arm JDS71 
 




Table 23. Primers used for sequencing TALEN assembly 
Primer name Primer sequence (5’ → 3’) 
TALEN-006seq Fwd TCGCAATCGCGTCGAACATTG 
TALEN-006seq Rev GCTTGCTTTCCCCCAATGTTC 
TALEN-007seq Fwd TCGCAATCGCGTCACATGAC 
TALEN-009seq Fwd TCGCAATCGCGTCAAATCAT 
TALEN-009seq Rev CTTGCTTTCCCCCATGATTT 
TALEN-010seq Fwd TCGGCAATCGCGTCAAACGGA 
TALEN-010seq Rev CTTGCTTTCCCCCTCCGTTT 
TALEN-011seq Fwd GTGGCCATTGCAAGCAACATC 
TALEN-011seq Rev GAGCCTGTTTGCCACCGATG 
TALEN-012seq Fwd TGGCCATTGCATCCCACGAC 
TALEN-012seq Rev CTGTTTGCCACCGTCGTGG 
TALEN-020seq Rev AATGCTTGTTTCCCTCCACCG 
TALEN-022seq Rev CTGCTTACCGCCATCATGG 
TALEN-024NHseq Rev AGCGCCTGCTTACCGCCATG 
TALEN-025seq Fwd TCGCCATCGCCTCGAATGGC 
TALEN-025seq Rev CTGCTTACCGCCGCCATTC 
 
Next, the assembled TALEN arms were cloned into vectors containing a CAG 
promoter and an antibiotic resistance gene (Table 24) that were already available in 
the lab. To do this, the TALEN arms were PCR amplified using PrimeSTAR Max DNA 
polymerase using primers listed in Table 25 and PCR conditions listed in Table 26. 
They were then purified using QIAquick PCR Purification Kit, digested by NheI 
restriction enzyme (New England Biolabs, #R0131S), blunted using Quick Blunting Kit 
(New England Biolabs, #E1201S) for 5 min at 72°C, purified using QIAquick PCR 
Purification Kit once more, digested by XhoI restriction enzyme (New England 
Biolabs, #R0146S), then gel purified by gel extraction. For the vectors, they were first 
digested by EcoRI-HF restriction enzyme (New England Biolabs, # R3101S), blunted 
as described earlier, purified using QIAquick PCR Purification Kit, digested by XhoI 
restriction enzyme, then gel purified by gel extraction. The TALEN arms were next 
ligated with their respective vector containing the appropriate antibiotic resistance 
gene by using T4 DNA ligase for 2 hours at room temperature. The final TALEN 
constructs were then sequenced to confirm that the TALEN arms were cloned in the 
correct orientation (Table 27). 
 




Table 24. Antibiotic resistance gene specific to each TALEN arm 
TALEN construct name Antibiotic resistance gene 
T1 left arm Puromycin 
T1 left arm Blasticidin 
T1 right arm Zeocin 
T2 left arm Puromycin 
T2 right arm Zeocin 
 
 
Table 25. Primers used to amplify TALEN arms 
Primer name Primer sequence (5’ → 3’) 
T7 fwd AATACGACTCACTATAG 
TALEN-pCAG-IRES Rev AACTTTTAAACCGGTCTCGAGCTGA 
 
 
Table 26. Parameters for PCR cycling reaction to amplify TALEN arms 











Soak 4°C Indefinite 1 
 
 
Table 27. Primers used for sequencing TALEN constructs 
Primer name Primer sequence (5’ → 3’) 
pre-KpnI TALEN-Core-Fwd GTTGTAAAACGACGGCCAGTG 
025seq-Fwd TCGCCATCGCCTCGAATGGC 
post-BamHI TALEN-Core-Rev TACGCCAAGCTTGCATGCAGG 
Fok1-Fwd GTGAACTGGAGGAGAAGAAATCTG 










A donor plasmid aimed at terminating transcription of GATA6 prematurely by 
inserting a ‘donor template’ through HR was also constructed. Within the donor 
plasmid is a cassette which contains 5’ and 3’ homology arms each 1kb in length 
recognising the flanking regions of the TALEN 1 target site, an EmGFP gene, a 
puromycin antibiotic resistant gene and a polyA tail. PCR amplification of genomic 
DNA from H9 hESC line and a vector already available in the lab containing the 
EmGFP gene, puromycin gene and polyA tail was performed to obtain PCR products 
of the 5’ and 3’ homology arms and the other components of the donor plasmid 
respectively (Table 28). PCR was performed using PrimeSTAR Max DNA polymerase 
and conditions listed in Table 26. The PCR products were then ligated and the final 
construct was sequenced to confirm that the donor plasmid was cloned successfully 
(Table 29). 
 
Table 28. Primers used to construct the donor plasmid 
Primer name Primer sequence (5’ → 3’) 
5' Arm-KpnI-GATA6 Fwd tcagGGTACCTTTGGGGTCGCCTCGGCTCTGG 
5' Arm-GATA6 Rev CTTGCTCACCATGGTGGCCACGGTCCGGCGCCGCTCCAA 
5' Arm-GATA6-emGFP Fwd CGCCGGACCGTGGCCACCATGGTGAGCAAGGGCGAGGAGC 
3' Arm-XbaI-TALEN1 Fwd tcagTCTAGAAAGCGCTTCGGGGCCGCGGGTG 
3' Arm-SacI-TALEN1 Rev tcagGAGCTCTGGCGCCCCCACGTAGGGCGAG 
 
 
Table 29. Primers used for sequencing donor plasmid 






M13-Rev (-24) GGAAACAGCTATGACCATG 
M13-Fwd (-20) GTAAAACGACGGCCAGT 








2.3.2. Introducing constructs into hPSCs 
Electroporation using the Amaxa Nucleofector Technology (Lonza, Human 
Stem Cell Nucleofector Kit 1) was used to introduce the TALEN constructs and donor 
plasmid into the hPSCs. Cells were grown in 6 well plates to a confluency of 70-80%, 
then washed once with D-PBS and treated with 0.5 ml of StemPro Accutase Cell 
Dissociation Reagent (Gibco, #A1110501) per well for 5 min at 37°C. 1 ml of 5% fetal 
bovine serum (FBS; Gibco, #10082147) diluted in D-PBS was added per well and the 
cells were detached from the wells by gentle pipetting. Cells were collected in a 15 
ml tube and an aliquot was taken for cell counting. Cell counting was performed 
using an automated cell counter (Biorad, TC20). 8 x 105 cells were used per 
electroporation and the appropriate volume that contained 8 x 105 cells was taken 
and divided into individual 15 ml tubes. The tubes were centrifuged at 1,200 rpm to 
pellet the cells. Cells were electroporated with a pre-determined amount of DNA for 
each construct. Electroporation was performed according to the manufacturer’s 
protocol using Nucleofector programme B-016. The electroporated cells were next 
plated as single cells onto 10 cm dishes containing 10 ml of E8 with ROCK inhibitor. 
 
  




2.4. Generation of GATA6 mutant lines 
2.4.1. Non-homologous end joining (NHEJ) pathway 
TALENs were introduced into H9 and FSPS13.B hPSC lines via electroporation 
as described in section 2.3.2. For electroporation, 2.5 μg of DNA for each of the 
corresponding TALEN arm was used (Table 30). 24 hr after electroporation, 
simultaneous antibiotic selection of 1 μg/ml puromycin (Sigma-Aldrich, #P8833) and 
2.5 μg/ml zeocin (Gibco, #R250-01) was done for 24 hr, after which the cells were 
allowed to recover and form colonies. Colonies formed approximately 7 days after 
the antibiotic selection, and they were individually picked using a pipette tip, re-
plated and expanded. During picking of each colony, half of one colony was re-plated 
whereas the other half was pipetted into 8-tube PCR strips for subsequent screening. 
 







Amount of DNA 
electroporated 
1 T1 left arm Puromycin 2.5 μg 
T1 right arm Zeocin 2.5 μg 
2 T2 left arm Puromycin 2.5 μg 
T2 right arm Zeocin 2.5 μg 
 
 
Screening of the colonies was performed by first extracting the genomic DNA 
of each colony using a direct PCR approach. 150-200 µl of D-PBS was added to each 
tube on the PCR strips. The strips were next centrifuged for 10 s to pellet the cells. 
The supernatant was removed carefully and 10 µl of Proteinase K reaction mix was 
added to each tube containing cells from one colony (Table 31 and Table 32). The 
strips were then loaded onto a PCR machine and subjected to conditions listed in 
Table 33 for genomic extraction. PCR of the genomic region flanking the TALEN 1 and 
2 target sites was performed using PrimeSTAR GXL DNA polymerase (Takara, 
#R050A) and the reagents were set up as shown in Table 34. PCR cycling conditions 
are shown in Table 35 using primers listed in Table 36. 
 
  




Table 31. 50X detergent mix formulation  
Component Volume 
Tween-20 10 µl 
Igepal CA-630 10 μl 
dH2O 180 μl 
 
Table 32. Proteinase K reaction mix formulation 
Component Volume 
50x detergents mix 0.2 µl 
5x PrimeSTAR GXL PCR Buffer 2 µl 
20 mg/mL Proteinase K 0.2 µl 
dH2O 7.6 µl 
 
Table 33. Parameters for PCR cycling conditions for genomic DNA extraction 
Temperature Time 
50°C 30 min 
95°C 5 min 
4°C Indefinitely 
 
Table 34. Volume of reagents in genomic PCR reaction 
Component Volume 
dH2O 13.4 µl 
5x PrimeSTAR GXL PCR Buffer 4 µl 
2.5 mM dNTP 1.6 µl 
100 μM Primer Fwd 0.05 µl 
100 μM Primer Rev 0.05 µl 
Genomic DNA 0.5 µl 
PrimeSTAR GXL DNA polymerase 0.4 µl 
 
Table 35. Parameters for PCR to amplify TALEN 1 and 2 genomic regions 






















Soak 4°C ∞ 1 




Table 36. Primers used to amplify TALEN 1 and 2 genomic regions 
TALEN target site  Primer sequence (5’ → 3’) 
1 F CTTTGAGAAGTCAGATCCCATTTGA 
R CGCCTCCGCTGCCGTATGGAGGGCT 
2 F CGCCAGCAAGCTGCTGTGGTCCAGC 
R TCCGCGCACCCGGACGAGAAAGTCC 
 
 The PCR products were next treated with ExoSAP-IT (Affymetrix, #78250) 
then digested with restriction enzymes AfeI (New England Biolabs, #R0652S) and PstI 
(New England Biolabs, #R0140S) for TALEN 1 and TALEN2 PCR products respectively 
for 1 hr at 37°C. The digested PCR products were analysed by agarose gel 
electrophoresis as a first pass screen for any mutations. PCR products of the colonies 
that showed a potential for the occurrence of mutations were next sent for 
sequencing as a second pass screen and confirmation for mutations using forward 
primers listed in Table 36.  
  




2.4.2. Homologous recombination (HR) pathway 
TALENs were introduced into H9 and FSPS13.B hPSC lines via electroporation 
as described in section 2.3.2. For electroporation, 2 μg of DNA for each TALEN arm 
targeting the TALEN 1 site and 1 μg of DNA for the donor plasmid was used (Table 
37). 24 hr after electroporation, simultaneous antibiotic selection of 3.5 μg/ml 
blasticidin and 1 μg/ml puromycin was done for 24 hr. After which, simultaneous 
antibiotic selection of 3.5 μg/ml blasticidin and 2.5 μg/ml zeocin was done for the 
next 24 hours. Colonies formed approximately 7 days after the antibiotic selection, 
and they were individually picked using a pipette tip, re-plated and expanded. 
Genomic DNA was performed the same way as described in section 2.4.1. Successful 
HR was determined by PCR using PrimeSTAR GXL DNA polymerase (Takara, #R050A) 
with reaction mix listed in Table 38. The PCR cycling conditions are shown in Table 39 
using forward and reverse primers for the TALEN 1 target site listed in Table 36. 
Colonies that showed positive HR via PCR were confirmed by sequencing. 
 







Amount of DNA 
electroporated 
1 T1 left arm Blasticidin 2 μg 
T1 right arm Zeocin 2 μg 
Donor plasmid Puromycin 1 μg 
 
 
Table 38. Volume of reagents in PCR reaction to check for HR 
Component Volume 
dH2O 13.4 µl 
5x PrimeSTAR GXL PCR Buffer 4 µl 
2.5 mM dNTP 1.6 µl 
100 μM Primer Fwd 0.05 µl 
100 μM Primer Rev 0.05 µl 
Genomic DNA 50 ng 
PrimeSTAR GXL DNA polymerase 0.4 µl 
 
  




Table 39. Parameters for PCR cycling reaction to check for HR 
TALEN target site Step Temperature Time Number of cycles 











Final extension 68°C 2 min 1 








2.5. Western blot 
2.5.1. Cell lysate preparation and normalisation 
hPSCs or their differentiated progenitors were washed once in D-PBS and 
incubated in 0.5 ml of Accutase per well of a 6 well plate for 5 min at 37°C. The 
Accutase was neutralised by adding 1 ml of 5% FBS diluted in D-PBS per well and the 
cells were dissociated by gentle pipetting. The cells were washed twice with D-PBS 
and pelleted by centrifuging at 1,200 rpm. The pelleted cells were re-suspended in 
50-200 µl of Lysis Buffer (Table 40) containing freshly added inhibitors cOmplete 
Protease Inhibitor Cocktail (Roche, #11697498001), Sodium Fluoride (NaF; New 
England Biolabs, #P0759), Sodium Vanadate (Na3VO4; New England Biolabs, #P0758) 
according to Table 41. One tablet of the cOmplete Protease Inhibitor Cocktail was 
dissolved in 1 ml of Lysis Buffer to make up a 25x stock solution. The cell lysates 
were kept on ice for at least 15 min, vortexed at maximum speed for 15 s then 
centrifuged for 30 min at 15,000 g at 4°C. The supernatants were collected and 
protein concentrations were determined by Bradford assay (Protein Assay Dye 
Reagent Concentrate, Bio-Rad) according to the manufacturer’s protocol. The 
protein concentrations of the cell lysates were normalised to 10 µg of protein for 
probing with GATA6 and GATA4 and 1 µg for probing with alpha-tubulin. The 
normalised cell lysates were heat denatured at 98°C in the presence of Laemmli 
Sample Buffer (Bio-Rad) and β-mercaptoethanol for 5 min, then subjected to SDS-
PAGE electrophoresis. 
 
Table 40. Lysis Buffer formulation 
Component Working concentration 
1M Tris-Cl pH 7.5 (Cambridge Bioscience, #600201) 50mM 
5M NaCl (Ambion, #AM9759) 150mM 
Triton X-100 (Sigma-Aldrich, #T8787) 1% 
Glycerol (Sigma-Aldrich, #49781) 10% 
Deocycholate (Sigma-Aldrich, #D6750) 0.1% 








Table 41. Lysis Buffer with protease inhibitors formulation 
Component Volume 
25x Complete solution 40 µl 
Lysis Buffer 930 µl 
50 mM NaF 20 µl 
100 mM Na3VO4 10 µl 
 
2.5.2. SDS-page, blotting and blocking 
  
Electrophoresis of NuPAGE Novex 4-12% Bis-Tris Protein Gels was performed 
using the XCell SureLock Mini-Cell (Invitrogen). 1x SDS Running Buffer was prepared 
by adding 50 ml of 20x NuPAGE MOPS SDS Running Buffer to 950 ml deionised 
water. Precision Plus protein kaleidoscope standards (Bio-Rad, #161-0375) protein 
ladder was used. Electrophoresis was carried out at a constant volt of 120 V until the 
ladders were completely separated. The separated proteins were next transferred 
from the gel onto Immun-Blot PVDF membrane (Bio-Rad, #162-0177) using Mini 
Trans-Blot Cell (Bio-Rad) at 25 V overnight at 4°C. 
 
2.5.3. Antibody incubation and detection 
 
The membranes were incubated shaking in 5% Blotting-Grade Blocker (Bio-
Rad, #170-6404) diluted in 0.1% Triton X-100 in D-PBS (PBST) for 1 hr at room 
temperature. The blocking solution was removed and primary antibodies (Table 42) 
diluted in PBST were added to the membranes and incubated shaking for 2 hr at 
room temperature. Membranes were then subjected to three 10 min washes in PBST 
and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies 
in 5% Blotting-Grade Blocker in PBST for 1 hr at room temperature while shaking. 
Unbound antibodies were removed by three 10 min washes while shaking in PBST. 
Proteins were detected via chemiluminescence using SuperSignal West Femto 
Maximum Sensitivity Substrate (ThermoFisher Scientific, #PI34095) and finally 








Table 42. Antibodies used in western blot experiments 
Primary antibody Dilution ratio Duration Expected molecular weight  
Rabbit anti-human GATA6 
(N-terminus;  
Cell Signaling, #5851) 
1:2000 2 hr Long isoform: 64 kDa 
Short isoform: 52 kDa 
Rabbit anti-human GATA6 
(C-terminus;  
Cell Signalling, #4253) 
1:2000 2 hr Short isoform: 52 kDa 
Rabbit anti-human GATA4 
(Cell Signalling, #36966) 
1:2000 2 hr 55 kDa 
Mouse anti-alpha-Tubulin 
(Sigma-Aldrich, #T6199) 
1:5000 1 hr 50 kDa 
Secondary antibody Dilution ratio Duration  
Anti-Rabbit IgG- 
Peroxidase antibody 
produced in goat  
(Sigma-Aldrich, #A6154) 
1:10,000 1 hr - 
Anti-Mouse IgG- 
Peroxidase antibody 
produced in goat  
(Sigma-Aldrich, #A5278) 
1:10,000 1 hr - 
 
  




2.6. Immunocytochemistry (ICC)  
2.6.1. Fixation and blocking 
Cells in 12 well plates were fixed by aspirating the culture media then 
immediately adding 500 µl of 4% paraformaldehyde (PFA; VWR, #43368.9M) solution 
diluted in D-PBS per well and incubating for 20 min at 4°C. They were then washed 
thrice in D-PBS. Cells were next incubated in 500 µl of PBST (0.1% Triton X-100 in D-
PBS) containing 10% donkey serum (AbD Serotec, #C06SB) per well for 20 min at 
room temperature for blocking. 
 
2.6.2. Antibody incubation and detection 
Cells in 12 well plates were then incubated overnight at 4°C with 300 µl of 
primary antibodies (Table 43) diluted in PBST containing 1% donkey serum. Cells 
were then washed thrice with PBST to remove unbound primary antibodies and 
thereafter incubated with 300 µl of fluorescence-dye-conjugated secondary 
antibodies (Table 43) diluted in PBST containing 1% donkey serum in for 1 hr at room 
temperature. Unbound antibodies were removed by three 5 min washes in D-PBS. 
4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich, #D-8417) at a 
dilution of 1:1000 was added to the first wash. 
  




Table 43. Antibodies used in immunocytochemistry experiments 
Primary antibody Dilution ratio Duration 
Goat anti-human Nanog (R&D, #AF1997) 1:100 Overnight 
Goat anti-human Sox2 (R&D, #AF2018) 1:100 Overnight 
Goat anti-human Oct4 (Santa Cruz, #sc-8628) 1:100 Overnight 
Rabbit anti-human Eomes (Abcam, #Ab23345) 1:100 Overnight 
Rabbit anti-human GATA6 (Cell Signaling, #5851) 1:200 Overnight 
Mouse anti-human GATA4 (Santa Cruz, #sc25310) 1:100 Overnight 
Goat anti-human Sox17 (R&D, #AF1924) 1:200 Overnight 
Goat anti-human FoxA2 (R&D, #AF2400) 1:100 Overnight 
Mouse anti-human Hex (Abcam, #Ab117864) 1:100 Overnight 
Mouse anti-human CDX2 (CDX-88; Abcam, #Ab86949) 1:100 Overnight 
Goat anti-human HNF1B C-20 (Santa Cruz, #sc7411) 1:100 Overnight 
Rabbit anti-human HNF4A H-171 (Santa Cruz, #sc8987) 1:100 Overnight 
Rabbit anti-human HNF6 H-100 (Santa Cruz, #sc13050) 1:100 Overnight 
Goat anti-human PDX1 (R&D, #AF2419) 1:100 Overnight 
Rabbit anti-human Sox9 H-90 (Santa Cruz, #sc20095) 1:100 Overnight 
Sheep anti-human NGN3 (R&D, #AF3444) 1:100 Overnight 
Mouse anti-human C-Peptide  
(Acris Antibodies, #BM270S) 
1:100 Overnight 
Goat anti-human Glucagon G-17 (Santa Cruz, #sc7780) 1:100 Overnight 
Rabbit anti-human Somatostatin (Daka, #A0566) 1:200 Overnight 
Secondary antibody Dilution ratio Duration 
Alexa Fluor 568 Donkey Anti-Goat IgG (H+L) 
(Invitrogen, #A11057) 
1:1000 1 hr 
Alexa Fluor 568 Donkey Anti-Mouse IgG (H+L) 
(Invitrogen, #A10037) 
1:1000 1 hr 
Alexa Fluor 568 Donkey Anti-Rabbit IgG (H+L) 
(Invitrogen, #A10042) 
1:1000 1 hr 
Alexa Fluor 568 Donkey Anti-Sheep IgG (H+L) 
(Invitrogen, #A21099) 
1:1000 1 hr 
Alexa Fluor 488 Donkey anti-Goat IgG (H+L) 
(Invitrogen, #A11055) 
1:1000 1 hr 
Alexa Fluor 488 Donkey anti-Mouse IgG (H+L) 
(Invitrogen, #A21202) 
1:1000 1 hr 
Alexa Fluor 488 Donkey anti-Rabbit IgG (H+L) 
(Invitrogen, #A21206) 
1:1000 1 hr 
Alexa Fluor 488 Donkey anti-Sheep IgG (H+L) 
(Invitrogen, #A11015) 
1:1000 1 hr 
Alexa Fluor 647 Donkey anti-Goat IgG (H+L) 
(Invitrogen, #A21447) 
1:1000 1 hr 
Alexa Fluor 647 Donkey anti-Mouse IgG (H+L) 
(Invitrogen, #A31571) 
1:1000 1 hr 
Alexa Fluor 647 Donkey anti-Rabbit IgG (H+L) 
(Invitrogen, #A31573) 
1:1000 1 hr 




2.7. Fluorescence activated cell sorting (FACS) analysis 
2.7.1. Cell preparation 
Cells in 12 well plates were washed twice in D-PBS and incubated in 0.3 ml of 
Accutase per well for 5 min at 37°C. The Accutase was neutralised by adding 0.6 ml 
of 5% FBS diluted in D-PBS and the cells were dissociated by gentle pipetting. Cells 
were re-suspended in D-PBS at approximately 0.1-1 x 106 cells/ml and washed twice 
with D-PBS. They were then pelleted and fixed by re-suspending in 500 µl of 4% PFA 
solution diluted in D-PBS per well and incubating at for 20 min at 4°C, then washed 
twice in D-PBS. 
 
2.7.2. Antibody incubation and detection 
Next, for all primary antibodies except CXCR4, cells were permeabilised in 
500 µl of D-PBS containing 1% Saponin (Sigma-Aldrich, #47036-50G-F) for 30 min at 
room temperature. Cells were then incubated for 2 hr at room temperature with 
primary antibody (Table 44) diluted in 100 µl of Staining Solution (1% Saponin and 
5% FBS in D-PBS). After which, they were washed three times with 1 ml of Staining 
Solution per wash and incubated with secondary antibodies (Table 44) diluted in 100 
µl of Staining Solution for 30 min at room temperature. Unbound antibody was then 
removed by three washes in 1 ml of Staining Solution per wash and cells were re-
suspended in 200 µl of 2% FBS diluted in D-PBS prior to analysis.  
 
For CXCR4 staining, cells were fixed in 4% PFA and washed as described 
above. Thereafter, primary antibody (Table 44) diluted in 100 µl of 5% FBS in D-PBS 
was added to the cells and incubated for 1 hr at room temperature. Unbound 
antibody was then removed by three washes of 1ml 2% FBS in D-PBS per wash. Cells 
were then re-suspended in 200 µl of 2% FBS in PBS prior to analysis.  
 
Analyses were performed using a BD LRSFortessa cell analyser (BD 
Biosciences). All flow cytometry experiments were gated using unstained cells. On all 
flow cytometry plots, the undifferentiated population is shown in blue. All gates 
shown on scatterplots were set according to the undifferentiated population control.    




Table 44. Antibodies used in FACS experiments 
Primary antibody Dilution ratio Duration 
Goat anti-human Sox17 (R&D, #AF1924) 1:20 2 hr 
Rabbit anti-human GATA6 (Cell Signaling, #5851) 1:20 2 hr 
Goat anti-human PDX1 (R&D, #AF2419) 1:20 2 hr 
Sheep anti-human NGN3 (R&D, #AF3444) 1:20 2 hr 
Mouse anti-human C-Peptide  
(Acris Antibodies, #BM270S) 
1:100 2 hr 
Goat anti-human Glucagon G-17 (Santa Cruz, #sc7780) 1:20 2 hr 
Rabbit anti-human Somatostatin (Daka, #A0566) 1:200 2 hr 
Secondary antibody Dilution ratio Duration 
Alexa Fluor 568 Donkey Anti-Goat IgG (H+L) 
(Invitrogen, #A11057) 
1:1000 30 min 
Alexa Fluor 568 Donkey Anti-Mouse IgG (H+L) 
(Invitrogen, #A10037) 
1:1000 30 min 
Alexa Fluor 568 Donkey Anti-Rabbit IgG (H+L) 
(Invitrogen, #A10042) 
1:1000 30 min 
Alexa Fluor 568 Donkey Anti-Sheep IgG (H+L) 
(Invitrogen, #A21099) 
1:1000 30 min 
Alexa Fluor 647 Donkey anti-Mouse IgG (H+L) 
(Invitrogen, #A31571) 
1:1000 30 min 
Alexa Fluor 488 Donkey anti-Rabbit IgG (H+L) 
(Invitrogen, #A21206) 
1:1000 30 min 
Conjugated primary and secondary antibody Dilution ratio Duration 
Anti-Human CD184 (CXCR4) PE  
(eBioscience, #12-9999-41) 
1:50 1 hr 
 
  




2.8. Quantitative RT-PCR (qRT-PCR) 
2.8.1. Total RNA isolation 
Cells were grown in 12 well plates for total RNA isolation. 3 wells were 
harvested per sample to obtain technical triplicates. RNeasy Mini Kit together with 
the Qiacube (Qiagen) was used for total RNA extraction. Cell culture media was 
aspirated and the cells were washed once with D-PBS. The D-PBS was completely 
aspirated and cells were lysed directly in the 12 well plates by adding 350 µl of Buffer 
RLT. Cell lysates were transferred to 2 ml tubes and were either frozen at -80°C or 
used immediately with the Qiacube for RNA extraction. Each sample was treated 
with RNase-Free DNase (Qiagen) to avoid DNA contamination. RNA was eluted in a 
volume of 30 µl. RNA was either frozen at -80°C or immediately taken to the next 
step of first strand cDNA synthesis. If RNA samples were frozen, they were thawed 
on ice to prevent degradation. 
 
2.8.2. First strand cDNA synthesis 
500 ng of RNA samples were made up to a total volume of 11.875 µl with 
nuclease free water. The following components were then added to a nuclease-free 
96 well plate (Table 45).  
 
Table 45. Reagents to denature RNA and primer 
Component Volume 
500 ng of total RNA 11.875 µl 
Random primer (Promega, #C1181) 0.5 µl 
dNTP (Promega, #U1511) 1 µl 
 
The plate was centrifuged briefly to ensure that the reagents were at the 
bottom of the tube. The plate was incubated in a PCR machine for 5 min at 65°C then 
quickly chilled on ice. The plate was again centrifuged briefly and the reagents listed 
in Table 46 were prepared as a master mix then added to the samples. The final 
volume of each sample was 20 µl.  
 




Table 46. Reagents for reverse transcription of RNA 
Component Volume 
5x First-strand buffer 4 µl 
0.1 M DTT 2 µl 
RNaseOUT™ Recombinant Ribonuclease Inhibitor (Invitrogen, 
#10777019) 
0.5 µl 
SuperScript® II Reverse Transcriptase (Invitrogen, #18064014) 0.125 µl 
 
 The plate was again centrifuged briefly to ensure that all reagents were at the 
bottom of the tube. The plate was then incubated in a PCR machine programmed at 
10 min at 25°C for the primer annealing step, 50 min at 42°C for the extension step, 
and finally 15 min at 70°C for the inactivation of the enzyme. The resulting cDNA was 
diluted to a final volume of 600 µl with nuclease-free water prior to use for qRT-PCR. 
 
2.8.3. qRT-PCR 
qRT-PCR master mix was prepared using Sensi Mix Sybr Low Rox Kit (Bioline, 
#QT625-20). The reaction was prepared according to Table 47.  
 
Table 47. Reagents for qRT-PCR 
Component Volume 
cDNA template 5 µl 
Forward primer (5 µM) 0.6 µl 
Reverse primer (5 µM) 0.6 µl 
Sensi Mix (2x) 7.5 µl 
Nuclease free water 1.3 µl 
 
 
qRT-PCR reactions were performed using Mx3005P system (Stratagene) with 
cycling conditions as listed in Table 48. Samples were run in technical triplicates and 
normalised to PBGD. Gene-specific primers are listed in Table 49. Data represents 
the mean of one experiment which is representative of three independent 








Table 48. Parameters for qRT-PCR cycling conditions 
Stage Cycles Temperature Time 
1 1 95°C 10 min 
2 40 95°C 30 s 
60°C 30 s 
72°C 30 s 
3 1 95°C 1 min 
55°C 30 s (↑ 1°C/30 s) 
95°C 30 s 
 
 
Table 49. Primers used in qRT-PCR 
Gene  Primer sequence (5’ → 3’) 
OCT4 F AGTGAGAGGCAACCTGGAGA  
R ACACTCGGACCACATCCTTC  
NANOG F CATGAGTGTGGATCCAGCTTG 
R CCTGAATAAGCAGATCCATGG 
SOX2 F TGGACAGTTACGCGCACAT 
R CGAGTAGGACATGCTGTAGGT 
GSC F GAGGAGAAAGTGGAGGTCTGGTT 
R CTCTGATGAGGACCGCTTCTG 
BRACHURY F TGCTTCCCTGAGACCCAGTT 
R GATCACTTCTTTCCTTTGCATCAAG 
EOMESODERMIN F ATCATTACGAAACAGGGCAGGC 
R CGGGGTTGGTATTTGTGTAAGG 
GATA4 F TCCCTCTTCCCTCCTCAAAT 
R TCAGCGTGTAAAGGCATCTG 
GATA6 F TGTGCAATGCTTGTGGACTC 
R AGTTGGAGTCATGGGAATGG 
SOX17 F CGCACGGAATTTGAACAGTA 
R GGATCAGGGACCTGTCACAC 
CXCR4 F CACCGCATCTGGAGAACCA 
R GCCCATTTCCTCGGTGTAGTT 
FOXA2 F GGGAGCGGTGAAGATGGA 
R TCATGTTGCTCACGGAGGAGTA 
GCG F AAGCATTTACTTTGTGGCTGGATT 
R TGATCTGGATTTCTCCTCTGTGTCT 
HLXB9 F CACCGCGGGCATGATC 
R ACTTCCCCAGGAGGTTCGA 
HNF1B F TCACAGATACCAGCAGCATCAGT 
R GGGCATCACCAGGCTTGTA 
HNF4A F CATGGCCAAGATTGACAACCT 
R TTCCCATATGTTCCTGCATCAG 




HNF6 F GTGTTGCCTCTATCCTTCCCAT 
R CGCTCCGCTTAGCAGCAT 
INSULIN F GAAGCGTGGCATTGTGGAAC 
R GCTGCGTCTAGTTGCAGTAGT 
NGN3 F GCTCATCGCTCTCTATTCTTTTGC 
R GGTTGAGGCGTCATCCTTTCT 
NKX6.1 F GGCCTGTACCCCTCATCAAG 
R TCCGGAAAAAGTGGGTCTCG 
PDX1 F GATTGGCGTTGTTTGTGGCT 
R GCCGGCTTCTCTAAACAGGT 
SST F CCCCAGACTCCGTCAGTTTC 
R TCCGTCTGGTTGGGTTCAG 
PBGD F GGAGCCATGTCTGGTAACGG 
R CCACGCGAATCACTCTCATCT 
SOX9 - Quantitect primers (QT00001498) 
 
  





2.9.1. Illumina sequencing 
Library preparation and deep sequencing were performed at the Wellcome 
Trust Sanger Institute (Hinxton, UK). RNA-sequencing was run on Illumina Hiseq v3 
with read length 75bp and paired-ends, and a library fragment size of 100-1000bp 
using a multi-plex strategy. Samples were run in biological triplicates. 
 
2.9.2. RNA enrichment analysis 
RNA-sequencing analyses were performed with partial help from Dr Pedro 
Madrigal. Tophat v2 (Kim et al., 2013), provided by Ensembl release 76 annotations, 
was used to align short reads from each sample to the reference human genome 
assembly (GRCh38/hg20). Feature counts was used to summarize paired-end reads 
and count fragments with parameters ‘-p -T 8 -t exon -g gene_id’ (Liao et al., 2014). 
DESeq2 Bioconductor package was used to search for significant differences 
between samples, requiring at least a 2 fold expression change and adjusted p-value 
less than 0.01 (Love et al., 2014). R package edgeR function ‘rpkm’ was used with 
default parameters to normalize count gene expression (Robinson et al., 2010). Raw 
bedGraphs were normalized per million mapped reads in the library per library size 
in all ChIP-seq and RNA-seq samples. Genome browser panels were generated using 
IGV (Thorvaldsdóttir et al., 2013).  
 
2.9.3. Functional annotations 
Gene Ontology (GO) analyses were performed using Amigo2 separately for 
up- and down- regulated differentially expressed genes (Carbon et al., 2009). 
Spearman’s correlation values were calculated for FPKM values for gene expressed 
at more than 5 FPKM in at least one sample. 
  




2.10. Chromatin Immunoprecipitation (ChIP) 
2.10.1. Cross-linking of protein and DNA 
Co-binding of DNA to DNA-binding proteins was determined by ChIP against 
GATA6 (Cell Signaling, #5851) on approximately 1 x 107 cells per antibody or control 
sample. hPSCs grown on 10 cm dishes were differentiated and harvested either at 
the endoderm (D3) or pancreatic progenitor (D12) stage. 1 x 10 cm dish of cells 
harvested at D3 was used for one antibody immunoprecipitation (IP). 1 x 10 cm dish 
of cells harvested at D12 was used for four antibody IPs. Cells were cross-linked by 
adding 312.5 µl of 16% formaldehyde (ThermoFisher UK, #11586711) to 5 ml of 
media to make a final concentration of 1%. The cells were incubated rocking for 10 
min at room temperature to allow cross-linking of protein-DNA complexes.  
 
The reaction was quenched by adding 312.5 µl of 2 M glycine (Millipore, 
#357002) to make a final concentration of 0.125 M and incubated for 5 min with 
rocking. Thereafter, the media was aspirated and cells were washed twice with 5 ml 
of ice-cold PBS. The cells were detached by scraping into 3 ml of ice-cold PBS 
containing freshly-added protease inhibitors (10 µl/ml of 5 mg/ml 
phenylmethylsulfonylfluoride (PMSF; Sigma-Aldrich, #93482), 10 µl/ml of 1 M 
Sodium Butyrate (Sigma-Aldrich, #303410) and 1 µl/ml of 1 mg/ml Leupeptin (Roche, 
#11017101001)) and pooled into 15 ml tubes, each tube containing approximately 2 
x 107 cells, or 2 IPs. The cells were then centrifuged for 5 min at 1,200 rpm at 4°C to 
pellet.  
 
For all subsequent steps, the samples were kept on ice. For all subsequent 
buffers used, the aforementioned protease inhibitors were added freshly to the 
buffers before use. The pelleted cells were subsequently re-suspended in 2 ml of ice-
cold Cell Lysis Buffer (10 mM Tris-Cl pH 8.0, 10 mM NaCl and 0.2% NP-40) per 15 ml 
tube and incubated on ice for 10 min. The cells were then centrifuged for 5 min at 
1,800 rpm at 4°C. The supernatant was discarded and the pellet was gently re-
suspended in 1.25 ml of ice-cold Nuclear Lysis Buffer (50 mM Tris-Cl pH 8.0, 10 mM 
EDTA and 1% SDS) per 15 ml tube and incubated on ice for 10 min. 0.75 ml of ice-




cold IP Dilution Buffer (20 mM Tris-Cl pH 8.0, 2 mM EDTA, 150 mM NaCl, 0.01% SDS, 
1% Triton X-100) was then added per 15 ml tube.  
 
The chromatin was then transferred into 15 ml Diagenode sonication tubes 
containing sonication beads (Diagenode, #C01020031) that were pre-washed twice 
with 10 ml D-PBS each time and once with 10 ml IP Dilution Buffer. Next, chromatin 
was sonicated in Diagenode Biorupter Pico for 10 cycles of 30s on/45s off. The 
sonicated chromatin were transferred to 1.5 ml tubes and centrifuged at 14,000 rpm 
for 10 min at 4°C to pellet debris. The pellet was discarded, and two 15 ml tubes, or 
4 IPs, worth of sonicated chromatin was pooled into a fresh 15 ml tube. 3.5 ml of IP 
Dilution Buffer was added and mixed gently. The cross-linked DNA was pre-cleared 
by incubating with rotation 10 μg of rabbit IgG (Sigma-Aldrich, #I5006) for 1 hr at 
4°C, followed by incubating with rotation 100 µl of Protein G agarose beads (50% 
v/v; Roche, #11243233001) pre-washed twice with D-PBS for 1 hr at 4°C. The 
samples were then centrifuged for 3 min at 3,000 rpm at 4°C and the supernatant 
was transferred to a fresh 15 ml tube. An aliquot of 300 µl for Input sample was 
transferred to a fresh 1.5 ml Eppendorf tube and stored at 4°C. 
 
2.10.2. Immunoprecipitation of protein-DNA complex 
The supernatant was split equally into four 15 ml tubes, each representing 
one sample i.e. 1 x 107 cells worth of material per tube. 10 μg of GATA6 antibody or 
rabbit IgG control was added per tube, and samples were incubated rotating 
overnight at 4°C. Antibody-bound chromatin was then collected using 60 µl of 
Protein G agarose beads (50% v/v) pre-washed twice with D-PBS for each tube by 
incubating with rotation for 1 hr at 4°C. Thereafter, the tubes were centrifuged for 3 
min at 3,000 rpm at 4°C. The supernatant was discarded and the pellet containing 








2.10.3. DNA extraction 
500 µl of IP Wash Buffer 1 (20 mM Tris-Cl pH 8.0, 2 mM EDTA, 50 mM NaCl, 
0.1% SDS and 1% Triton X-100) was added to each tube and the tubes were 
vortexed. The samples were transferred to fresh 1.5 ml Eppendorf tubes and were 
then centrifuged at 14,000 rpm for 1 min at 4°C. The samples were washed with IP 
Wash Buffer 1 once more by removing the supernatant, adding 500 µl of IP Wash 
Buffer 1, vortexing, and centrifuging at 14,000 rpm for 1 min at 4°C. 500 µl of IP 
Wash Buffer 2 (10 mM Tris-Cl pH 8.0, 1 mM EDTA, 0.25 M LiCl, 1% NP-40 and 1% 
Sodium deoxycholic acid) was then added to each tube after removing the 
supernatant and the tubes were vortexed and centrifuged at 14,000 rpm for 1 min at 
4°C.  The wash was repeated once more. Thereafter, the samples were washed twice 
with 500 µl of TE Buffer (10mM Tris-Cl pH 8.0, 1mM EDTA) according to the 
procedures above. After the supernatant was aspirated, the chromatin was eluted 
from the Protein G beads by washing twice with 150 µl of Elution Buffer (100 mM 
NaHCO3 and 1% SDS), vortexing and centrifuging at 14,000 rpm for 1 min at 4°C. The 
supernatants were collected and pooled in fresh 1.5 ml Eppendorf tubes.  
 
ChIP and Input DNA cross-links were reversed and RNA degraded by adding 1 
μl of 1 mg/ml RNase A and 18 μl of 5M NaCl and incubating at 67°C in a heat block 
with shaking at 1,300 rpm overnight. Protein was degraded by adding 3 μl of 20 
mg/ml Proteinase K and incubating for 3 hrs at 45°C in a heat block with shaking at 
1,300 rpm. DNA was extracted using 300 µl of phenol/chloroform wash with 
vortexing then centrifuged at 14,000 rpm for 5 min at room temperature. The 
aqueous layer containing pulled down genomic DNA was transferred to fresh 1.5 ml 
Eppendorf tubes. 30 μl of 3M NaAc pH 5.2 (Ambion, #AM9740), 30 μg glycoblue 
(Ambion, #AM9516) and 750 μl of 100% ethanol were added to the samples, which 
were then vortexed. The samples were next incubated for at least 30 min at -80°C to 
precipitate the DNA. Precipitated DNA was pelleted by centrifuging at 14,000 rpm for 
30 min at 4°C. The DNA pellet was then washed with ice-cold 70% ethanol and 
centrifuged at 14,000 rpm for 5 min at 4°C. The ethanol was removed and the pellet 




air dried. 70 µl of deionised water was added to Input samples whereas 30 µl of 
deionised water was added to ChIP samples. 
 
2.10.4. Bioanalyser 
Chromatin fragments after sonication were determined by a Bioanalyser 
(Agilent 2100 Bioanalyzer) to ensure that fragmented chromatins are within the 
range of 150-300 base pairs in size.  
 
A 10 µl aliquot was taken directly from freshly sonicated samples and 
transferred to a clean 1.5 ml Eppendorf tube. The tubes were centrifuged at 14,000 
rpm for 10 min at 4°C to remove any insoluable material. The supernatant was 
transferred to a fresh 1.5 ml Eppendorf tube. Thereafter, fast reversal of the cross-
links was performed by adding 74 µl of nuclease free water, 4 µl of 5M NaCl, 8 µl of 
20 mg/ml Proteinase K and 4 µl of 10 mg/ml RNase A to the aliquots. The aliquots 
were incubated at 65°C for 2 hr in a heat block with shaking at 1,300 rpm. DNA was 
purified using QIAquick PCR Purification Kit (Qiagen) and DNA was eluted in 20 µl of 
elution buffer. DNA was diluted 1:10 in nuclease free water and 1 µl was used for 
analysis using High Sensitivity DNA Kit (Agilent, #5067-4626) according to the 
manufacturer’s protocol. 
 
2.10.5. qPCR detection 
Pulldown enrichment was validated by qPCR using KAPA SYBR FAST Master 
Mix (2X) ROX Low qPCR Kit (KAPA Biosystems). Gene-specific primers kindly provided 
by our collaborator, Jorge Ferrer’s group, are listed in Table 50. Results were 
expressed as normalised values against a negative control region and fold change 
compared between antibody pulldown and IgG control. 
  




Table 50. Primers used in ChIP qPCR 
Primer name  Primer sequence (5’ → 3’) 
hGATA6 positive region F CATGGAGACAGCAACAGTCC 
hGATA6 positive region R ACCGCCCGGTTATCTTATTG 
hPDX1 positive region F TTTCTCGCTGCCCTTTACTC 
hPDX1 positive region R GTGCTGTGGCTCAACTCTGA 
NR0B2 positive for hGATA6 and hPDX1 F GCTGCCCCTTATCAGATGAC 
NR0B2 positive for hGATA6 and hPDX1 R CTGGCTTAGCAAAAGCCCTA 
Amy2A negative control F TGCTGCCAGAACCTAAGAAAA 
Amy2A negative control R TTGAGGGCAAACTGTTTATTCA 
Nanog negative control F AAAGCTTGCCTTGCTTTGAA 
Nanog negative control R AGTCTCCGTGTGAGGCATCT 
  





2.11.1. Illumina sequencing 
Library preparation and deep sequencing were performed at the Wellcome 
Trust Sanger Institute (Hinxton, UK). RNA-sequencing was run on Illumina Hiseq v4 
with read length 75bp and paired-ends, and a library fragment size of 100-1000bp 
using a multi-plex strategy. Samples were run in biological duplicates. 
 
2.11.2. Bioinformatics analyses 
ChIP-sequencing analyses were performed with partial help from Dr. Pedro 
Madrigal and Dr. Denil Simon Lieven Imanuel Johannes. Short-insert paired-end 
reads were aligned to the reference human genome assembly (GRCh38/hg18) using 
the Burrows-Wheeler Aligner (BWA) 0.5.10 (Li and Durbin, 2009) with -q 15 and 
default for the rest of parameters. Reproducibility between replicates was first 
assessed using the Pearson Correlation Coefficient (PCC) for the two biological 
replicates, using the genome-wide normalized read (extended to 300 bp) count 
distribution on a single nucleotide resolution. For this, the UCSC tool bigwigCorrelate 
provided in http://hgdownload.cse.ucsc.edu/admin/exe/. PCC is equal to 0.949326 
was used. 
 
Peak calling was performed using MACS version 2.0.10 (Zhang et al., 2008), 
allowing a p-value cut-off of p-value ≤ 1e-3, and default for the rest of parameters. 
Relaxed thresholds are suggested in order to enable the correct computation of IDR 
values (Landt et al., 2012). Following the recommendations for the analysis of self-
consistency and reproducibility between replicates, the negative control samples 
(IgG and input DNA) were combined into one single control; code for IDR analysis 
was downloaded from https://sites.google.com/site/anshulkundaje/projects/idr (Li 
et al., 2011). This is also beneficial as control samples with substantially higher 








To estimate the Irreproducible Discovery Rate (IDR) between replicates, top 
35k peaks for each biological replicate were submitted for IDR analysis. For IDR 
computation using MACS results, we used p-values rather than q-values as suggested 
in https://sites.google.com/site/anshulkundaje/projects/idr (Li et al., 2011). The 
number of peaks found passing a threshold of IDR ≤ 5% (12,107) was selected as a 
conservative estimated number of candidate transcription factor binding sites. 
Autosomal and sex chromosomes were also excluded.  
 
Co-localization plots of the transcription factors GATA6, EOMES and 
SMAD2/3 ChIP-seq, was generated with deepTools (Ramirez et al., 2014). The input 
data was obtained by combining my ChIP data of H9 cells at day 3 (GATA6) with 
previously published EOMES (Teo et al., 2011) and SMAD2/3 ChIP data (Brown et al., 
2011). To make the results more comparable, the 3 data sets were re-mapped with 
STAR v2.5.1a (Dobin et al., 2013) (BWA failed on short single end SMAD reads) and 
processed with MACS version 2.0.10 and IDR as described earlier. The resulting peak 
files (bed format) were used as input for deepTools. The mapped read files (bam 
format) were pre-processed with deepTools' "bamCompare" function (bin size = 50, 
assumed genome size = 2451960000 bp, ignoring chromosomes X and Y for 
normalization and extending single end reads by 250bp). 
 
2.12. Statistical analyses 
Unpaired two-tailed Student’s t-test were used to assess statistical 
significance. Statistical analysis was done by GraphPad Prism software (Version 6.0 
for Windows. GraphPad Software, San Diego, CA). p value < 0.05 was considered as 
statistically significant, *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. Data 
are presented as mean ± s.d. as indicated in the figure legends. All sample numbers 
listed indicate the number of biological replicates employed in each experiment. For 
experiments showing data of one experiment that is representative of three 
independent experiments, this was done due to variations between different 
differentiation experiments; combining the experiments resulted in inaccurately 




CHAPTER 3  RESULTS 
 
3.1. An in vitro culture system to study the development of the pancreas 
3.1.1. An efficient protocol to differentiate hPSCs into endocrine 
progenitors  
 
To study human pancreas development in an in vitro system, a chemically 
defined and feeder-free pancreatic specification protocol that was previously 
established in the lab (refer to Chapters 2.1.3 and 2.1.4) was used to differentiate 
hPSCs into endocrine progenitors. To confirm the efficiency of the protocol in 
generating a near homogenous population of pancreatic progenitors from hPSCs, I 
performed comprehensive analyses throughout the differentiation protocol; cells 
were analysed at key stages of the pancreas development and assessed for the 
expression of key markers to ensure successful commitment to the pancreatic 
lineage (Figure 10).  
 
I first performed pancreatic differentiation on H9, a well-characterised hESC 
line that was routinely used in the lab and has been extensively tested for successful 
pancreatic differentiation. Cells were assayed by qRT-PCR and immunocytochemistry 
(ICC) on days 3 (DE), 6 (primitive gut tube), 9 (posterior foregut), 12 (pancreatic 
endoderm), 15, 18 and 24 (endocrine progenitor) of pancreatic differentiation, while 
FACS was performed on days 3, 12, 15 and 24 of pancreatic differentiation. 
 
On day 0 of differentiation, the high expression levels of pluripotency factors 
(OCT4, SOX2 and NANOG) as shown in ICC and the absence of early germ layer 
markers (EOMES and SOX17) (Figure 11) indicated that the H9 cells were indeed in a 
fully undifferentiated and pluripotent state.  
 




Figure 10. Schematic of the 24-day differentiation protocol. DE, definitive 
endoderm; DFG, dorsal foregut; PE, pancreatic endoderm; EP, endocrine 
progenitors.  The culture medium and supplements indicated are BMP, bone 
morphogenetic protein 4; the PI3 kinase inhibitor Ly294002; the GSK3 inhibitor CHIR, 
CHIR99021; CDM, chemically defined medium; Adv-BSA, Advanced Dulbecco's 
Modified Eagle Medium/Ham's F-12 medium supplemented with BSA and L-
glutamine; RA, retinoic acid; the ALK4/5/78 inhibitor SB-431542 (SB); FGF2, 
Fibroblast growth factor 2; FGF10, Fibroblast growth factor 10; the Hedgehog 
inhibitor, CYCP, Cyclopamine-KAAD; B27 supplement; the NOTCH inhibitor, DAPT. 




Figure 11. H9 cells are pluripotent and undifferentiated. Cells were grown in feeder-
free culture conditions that maintain pluripotency and analysed via 
immunofluorescence. Cells were fixed on day 0 and were stained for pluripotency 
markers NANOG, OCT4 and SOX2 and early germ layer markers SOX17 and EOMES. 
Scale bar, 100 µm. 
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ICC analyses of DE differentiation after day 3 showed the up-regulation of 
endoderm marker SOX17 and early foregut marker FOXA2 accompanied by the 
down-regulation of pluripotency marker NANOG (Figure 12), indicating that the H9 
cells successfully differentiated into the DE. FACS analyses revealed efficient DE 
formation with populations of 76.6% of SOX17+ cells and 67.7% of CXCR4+ cells 
(Figure 13). In addition, morphological analyses showed that the cells lost the 
compact colony morphology characteristic of stem cells and adapted a spread out 
“cobblestone-like” morphology indicating an epithelial-mesenchymal transition 




Figure 12. ICC of H9 cells differentiated into the DE. Cells were grown in culture 
conditions that specified them toward the DE lineage and analysed via 
immunofluorescence. Cells were fixed on day 3 and were stained for the 
pluripotency marker NANOG, as well as DE markers SOX17 and FOXA2. Scale bar, 
100 µm. 
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    IgG                   hESC 
Figure 13. FACS of H9 cells differentiated into the DE. Cells were fixed on day 3 and 
were stained for DE markers SOX17 and CXCR4. Data show results of one experiment 
that is representative of at least 3 independent experiments. 
  Day 0        Day 3 
  
Figure 14. H9 exhibiting morphological changes upon differentiation into the DE. 
Bright field microscopy images showing the different morphologies between 
undifferentiated and DE cells.  
 
Further differentiation toward the primitive gut tube on day 6 led to a near 
homogenous population of cells expressing key foregut markers such as FOXA2, 
HNF1B and HNF4A, as shown by ICC (Figure 15). Notably, the absence of HEX and 
CDX2 suggested a dorsal identity for these foregut cells (Figure 15). The cells 
continued to proliferate, resulting in a denser monolayer as the differentiation 
process progressed.  














Figure 15. ICC of H9 cells differentiated into the primitive gut tube. Cells were 
grown in culture conditions that specified them toward the dorsal foregut and 
analysed via immunofluorescence. Cells were fixed on day 6 and were stained for 
key markers FOXA2, HNF1B and HNF4A and negative markers CDX2 and HEX. Scale 
bar, 100 µm. 
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Three days later on day 9, the cells continued expressing key foregut markers 
FOXA2, HNF1B, SOX2 and HNF6 (Figure 16). The key pancreatic marker PDX1 was 
shown to be almost homogeneously expressed by the end of day 12, indicating 
acquisition of pancreatic fate (Figure 17), and FACS analyses confirmed this by 




Figure 16. ICC of H9 cells differentiated into the posterior foregut. Cells were grown 
in culture conditions that specified them toward the foregut lineage and analysed via 
immunofluorescence. Cells were fixed on day 9 and were stained for key markers 
FOXA2, HNF1B, SOX2 and HNF6. Scale bar, 100 µm. 
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Figure 17. ICC of H9 cells differentiated into the pancreatic endoderm. Cells were 
grown in culture conditions that specified them toward the pancreatic endoderm 
lineage and analysed via immunofluorescence. Cells were fixed on day 12 and were 
stained for the key pancreatic marker PDX1. Scale bar, 100 µm. 
 
 
            
 
    IgG                          hESC 
Figure 18. FACS of H9 cells differentiated into the pancreatic endoderm. Cells were 
fixed on day 12 and were stained for the key pancreatic marker, PDX1. Data show 
results of one experiment that is representative of at least 3 independent 
experiments. 
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On day 15, NGN3 was shown to be expressed by ICC (Figure 19) and FACS, at 
a population of 12.1% (Figure 20). Endocrine progenitors on day 18 revealed an 
expression of the key pancreatic marker PDX1 and endocrine progenitor markers C-
PEPTIDE, SST and GCG via ICC (Figure 21). From day 18 to day 24 as the cells matured 
into immature β-cells, ICC showed an increased number of cells expressing C-
PEPTIDE, SST and GCG (Figure 22). FACS analyses revealed populations of 10.4% C-
PEPTIDE+ cells, 1.76% SST+ cells, and 3.79% GCG+ cells (Figure 23) and 7.9% of 




Figure 19. ICC of H9 cells on day 15. Cells were grown in culture conditions that 
allowed them to mature into endocrine progenitors and analysed via 
immunofluorescence. Cells were fixed on day 15 and were stained for NGN3. Scale 
bar, 100 µm. 
 
            
 
       IgG                    hESC 
 
Figure 20. FACS of H9 cells on day 15. Cells were fixed on day 15 and were stained 
for NGN3. Data show results of one experiment that is representative of 3 
independent experiments. 
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Figure 21. ICC of H9 cells on day 18. Cells were grown in culture conditions that 
allowed them to mature into endocrine progenitors and analysed via 
immunofluorescence. Cells were fixed on day 18 and were stained for key markers 
SST, C-PEPTIDE and GCG. Scale bar, 100 µm. 
 
     
 
Figure 22. ICC of H9 cells differentiated into endocrine progenitors. Cells were 
grown in culture conditions that that allowed them to mature into endocrine 
progenitors and analysed via immunofluorescence. Cells were fixed on day 24 and 
were stained for key markers SST, C-PEPTIDE and GCG. Scale bar, 100 µm. 
          SST                            C-PEPTIDE                         GCG 
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          SST                           C-PEPTIDE                          GCG 
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                                        IgG 
Figure 23. FACS of H9 cells differentiated into endocrine progenitors. Cells were 
fixed on day 24 and triple-stained for key markers, C-PEPTIDE, SST and GCG. Cell 
populations represent a combination of both poly- and mono-hormonal cells. Data 




Figure 24. FACS of mono-hormonal H9 cells on day 24. Cell population consists of 
poly- or mono-hormonal cells which are C-PEPTIDE+ (C-PEPTIDE population of 10.4% 
from Figure 23). Q1 represents C-PEPTIDE+ and GCG+ poly-hormonal cells; Q2 
represents C-PEPTIDE+, SST+ and GCG+ poly-hormonal cells; Q3 represents C-
PEPTIDE+ mono-hormonal cells; Q4 represents C-PEPTIDE+ and SST+ poly-hormonal 
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Further qRT-PCR analyses not only validated the expression of key markers 
described earlier at each time point, but also provided an overview of the expression 
patterns of each marker over the course of pancreatic specification (Figure 25).  
 
Figure 25. qRT-PCR analyses of H9 cells specified toward the pancreatic lineage. 
RNA was extracted at specific stages and the expression patterns of key markers 
were determined. Data are triplicate samples of one experiment and representative 
of three independent experiments. Error bars indicate standard deviation. Values are 
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 To investigate the functional potential of the endocrine progenitors 
generated from the H9 hESCs, I performed C-peptide ELISA on cells that have 
undergone the 24-day differentiation protocol derived from the lab. C-peptide is 
often used as an alternative measurement for insulin at protein level, including 
ELISA, ICC and FACS. A major reason for this is because cells take up insulin present 
in the cell culture media, which may lead to false positive signals of insulin 
expression and contents in cells. The proteolytic cleavage of proinsulin prior to 
secretion produces the mature insulin molecule and the connecting peptide (C-
peptide). As C-peptide is secreted in equimolar quantities to insulin, it serves as a 
substitute for the measurement of insulin. The 10% of H9-derived insulin-expressing 
cells seemed to elicit an inverse C-peptide releasing response upon glucose 
stimulation (Figure 26). 
 
 
Figure 26. C-peptide secretion upon glucose stimulation on day 24. Cells were 
differentiated using the lab-derived protocol and assayed on day 24. Data are 
presented as the average of 3 biological replicates of one experiment and 
representative of three independent experiments. Error bars indicate standard 
deviation. LG1 is first incubation of low glucose; HG1 is first incubation of high 
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To enhance the reproducibility of the results, a second hPSC line was 
introduced into the project. This was a hIPSC line derived previously in the lab, 
named FSPS13.B. Pancreatic differentiation was performed on these cells and qRT-
PCR and FACS analyses were done at various time points of the protocol. Expression 
patterns of the key genes analysed via qRT-PCR corroborated those from H9 cells 
(Figure 27). FACS analyses revealed 70.8% of SOX17+ cells and 83.7% of CXCR4+ cells 
on day 3 (Figure 28), and 86.8% of PDX1+ cells on day 12 (Figure 29), indicating 
similar differentiation efficiencies toward the DE and pancreatic endoderm lineages 
between H9 and FSPS13.B cells.  
  
Figure 27. qRT-PCR analyses of FSPS13.B cells specified toward the pancreatic 
lineage. RNA was extracted at specific stages and the expression patterns of key 
markers were determined. Data are triplicate samples of one experiment and 




























































































































           
 
      IgG                                hESC 
Figure 28. FACS of FSPS13.B cells differentiated into the DE. Cells were grown in 
culture conditions that specified them toward the DE lineage and then analysed by 
FACS. Cells were fixed on day 3 and were stained for the DE markers SOX17 and 
CXCR4. Data show results of one experiment that is representative of at least 3 
independent experiments. 
 
            
 
    IgG                                hESC 
Figure 29. FACS of FPS13.B cells differentiated into the pancreatic endoderm. Cells 
were grown in culture conditions that specified them toward the pancreatic 
endoderm lineage and then analysed by FACS. Cells were fixed on day 12 and were 
stained for the pancreatic marker, PDX1. Data show results of one experiment that is 
representative of at least 3 independent experiments. 
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On day 24, however, FSPS13.B displayed lower endocrine progenitor 
differentiation efficiency as compared with H9, with FACS analysis showing 5.75% of 
C-PEPTIDE+ cells (Figure 30). Due to the low number of C-PEPTIDE+ cells, I could not 
perform triple staining of C-PEPTIDE, SST and GCG to determine the percentage of 
mono-hormonal and poly-hormonal cells as was done on H9 cells (Figure 24) 
 
 
             
 
    IgG                               hESC 
Figure 30. FACS of FPS13.B cells differentiated into the endocrine progenitors. Cells 
were grown in culture conditions that specified them toward the endocrine 
progenitor lineage and then analysed by FACS. Cells were fixed on day 24 and were 
stained for the endocrine marker, C-PEPTIDE. Data show results of one experiment 
that is representative of at least 3 independent experiments. 
 
Together, except for the C-peptide ELISA, these results recapitulate 
pancreatic differentiation that was previously published (Cho et al., 2012), indicating 
to a large extent, the consistency of the pancreatic differentiation protocol in 
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3.1.2. GATA6 is up-regulated upon definitive endoderm formation  
To better understand of the role of GATA6 in the development of the human 
pancreas, I closely investigated the expression profile of GATA6 over the course of 
pancreatic specification. Using H9 cells, in vitro pancreatic differentiation was 
performed according to the protocol described in Chapters 2.1.3 and 2.1.4. 
 
On day 0 of differentiation, GATA6 expression was demonstrated to be 
absent in undifferentiated and pluripotent cells, as shown by ICC (Figure 31) and 
qRT-PCR (Figure 33).  
 
 
                                  
Figure 31. GATA6 expression is negligible in undifferentiated state. Cells were 
grown in culture conditions that maintained pluripotency and analysed via 
immunofluorescence. Cells were fixed on day 0 and were stained for pluripotency 
markers NANOG, OCT4 and SOX2 and early DE marker SOX17. Scale bar, 100 µm. 
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On day 3, ICC showed that GATA6 is highly expressed in the DE and is co-
localised with key DE markers (Figure 32). The rapid up-regulation of GATA6 on day 3 
was confirmed by qRT-PCR (Figure 33). FACS analysis showed that 97.8% of the cells 




           
Figure 32. GATA6 is co-expressed with key DE markers. Cells were grown in culture 
conditions that specified them toward the DE lineage and analysed via 
immunofluorescence. Cells were fixed on day 3 and were stained for the 
pluripotency marker NANOG, as well as DE markers SOX17 and FOXA2. Scale bar, 
100 µm. 
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Figure 33. qRT-PCR analyses of GATA6 expression levels in of H9 cells specified 
toward the pancreatic lineage. RNA was extracted at specific stages and the 
expression patterns of key markers were determined. Data are triplicate samples of 
one experiment and representative of three independent experiments. Error bars 
indicate standard deviation. Values are relative to the housekeeping gene PBGD. 
 
             
 
              IgG                                hESC 
Figure 34. FACS of GATA6+ H9 cells at day 3. Cells were grown in culture conditions 
that specified them toward the DE lineage and then analysed by FACS. Cells were 
fixed on day 3 and were stained for GATA6. Data show results of one experiment 
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3.1.3. GATA6 is expressed throughout pancreatic development  
On day 6, GATA6 continues to be expressed during pancreatic differentiation, 
although at lower levels compared with day 3 as indicated by the decreased staining 
intensity by ICC (Figure 35) and decreased relative expression level by qRT-PCR 
(Figure 33). On days 9 and 12, GATA6 remains expressed and co-localised with the 
key markers at each respective stage (Figure 36 and Figure 37). FACS analysis 




       
Figure 35. GATA6 is co-localised with key markers of the primitive gut tube. Cells 
were grown in culture conditions that specified them toward the dorsal foregut and 
analysed via immunofluorescence. Cells were fixed on day 6 and stained for key 
markers FOXA2 and HNF1B and negative markers CDX2 and HEX. Scale bar, 100 µm. 
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Figure 36. GATA6 is co-localised with key markers of the posterior foregut. Cells 
were grown in culture conditions that specified them toward the foregut lineage and 
analysed via immunofluorescence. Cells were fixed on day 9 and were stained for 
key markers FOXA2, HNF1B and SOX2. Scale bar, 100 µm. 
 
 
       
Figure 37. GATA6 is co-localised with key marker of the pancreatic endoderm. Cells 
were grown in culture conditions that specified them toward the pancreatic 
endoderm lineage and analysed via immunofluorescence. Cells were fixed on day 12 
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         IgG                                hESC 
Figure 38. FACS of GATA6+ H9 cells at day 12. Cells were grown in culture conditions 
that specified them toward the pancreatic endoderm lineage and then analysed by 
FACS. Cells were fixed on day 12 and were stained for GATA6. Data show results of 
one experiment that is representative of at least 3 independent experiments. 
 
On day 24, GATA6 continues to be expressed at high levels as shown by ICC 
(Figure 39) and qRT-PCR (Figure 33). Together, these results suggest that GATA6 




    
Figure 39. GATA6 is co-localised with key markers of endocrine progenitors. Cells 
were grown in culture conditions that allowed them to mature into endocrine 
progenitors and analysed via immunofluorescence. Cells were fixed on day 24 and 
were stained for key markers C-PEPTIDE and GCG. Scale bar, 100 µm. 
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3.2. Successful derivation of GATA6 mutant lines 
Using an efficient endocrine progenitor differentiation protocol, I have 
determined the expression profile of the transcription factor GATA6, where its 
expression is first detected during the formation of the DE and continues to be 
expressed throughout human pancreas development. Next, I sought to generate 
heterozygous and homozygous GATA6 mutant cell lines in order to further 
investigate the role of GATA6 in the formation of the human pancreas. To generate 
GATA6 mutants, I employed TALENs to induce mutations at two specific target sites 
that were selected based on their close proximity downstream of the first and 
second start codons of the GATA6 gene to avoid generating partial protein products. 
 
3.2.1. NHEJ pathway 
To generate GATA6 mutants via the NHEJ pathway, I employed TALENs to 
induce mutations at both target sites in the GATA6 gene as described in Chapter 
2.3.1 in both H9 and FSPS13.B cell hPSC lines. In the first instance, H9 cells were 
targeted at both GATA6 TALEN1 and TALEN2 sites (Figure 40) and as described in 
Chapters 2.3.1 and 2.4.1. After TALEN targeting via electroporation, antibiotic 
selection and recovery, approximately 20-80 colonies derived from single cells were 
present in each culture dish. To reveal potential heterozygous or homozygous 
clones, restriction digest was performed to screen for mutations. Genomic DNA 
extracted from each colony was digested using restriction enzymes AfeI and PstI for 
TALEN1 and TALEN2 respectively. Colonies that were successfully cut by the TALENs 
and incorporated mutations upon DNA repair, and thus and remained undigested 
due to a disruption within the restriction enzyme site. Colonies that did not harbour 
any mutations have the restriction enzyme site intact, and therefore resulted in 
smaller and more numerous DNA fragments. This is apparent in Figure 41 where 
colonies numbered in red are colonies with a disrupted AfeI site showing a band 
resembling the undigested wild-type band, hence indicating the occurrence of a 
likely mutational event in an allele. These clones also showed the PCR fragments 
resulting from AfeI digestion on a wild-type allele, suggesting that they were likely 
heterozygous GATA6 mutants. 




Figure 40. Schematic of TALEN1 and TALEN2 cut sites on the GATA6 locus. Top row 
represents GATA6 cDNA showing the exons as boxes numbered accordingly and 
introns as lines. Grey regions of the exons represent non-coding regions while blue 
regions represent coding regions. The number of base pairs in each exon is shown in 
black text; the number of base pairs in each intron is shown in blue text; number of 
amino acids in each exon is shown in orange text. Bottom row illustrates the GATA6 
protein and the grey lines connecting the cDNA to protein represents the 
corresponding area of the protein that each exon codes for. Protein translation 
commencing from the first ATG forms the long isoform of GATA6, which has a length 
of 595 amino acids. Protein translation commencing from the second ATG forms the 
short isoform of GATA6, which has a length of 449 amino acids. Green and orange 
asterisks indicate the locations of Patient A, GATA6R465C/+ and Patient B, GATA6c.1136-
2A>G /+ mutations respectively. 
 
 
Figure 41. Representative DNA agarose gel picture of colonies screened via 
restriction enzyme digest. Genomic DNA was extracted from picked colonies and 
subjected to restriction digest using AfeI. Undigested and digested DNAs were run 
simultaneously. Colonies numbered red indicate the presence of heterozygous 
mutations while colonies numbered in black indicate wild-type. 
* * 
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24 clones were screened for each TALEN1 and TALEN2 targeting, with an 
observed cutting efficiency of approximately 80% at either targeting site, and a 
cutting efficiency of approximately 5% on both alleles at the TALEN2 target site. 
Unfortunately, no homozygous mutant for the TALEN1 cut site was generated in H9 
cells. The colonies were then sequenced via Sanger sequencing to confirm their 
genotype. One heterozygous mutant derived from TALEN1 and TALEN2 target sites 
and one homozygous mutant derived from TALEN2 target site that harboured out of 
frame frameshift mutations resulting in a premature stop codon were selected for 
further western blotting validation (Figure 42). The TALEN-derived mutant lines were 
labelled according to their TALEN cut site (e.g. T1 for TALEN1 cut site or T2 for 
TALEN2 cut site) followed by the colony number.  
 
To control for any potential off-target effects, I selected one colony that had 
been treated similarly to the mutants i.e. had undergone the TALEN targeting, 
antibiotic selection and re-growth process but harboured no observable mutations 








Figure 42. Schematic of selected H9 TALEN-derived GATA6 cell lines. Four TALEN-
derived cell lines were selected for use in downstream experiments. TALEN1_#9 is a 
TALEN-targeted but wild-type line; TALEN1_#16 contains a 2 base pair deletion 
frameshift mutation at the TALEN1 cut site; TALEN2_#15 contains a 4 base pair 
insertion frameshift mutation at the TALEN2 cut site; TALEN2_#17 contains an 
identical 4 base pair deletion on both GATA6 alleles at the TALEN 2 cut site. All 
frameshift mutations were out of frame resulting in a premature stop codon. 
 
Next, I performed western blotting to investigate GATA6 protein level in the 
TALEN-derived mutant lines. Cells were harvested on day 0 (D0) for negative control 
and day 3 (D3), as GATA6 is highly expressed on this day. Two antibodies, one 
recognising the N-terminus of the GATA6 protein and the other recognising the C-
terminus of the GATA6 protein, were used. Expectedly, the N-terminal GATA6 
antibody detected a partial protein product (PPP) for the mutants derived from the 
TALEN2 cut site, confirming the presence a truncated GATA6 protein caused by a 
premature stop codon in one GATA6 allele (T2_#15) or both GATA6 alleles (T2_#17) 
(Figure 43). The absence of GATA6 protein for T2_#17 mutant line using the C-
terminal GATA6 antibody confirmed that this line was a homozygous mutant (Figure 
44). The wild-type GATA6 allele of heterozygous mutants T1_#16 and T2_#15 









Figure 43. Western blot analysis of GATA6 protein levels in TALEN-derived H9 
mutant lines using an N-terminal GATA6 antibody. Cells were harvested on day 0 
(undifferentiated) and day 3 (DE). Alpha-tubulin was used as a loading control. Long 
and short isoforms of wild-type GATA6 are 64 kDa and 52 kDa respectively; the 
partial protein products for T2_#15 and T2_#17 are approximately 30 kDa and 18 
kDa for the long and short isoforms respectively. 
 
 
        
Figure 44. Western blot analysis of GATA6 protein levels in TALEN-derived H9 
mutant lines using a C-terminal GATA6 antibody. Cells were harvested on day 0 
(undifferentiated) and day 3 (DE). Alpha-tubulin was used as a loading control. Long 
and short isoforms of wild-type GATA6 are 64 kDa and 52 kDa respectively. No 
GATA6 protein was present for the T2_#17 mutant. 
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Gene editing was next performed in FSPS13.B cells. I focused on using the 
TALEN1 cut site with the intention of eliminating the PPP and obtaining complete 
loss of function GATA6 alleles. 78 clones were screened with an observed cutting 
efficiency of approximately 10% on one allele. I obtained an identical mutant for 
FSPS13.B, referred to as T1_#50, that contained the same 2 base pair deletion as 
T2_#16 in H9 cells (Figure 45). Similar to H9 cells, no homozygous mutant for the 
TALEN1 cut site was recovered. Thus, I subjected the T1_#50 mutant line to re-
targeting at the TALEN1 site. 48 clones were screened with an observed cutting 
efficiency of approximately 2% of the remaining wild-type allele. A homozygous 
mutant, referred to as T1_#50_#42, containing the same 2 base pair deletion on 




Figure 45. Schematic of selected FSPS13.B TALEN-derived GATA6 cell lines at the 
TALEN1 cut site. Three TALEN-derived cell lines were selected for use in downstream 
applications. T1_#6 is a TALEN-targeted but wild-type line; T1_#50 contains a 2 base 
pair deletion frameshift mutation; T1_#50_#42 contains an identical 2 base pair 
deletion frameshift mutation on both GATA6 alleles. All frameshift mutations were 
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Surprisingly, upon performing western blot to verify the complete loss of 
GATA6 protein in the T1_#50_#42 mutant, the short protein isoform of GATA6 was 
observed using both N- and C-terminus GATA6 antibodies (Figure 46). The simplest 
explanation for this finding is ribosomal read through and translational initiation at 
the second GATA6 ATG (Figure 47). 
 
 
Figure 46. Western blot analysis of GATA6 protein expression in TALEN-derived 
FSPS13.B mutant lines using N- and C-terminal antibodies. Cells were harvested on 
day 3 (DE). Alpha-tubulin was used as a loading control. Long and short isoforms of 
wild-type GATA6 are 64 kDa and 52 kDa respectively. The short isoform of GATA6 
protein was present for the T1_#50_#42 mutant. 
 
 
Figure 47. Schematic of selected FSPS13.B TALEN-derived GATA6 cell lines at the 
TALEN1 cut site with read-through. The ribosomal read through and translational 
initiation at the second GATA6 ATG led to the translation of the short GATA6 isoform 
in the mutants. Blue dotted lines represent the second start codon. 
(+/+)    (+/-)     (-/-) 
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Since it is now clear that the TALEN1 cut site is not suitable for generating 
GATA6 loss of function mutant lines, I proceeded to target the FSPS13.B cell line at 
the TALEN2 cut site. 33 clones were screened with an observed cutting efficiency of 
30% of one allele. I selected three colonies which after sequencing were found to 
harbour out of frame heterozygous frameshift mutations resulting in premature stop 
codons (Figure 48). Again, no homozygous mutants were obtained and so I 
proceeded to retarget mutant T2_#8 which harbours a 14 base pair out of frame 
frameshift mutation. 24 clones were screened with an observed cutting efficiency of 
30% of the remaining wild-type allele. A homozygous mutant, referred to as 
T2_#8_#4, containing an 11 base pair out of frame frameshift mutation in the other 




Figure 48. Schematic of selected FSPS13.B TALEN-derived GATA6 cell lines at the 
TALEN2 cut site. Four TALEN-derived cell lines were selected for use in downstream 
applications. T2_#3 is a TALEN-targeted but wild-type line; T2_#7 contains a 1 base 
pair insertion frameshift mutation; T2_#8 contains a 14 base pair deletion frameshift 
mutation; T2_#31 contains a 21 and 8 base pair deletion frameshift mutation; 
T2_#8_#4 contains a 14 base pair deletion frameshift mutation in one GATA6 allele 
and 11 in the other. All frameshift mutations were out of frame resulting in a 
premature stop codon. 
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GATA6 heterozygous and homozygous mutant H9 and FSPS13.B cell lines 
derived from TALEN targeting at the TALEN2 site that were selected for subsequent 
experiments are summarised in Table 51 with precise details of their genotypes. The 
nomenclature for the mutants that is used throughout the remainder of this thesis is 
listed in Table 51. All mutant lines were verified by western blotting and sequencing. 




Table 51. Summary of selected H9 and FSPS13.B mutants generated via NHEJ 
pathway 
Cell line TALEN cut site and 
colony number 
Genotype Nomenclature 
H9 T1_#9 GATA6 +/+ (wild-type) H9*  
(WT) 
H9 T2_#15 GATA6 c.618_619insTGCA/+ GATA6 4ins/+ 
(Het) 
H9 T2_#17 GATA6 c.611_614delACCT/c.611_614delACCT GATA6 Δ4/Δ4 
(Hom) 
FSPS13.B T2_#3 GATA6 +/+ (wild-type) FSPS13.B* 
(WT) 
FSPS13.B T2_#7 GATA6 c.615_616insC/+ GATA6 1ins/+ 
(Het) 
FSPS13.B T2_#8 GATA6 c.del614_627TGCAGGGGTCGGGC/+ GATA6 Δ14/+ 
(Het) 
FSPS13.B T2_#31 GATA6 c.600_621delinsTGGGCCAG/+  GATA6 Δ21_8ins/+ 
(Het) 







  Results 
113 
 
3.2.2. HR pathway 
Next, I generated GATA6 knockout hPSC lines that are entirely devoid of a 
PPP. To accomplish this, I performed TALEN targeting at the TALEN1 site and 
introduced a donor/targeting vector (TG) that contained an emerald GFP (emGFP) 
reporter in frame with the endogenous GATA6 ATG and a puromycin-resistance 
cassette (Figure 49). TALEN cutting and successful HR via the 5’ and 3’ homology 
arms results in either a heterozygous or homozygous loss-of-function GATA6 
mutation (Figure 49).  
 
I targeted both H9 and FSPS13.B cells. Initial PCR screens on genomic DNA 
extracted from picked colonies using forward and reverse primers within exon 1 and 
intron 2 respectively as indicated by the red arrows in Figure 49 revealed the “knock-
in” of the donor template from the targeting vector (Figure 50). For H9 cells, 12 
clones were screened with an observed HR efficiency of approximately 20% on one 
allele and 10% on two alleles. For FSPS13.B cells, 24 clones were screened with an 
observed HR efficiency of 50% of one allele. Unfortunately, no homozygous mutants 
were obtained even after I attempted to re-target a heterozygous mutant and 
screened through 24 clones.  
 
       
Figure 49. Schematic of generating heterozygous or homozygous loss-of-function 
GATA6 mutations via HR. A “knock-in” vector that introduces an emerald GFP 
(emGFP) reporter in-frame with the first GATA6 ATG and a puromycin resistance 
cassette into GATA6 exon 2 is depicted.  Successful homologous recombination 
resulted in both heterozygous (GATA6 GFP/+) and homozygous (GATA6 GFP/GFP) mutant 
cells. Red arrows indicate the positions of the primers used for PCR screening. 




Figure 50. Representative DNA agarose gel picture of colonies screened via PCR to 
assess for successful HR. Genomic DNA was extracted from picked colonies and 
subjected to PCR using forward and reverse primers within exon 1 and intron 2 of 
the GATA6 gene respectively. Successful HR of the donor template resulted in a 
2765bp insertion as seen in colonies #4 and #10. 
 
 For H9 cells, I selected two heterozygous mutants and one homozygous 
mutant for use in downstream applications (Figure 51). For FSPS13.B cells, I selected 
two heterozygous mutants for use in downstream applications. To control for any 
potential off-target effects, I selected one colony that had been treated similarly to 
the mutants but harboured no observable HR or insertion of the donor template. 
 
 
Figure 51. Schematic of selected H9 TALEN-derived GATA6 cell lines via HR. Four 
TALEN-derived cell lines were selected for use in downstream applications. 
T1_TG_#3 is a TALEN-targeted but wild-type line; T1_TG_#1 and T1_TG_#5 are 
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Western blotting using both N- and C-terminal antibodies confirmed the 
complete absence of GATA6 protein in GATA6 GFP/GFP (Figure 52). All mutant lines 
were sequenced to ensure correct insertion of the donor template. This was done by 
sequencing the 3640bp PCR product containing the inserted fragment from the 
donor vector as shown in colonies #4 and #10 (Figure 50). They were also karyotyped 
and found to be normal and absent of any chromosomal abnormality. The mutants 
were further validated by the expression of emGFP (Figure 53). 
 
 
Figure 52. Western blot analysis of GATA6 and GATA4 protein levels in GATA6 
mutant lines. H9*, GATA6 4ins/+, GATA6 Δ4/Δ4, GATA6 GFP/+, GATA6 GFP/GFP mutant cells 
as well as Patients A and B were differentiated to day 3 (DE) and harvested. Alpha-
tubulin was used as a loading control. Long and short isoforms of wild-type GATA6 
are 64 kDa and 52 kDa respectively; the partial protein products for GATA64ins/+ are 
30 kDa and 18 kDa for the long and short isoforms respectively; the partial protein 
products for GATA6Δ4/Δ4 are 27 kDa and 15 kDa for the long and short isoforms 
respectively. No GATA6 protein was present for the GATA6 GFP/GFP mutant. 
 
 




Figure 53. Immunofluorescence showing emGFP-expressing heterozygous GATA6 
GFP/+ and homozygous GATA6 GFP/GFP mutant cells on day 3. Cells were differentiated 
toward the DE and checked for the expression of emGFP. 
 
 
GATA6 heterozygous and homozygous mutant H9 and FSPS13.B cell lines 
derived from TALEN targeting at TALEN1 site following HR repair pathway that were 
selected for use in downstream experiments are summarised in Table 52. The 
nomenclature for the mutants that is used for the subsequent sections of this report 
is also listed in Table 52. 
 
 
Table 52. Summary of selected H9 and FSPS13.B mutants generated via HR 
pathway 
Cell line TALEN cut site and colony number Nomenclature 
H9 T1_TG_#3 H9* (WT) 
H9 T1_TG_#1 GATA6 GFP/+ (Clone 1) (Het) 
H9 T1_TG_#5 GATA6 GFP/+ (Clone 2) (Het) 
H9 T1_TG_#10 GATA6 GFP/GFP (Hom) 
FSPS13.B T1_TG_#2 FSPS13.B* (WT) 
FSPS13.B T1_TG_#4 GATA6 GFP/+ (Clone 1) (Het) 
FSPS13.B T1_TG_#10 GATA6 GFP/+ (Clone 2) (Het) 
 
  Results 
117 
 
3.2.3. Reprogramming of GATA6 patient fibroblasts 
In addition to the TALEN-derived GATA6 mutants, I also obtained fibroblasts 
from two GATA6 patients in collaboration with Professor Andrew Hattersley.  
 
Genotyping via Sanger sequencing revealed that Patient A (GATA6 R456C/+) has 
a missense mutation within the second zinc finger DNA-binding domain of the 
GATA6 protein, while Patient B (GATA6 c.1136-2A>G/+) contains a splice acceptor 
mutation in exon 3 (Figure 54). After reprogramming of the fibroblasts, three 
independent hiPSC clones were selected for each patient line, and these clones were 
also monitored for absence of the Sendai virus (Figure 55). All patient-derived cell 
lines were karyotypically normal and pluripotent (Figure 56). 
 
Western blot analyses revealed the presence of both short and long isoforms 
of the GATA6 protein in both Patient A and B cell lines, suggesting the absence of a 




Figure 54. Genotype confirmation of Patients A and B by Sanger sequencing. Two 
GATA6 patient-derived hiPSC lines—Patient A, GATA6R465C/+ and Patient B, 
GATA6c.1136-2A>G /+ were sequenced to confirm their heterozygous mutations. 
 
  




Figure 55. PCR showing loss of transgenes in Patient A mutant line, clone 1 
compared with positive control. Picture is representative of 3 clones derived from 




Figure 56. Immunofluorescence showing successful reprogramming of patient-
derived Patient A (GATA6 R465C/+) mutant line via expression of pluripotency 
markers. Scale bars, 400 µm. Picture is representative of 3 clones derived from each 
Patient A and Patient B (GATA6 c.1136-2A>G/+) mutant lines. 
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3.2.4. Genome editing does not affect pluripotency 
Next, I wanted to determine whether genome editing of the GATA6 gene 
would affect pluripotency in the TALEN-derived GATA6 mutants. ICC analyses on 
undifferentiated H9 GATA6 4ins/+ and GATA6 Δ4/Δ4 mutant cells showed high 
expression levels of key pluripotency markers NANOG, OCT4 and SOX2 and absence 
of key DE marker SOX17 as well as GATA6, indicating that the cells are indeed in a 




Figure 57. Pluripotency is maintained in GATA6 4ins/+ H9 cells. Cells were grown in 
culture conditions that maintained pluripotency and analysed via 
immunofluorescence. Cells were fixed on day 0 and were stained for the 
pluripotency markers NANOG, OCT4 and SOX2 and early DE marker SOX17. Scale bar, 
100 µm. 
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Figure 58. Pluripotency is maintained in GATA6 Δ4/Δ4 H9 cells. Cells were grown in 
culture conditions that maintained pluripotency and analysed via 
immunofluorescence. Cells were fixed on day 0 and were stained for the 
pluripotency markers NANOG, OCT4 and SOX2 and early DE marker SOX17. Scale bar, 
100 µm. 
 
Subsequent qRT-PCR analyses of the H9, FSPS13.B and patient GATA6 mutant 
lines at D0 focusing on pluripotency genes such as OCT4 and SOX2 indicated that the 
mutant cell lines were similarly pluripotent , as described further in the next 
sections. Together, these results suggest genome editing on the GATA6 gene does 
not affect pluripotency. 
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3.2.5. TALEN-derived wild-type cell lines resemble untargeted hPSCs 
To assay for any potential off target effects, I differentiated TALEN-derived 
wild-type cells lines designated H9* and FSPS13.B* alongside their respective 
unmanipulated wild-type counterparts (H9 and FSPS13.B). qRT-PCR and FACS results 
show similar levels of key markers between the respective cell lines, indicating that 
DE and pancreatic differentiation were unaffected by the TALEN targeting, and 
further suggesting that there were no observable off target effects from the TALEN 
targeting (Figure 59, Figure 60 and Figure 61).  
 
 
Figure 59. qRT-PCR analyses of H9 and H9* cells on days 1, 2 and 3. RNA was 
extracted at specific stages and the expression patterns of key markers were 
determined. Data are triplicate samples of one experiment and representative of 

















Figure 60. qRT-PCR analyses of H9 and H9* cells on days 3, 6, 12 and 24. RNA was 
extracted at specific stages and the expression patterns of key markers were 
determined. Data are triplicate samples of one experiment and representative of 
three independent experiments. Error bars indicate standard deviation. 
 
            
Figure 61. Summary of PDX1+ (day 12) and C-PEPTIDE+ (day 24) cells via FACS for 
H9, H9*, FSPS13.B and FSPS13.B. For PDX1, H9 and FSPS13.B cells are normalised to 
100% and the relative PDX1+ cells to their respective mutant cell lines are shown. 
Data show results of three independent experiments and error bars indicate 
standard deviation. For C-PEPTIDE, absolute percentages of C-PEPTIDE+ cells in all 
cell lines are shown. Each bar represents one biological sample, and the graph was 
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3.3. Endodermal formation is inconsistently impaired by heterozygous GATA6 
mutations  
 
Next, to study the effects of heterozygous or homozygous loss of GATA6 
during human pancreatic development, I subjected the mutant lines to pancreatic 
differentiation in order to characterise their phenotypes and perform phenotypical 
comparisons between the various genotypes with an initial focus at the DE stage.  
 
3.3.1. Biallelic loss of N-terminal of GATA6 protein impairs DE formation 
To determine if loss of the N-terminal GATA6 protein upstream of the second 
start codon affects the formation of the DE, I differentiated the FSPS13.B lines 
derived from TALEN1 targeting toward the DE and performed FACS of key DE marker 
CXCR4 at day 3 (refer to Figure 47). Results from FACS suggested that in FSPS13.B 
cells, the loss of GATA6 protein between the first and second start codon on one 
allele does not affect DE differentiation (84% of CXCR4+ cells for T1_#50), but the 
biallelic loss of GATA6 protein between the first and second start codon impairs DE 
specification by approximately 30% (57% of CXCR4+ cells for T1_#50_#42) (Figure 
62). This is in concordance to an early study where it was reported that the N-
terminal 146 amino acids of GATA-6 contains transactivational activity, and its 






                                                          hiPSC                  CXCR4  
Figure 62. FACS of CXCR4+ cells for FSPS13.B TALEN1-targeted mutant cells on day 
3. Cells were grown in culture conditions that specified them toward the DE lineage 
and they were analysed via FACS. Cells were fixed on day 3 and were stained for 
CXCR4. Gates are set according to undifferentiated FSPS13.B cells. Data show results 
of one experiment that is representative of at least 3 independent experiments. 
T1_#6 (GATA6 +/+)         T1_#50 (GATA6 -/+)        T1_#50_#42 (GATA6 -/-)  




   Texas Red 
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3.3.2. Homozygous GATA6 mutants fail to form the DE 
It was reported that mouse embryos lacking both copies of Gata6 die during 
gastrulation (Morrisey et al., 1998, Koutsourakis et al., 1999). This early embryonic 
lethality is believed to be a consequence of extraembryonic endoderm dysfunction 
and arrest development at E6.5-7, as this deficiency could be overcome by providing 
Gata6-null embryos with a wild-type extraembryonic endoderm with the use of 
tetraploid embryo complementation (Zhao et al., 2005). 
 
To determine if this early endoderm dysfunction is recapitulated in humans 
using our in vitro model system, I differentiated TALEN-derived homozygous mutants 
in both H9 (GATA6 Δ4/Δ4 and GATA6 GFP/GFP) and FSPS13.B (GATA6 Δ14/Δ11) cell lines. At 
day 3, the loss of pluripotency marker NANOG in all cell lines (Figure 63) and the high 
expression of key DE marker SOX17 in H9* cells (Figure 64) indicated the successful 
differentiation of cells toward the DE lineage. H9-derived GATA6 Δ4/Δ4 and GATA6 
GFP/GFP homozygous mutants, however, displayed negligible expression of SOX17 as 
shown by ICC (Figure 64). FACS analyses showed a 90-100% decrease of SOX17+ and 
CXCR4+ cells (Figure 65 and Figure 66). FACS analyses of FSPS13.B-derived GATA6 
GFP/GFP homozygous mutant also showed a similar result (Figure 67). The loss of DE 
markers in these homozygous mutants was confirmed by qRT-PCR analyses (Figure 
68, Figure 69 and Figure 70). That CXCR4+ cells were similarly abolished in H9-
derived GATA6 Δ4/Δ4 and GATA6 GFP/GFP mutants suggest that the PPP in GATA6 Δ4/Δ4 
mutant cells does not have a functional role during differentiation (Figure 71). 
Expectedly, the homozygous mutants failed to develop into the subsequent key 
stages toward pancreatic development such as the dorsal foregut (Figure 72, Figure 
73 and Figure 74).  
 
Taken together, these results are in concordance with previously published 
data in mice where Gata6 -/- embryos displayed early embryonic lethality, which is 
believed to be a consequence of extraembryonic endoderm dysfunction. My results 
show that absence of GATA6 in GATA6 -/- hPSC mutants generated from TALEN 
genome editing abolished the formation of the DE.  




Figure 63. GATA6 4ins/+and GATA6 Δ4/Δ4 mutants had the capacity to differentiate. 
Cells were grown in culture conditions that specified them toward the DE lineage 
and analysed via immunofluorescence. Cells were fixed on day 3 and were stained 




Figure 64. SOX17 expression is abolished GATA6 Δ4/Δ4 cells. Cells were grown in 
culture conditions that specified them toward the DE lineage and analysed via 
immunofluorescence. Cells were fixed on day 3 and were stained for the DE marker 
SOX17. Scale bar, 100 µm. 
NANOG                 GATA6                    DAPI                   Merged 
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GATA6 4ins/+ 
GATA6 Δ4/Δ4 
 SOX17                 GATA6                    DAPI                   Merged 
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GATA6 4ins/+ 
GATA6 Δ4/Δ4 





                                 IgG                   hESC                   CXCR4 or SOX17 
Figure 65. The number of CXCR4+ and SOX17+ cells are decreased in GATA6 4ins/+ 
cells and are almost completely absent in GATA6 Δ4/ Δ4 H9 cells. Cells were fixed on 
day 3 and were stained for the DE markers SOX17 and CXCR4. Data show results of 




                                    IgG                   hESC                   CXCR4 or SOX17 
Figure 66. The number of CXCR4+ and SOX17+ cells are decreased in GATA6 GFP/+ 
cells and are almost completely absent in GATA6 GFP/ GFP H9 cells. Cells were fixed 
on day 3 and were stained for the DE markers SOX17 and CXCR4. Data show results 
of one experiment that is representative of at least 3 independent experiments. 
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                      hIPSC                  CXCR4  
Figure 67. The number of CXCR4+ is decreased in GATA6 Δ14/+ cells and are almost 
completely absent in GATA6 Δ14/ Δ11 FSPS13.B cells. Cells were fixed on day 3 and 
were stained for the DE marker CXCR4. Data show results of one experiment that is 
representative of at least 3 independent experiments. 
 
 
Figure 68. qRT-PCR analyses of H9*, GATA6 4ins/+ and GATA6 Δ4/Δ4 cells on days 1, 2 
and 3. RNA was extracted at specific stages and the expression patterns of key 
markers were determined. Data are triplicate samples of one experiment and 
representative of three independent experiments. Error bars indicate standard 
deviation. 
 FSPS13.B*                  GATA6 Δ14/+                    GATA6 Δ14/Δ11 
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Figure 69. qRT-PCR analyses of H9*, GATA6 GFP/+ and GATA6 GFP/GFP cells on day 3. 
RNA was extracted on day 3 and the expression patterns of key endoderm markers 
were determined. Data are triplicate samples of one experiment and representative 
of three independent experiments. Error bars indicate standard deviation. 
 
 
Figure 70. qRT-PCR analyses of FSPS13.B*, GATA6 Δ14/+, GATA6 GFP/+ and           
GATA6 Δ14/Δ14 cells on day 3. RNA was extracted on day 3 and the expression 
patterns of key endoderm markers were determined. Data are triplicate samples of 
one experiment and representative of three independent experiments. Error bars 





























Figure 71. Summary of CXCR4+ cells via FACS for all H9-derived mutant cells on day 
3. Wild-type H9 cells are normalised to 100% and the relative CXCR4+ cells of H9* or 
mutant cells are shown. Data show results of two experiments and error bars 
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3.3.3. GATA6 heterozygous mutants exhibit endodermal defects using lab-
derived protocol 
 
After determining the phenotypic consequence of homozygous GATA6 
mutations, I here shift my focus to heterozygous GATA6 hPSC lines.  
 
In H9-derived GATA6 4ins/+ heterozygous mutant cells, SOX17 is expressed on 
day 3, indicating that DE formation is not abolished (Figure 64). FACS analyses on day 
3 for key DE markers CXCR4 and SOX17 for GATA6 4ins/+ and GATA6 GFP/+ mutant cells 
shows a moderate decrease in the number of CXCR4+ and SOX17+ cells of 
approximately 20% (Figure 65 and Figure 66). The relative number of CXCR4+ cells 
from FACS analyses comparing the GATA6 4ins/+ and GATA6 GFP/+ clones 1 and 2 
mutants to H9* cells (normalised to 100%) indicate that the population of CXCR4+ 
cells for heterozygous mutants are consistently approximately 80% (Figure 71). The 
phenotypic similarity between GATA6 4ins/+ and both clones 1 and 2 of GATA6 GFP/+ 
also suggests that the one copy of the PPP present in the GATA6 4ins/+ mutant cells is 
non-functional during differentiation. ICC analyses showing expression of FOXA2 on 
days 3 and 6 (Figure 72), the absence of CDX2 (Figure 75) and HEX (Figure 76) on day 
6 and expression of HNF1B on day 6 and SOX2 on day 9 (Figure 77) indicate that 
GATA6 4ins/+ mutant cells are capable of differentiating into the dorsal foregut and 
foregut lineages.  
 
Using the H9-derived GATA6 4ins/+ and GATA6 Δ4/Δ4 lines, I next asked whether 
GATA6 haploinsufficiency impacts the very early differentiation from mesendoderm 
(corresponding to days 1 and 2) to DE (day 3). qRT-PCR analyses revealed the 
expression of primitive streak (BRACHYURY) and mesendoderm (EOMESODERMIN 
(EOMES)) markers were relatively unchanged across the control H9* and mutant 
lines, suggesting that early mesendoderm formation was not affected by either 
single or biallelic loss of GATA6 (Figure 68). In contrast, consistent with FACS 
analyses, key DE markers SOX17 and CXCR4 were downregulated beginning on day 2 
by approximately 30% in GATA6 4ins/+ and clones 1 and 2 of GATA6 GFP/+ cells (Figure 
68 and Figure 69).  




Figure 72. FOXA2 expression is abolished in GATA6 Δ4/Δ4 cells and decreased in 
GATA6 4ins/+ cells on day 3. Cells were grown in culture conditions that specified 
them toward the DE lineage and analysed via immunofluorescence. Cells were fixed 




Figure 73. FOXA2 expression is abolished in GATA6 Δ4/Δ4 cells on day 6. Cells were 
grown in culture conditions that specified them toward the dorsal foregut lineage 
and analysed via immunofluorescence. Cells were fixed on day 6 and were stained 
for the foregut marker FOXA2. Scale bar, 100 µm. 
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Figure 74. HNF1B expression is abolished in GATA6 Δ4/Δ4 cells on day 6. Cells were 
grown in culture conditions that specified them toward the dorsal foregut lineage 
and analysed via immunofluorescence. Cells were fixed on day 6 and were stained 




Figure 75. CDX2 remains unexpressed in all cells on day 6. Cells were grown in 
culture conditions that specified them toward the dorsal foregut lineage and 
analysed via immunofluorescence. Cells were fixed on day 6 and were stained for the 
hindgut marker CDX2. Scale bar, 100 µm. 
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Figure 76. HEX remains unexpressed in all cells on day 6. Cells were grown in 
culture conditions that specified them toward the dorsal foregut lineage and 
analysed via immunofluorescence. Cells were fixed on day 6 and were stained for the 




Figure 77. SOX2 expression is abolished in GATA6 Δ4/Δ4 cells on day 9. Cells were 
grown in culture conditions that specified them toward the foregut lineage and 
analysed via immunofluorescence. Cells were fixed on day 9 and were stained for the 
foregut marker SOX2. Scale bar, 100 µm. 
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As GATA6 and GATA4 have been shown to interact with each other (Charron 
et al., 1999), I looked at the mRNA levels of GATA4 to investigate whether its 
regulation is affected by mutations in the GATA6 gene. Notably, on day 3 at the 
transcriptional level, I observed that GATA4 expression was decreased in H9-derived 
GATA6 4ins/+ and GATA6 Δ4/Δ4 mutant cells (Figure 68), suggesting that the GATA6 PPPs 
generated from these mutant alleles interact with GATA4 to negatively impact its 
expression, leading to its down-regulation. This was in contrast to the GATA4 levels 
observed in GATA6 GFP/+ and GATA6 GFP/GFP cells, where GATA4 levels remained 
relatively unchanged at day 3 (Figure 69). Nevertheless, a similar DE phenotype was 
seen with H9-derived GATA6 GFP/+ and GATA6 GFP/GFP cells based on SOX17 levels 
(Figure 69), suggesting that even though the PPPs seemed to decrease GATA4 levels, 
the defect on DE development is independent of this decrease. 
 
Interestingly, in FSPS13.B-derived heterozygous mutants, differing DE 
phenotypes were observed as compared to H9-derived heterozygous mutants. FACS 
analyses of CXCR4 on day 3 in GATA6 1ins/+, GATA6 Δ14/+ and GATA6 Δ21_8ins/+ mutant 
cells showed a 40-60% decrease in CXCR4+ cells (Figure 67 and Figure 79), indicating 
a stronger defect in these cells compared to the respective H9 mutant (GATA6 4ins/+). 
qRT-PCR was consistent with this observation, showing an approximately 50% 
decrease of SOX17 expression levels in GATA6 Δ14/+ mutant cells (Figure 70). At the 
transcriptional level on day 3, similar to H9-derived GATA6 4ins/+ and GATA6 Δ4/Δ4 
mutant cells, I also observed that GATA4 expression was decreased in GATA6 Δ14/+ 
and GATA6 Δ14/ Δ11 cells (Figure 70). 
 
In contrast, FACS analyses of the key DE markers CXCR4 and SOX17 on day 3 
in FSPS13.B-derived heterozygous mutants GATA6 GFP/+ clones 1 and 2 both displayed 
no defects in DE formation (Figure 78 and Figure 79). This data was recapitulated by 
qRT-PCR analyses where expression levels of SOX17, GATA6 and GATA4 had no 
significant changes (Figure 70). 
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Consistent with H9-derived homozygous GATA6 Δ4/Δ4 and GATA6 GFP/GFP 
mutant cells, FSPS13.B-derived homozygous GATA6 Δ14/Δ11 mutant cells failed to form 
the DE as shown by FACS analyses of CXCR4 at day 3 (Figure 67 and Figure 79). qRT-
PCR analyses also showed almost complete ablation of SOX17, and strong decrease 
of GATA6 and GATA4 (Figure 70). 
 
Patient A (clones 1-3) and Patient B (clones 1-3) displayed a similar DE 
phenotype to FSPS13.B-derived heterozygous GATA6 1ins/+, GATA6 Δ14/+ and GATA6 
Δ21_8ins/+ mutants cells, where FACS analyses of the key DE marker CXCR4 at day 3 
showed a 50-60% decrease in CXCR4+ cells (Figure 80, Figure 81, Figure 82 and 
Figure 83). qRT-PCR analyses also showed a strong down-regulation of DE markers 
SOX17 and CXCR4 in both patient lines (Figure 84). GATA4 levels, and to a lesser 
extent GATA6, in both patient lines were also down-regulated (Figure 84). 
 
Taken together, these finding suggest that complete loss of GATA6 in TALEN-
edited hPSCs significantly perturbs the gene regulatory network (GRN) required for 
DE specification, resulting in the failure of DE formation.  Heterozygous loss of 
GATA6 seems to impair DE formation with a varying penetrance of phenotype from 
20% in H9-derived heterozygous mutants, to 40-60% in FSPS13.B-derived 
heterozygous mutants and Patients A and B, and to no impairment in FSPS13.B-
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                                       IgG                   hIPSC                  CXCR4 or SOX17 
Figure 78. The number of CXCR4+ and SOX17+ cells is not decreased in both clones 
1 and 2 of GATA6 GFP/+ FSPS13.B cells. Cells were fixed on day 3 and were stained for 
the DE markers SOX17 and CXCR4. Data show results of one experiment that is 
representative of at least 2 independent experiments. 
 
                      
Figure 79. Summary of CXCR4 levels via FACS for all FPSP13.B-derived mutant cells 
on day 3. Wild-type FSPS13.B cells are normalised to 100% and the relative CXCR4 
expression levels of FSPS13.B* or mutant cells are shown. Data show results of two 
experiments and error bars indicate standard deviation.  
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 FSPS13.B*       GATA6 GFP/+ (Clone 1)    GATA6 GFP/+ (Clone 2) 
 
 

















  Results 
137 
 
                      
 
 
                                       IgG                   hESC                  CXCR4  
Figure 80. The number of CXCR4+ cells is decreased in Patient A. Cells were fixed on 
day 3 and were stained for the DE marker CXCR4. Data show results of one 
experiment that is representative of at least 3 independent experiments. 
 
       
 
Figure 81. Summary of CXCR4 levels via FACS for Patient A cells on day 3. Wild-type 
FSPS13.B cells are normalised to 100% and the relative CXCR4 expression levels of 
clones 1, 2 and 3 of Patient A are shown. Data show results of two experiments and 
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                                       IgG                   hESC                  CXCR4  
Figure 82. The number of CXCR4+ cells is decreased in Patient B. Cells were fixed on 
day 3 and were stained for the DE marker CXCR4. Data show results of one 
experiment. 
 
       
 
Figure 83. Summary of CXCR4 levels via FACS for Patient B cells on day 3. Wild-type 
FSPS13.B cells are normalised to 100% and the relative CXCR4 expression levels of 
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Figure 84. qRT-PCR analyses of Patient A and B cells on day 3. RNA was extracted on 
day 3 and the expression patterns of key endoderm markers were determined. Data 
are triplicate samples of one experiment and representative of two independent 




              
Figure 85. Summary of CXCR4 levels via FACS for H9 and FSPS13.B selected 
heterozygous mutant cells, and Patients A and B on day 3. H9 and FSPS13.B cells 
are normalised to 100% and the relative CXCR4 expression levels of their respective 
mutant cell lines are shown. Data show results of three independent experiments 
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3.3.4. GATA6 heterozygous mutants display similar endodermal defects 
using a commercial kit from STEMCELL Technologies 
 
I further validated these results using the STEMdiff Definitive Endoderm kit 
from Stem Cell Technologies (SCT) using H9*, H9-derived GATA6 4ins/+ and GATA6 
Δ4/Δ4 lines. A similar endoderm defect was observed in the H9-derived GATA6 4ins/+ 
and GATA6 Δ4/Δ4 cells using this protocol as compared to the lab protocol. FACS 
analyses at day 3 showed that SOX17+ and CXCR4+ cells were decreased by 
approximately 30-50% in GATA6 4ins/+ cells and 90% in GATA6 Δ4/Δ4 cells (Figure 86). 
This was consistently seen in qRT-PCR analyses (Figure 87). Expression patterns of 
OCT4, GATA6 and GATA4 on days 3 and 6 also resembled that of the lab’s in-house 
protocol (Figure 87). These results using a commercially available kit align well with 
those presented earlier in this chapter and give me confidence in my conclusion that 
GATA6 haploinsufficiency indeed impacts early formation of the DE lineage. 
  





                                 IgG                   hESC                   CXCR4 or SOX17 
Figure 86. The number of CXCR4+ and SOX17+ cells is decreased in GATA6 4ins/+ cells 
and are almost completely absent in GATA6 Δ4/ Δ4 H9 cells differentiated via 
STEMCELL Technologies kit. Cells were fixed on day 3 and were stained for the DE 
markers SOX17 and CXCR4. Data show results of one experiment that is 
representative of at least two independent experiments. 
 
Figure 87. qRT-PCR analyses of H9*, GATA6 4ins/+ and GATA6 Δ4/Δ4 cells on days 3 
and 6 differentiated via STEMCELL Technologies kit . RNA was extracted at specific 
stages and the expression patterns of key markers were determined. Data are 
triplicate samples of one experiment and representative of three independent 
experiments. Error bars indicate standard deviation. 
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3.3.5. GATA6 heterozygous mutants did not exhibit endodermal defects 
using PSC Definitive Endoderm Induction Kit from Life Technologies 
 
In addition to the commercial kit from SCT, I also performed DE 
differentiation using PSC Definitive Endoderm Induction Kit from Life Technologies. 
H9 and FPSP13.B cells were differentiated alongside the TALEN-derived and Patient B 
lines as a control for DE differentiation efficiency compared to the lab and the 
STEMdiff Definitive Endoderm kit from SCT. From FACS analyses, CXCR4+ cells were 
consistently over 80% in both H9 and FSPS13.B cells, suggesting a slightly more 
efficient DE differentiation than the lab and SCT protocols (Figure 88).  
 
TALEN-derived FSPS13.B*, GATA6 Δ14/+ and GATA6 GFP/+, GATA6 Δ14/Δ11 cell 
lines and Patient B (clone 1) were differentiated using the PSC DE induction kit. 
Interestingly, FACS analyses revealed no endodermal defect in the GATA6 Δ14/+ and 
GATA6 GFP/+ and Patient B heterozygous mutant cell lines (Figure 88). qRT-PCR 
analyses recapitulate results from FACS, except for Patient B (Figure 89). However, 
qRT-PCR was only performed once, whereas FACS was performed twice. So, it is 
possible that there could have been an error with the qRT-PCR result of Patient B. 
FACS and qRT-PCR results for GATA6 Δ14/Δ11 cell line was consistent with both lab and 
SCT protocols, with an approximately 90% decrease of CXCR4+ cells (Figure 88 and 
Figure 89). 
 
I attempted to pursue this inconsistency between protocols further by 
requesting to know the components of the PSC DE Kit, but Life Technologies was 
unwilling to share the formulation of their kit. Hence, I was unable to compare the 
components between the protocols and determine which growth factor(s) and/or 
pathway inhibitors could have attributed to this discrepancy in the results. Taken 
together, the results from the PSC DE kit suggest that the impaired DE phenotype 
seen in the heterozygous GATA6 mutant lines could be attributed to a protocol-
dependent defect.   






                         
            IgG                   hESC                   CXCR4 
Figure 88. The number of CXCR4+ cells is not decreased in GATA6 heterozygous 
FSPS13.B mutant cells and Patient B differentiated via PSC Definitive Endoderm 
Induction Kit from Life Technologies. Cells were fixed on day 3 and were stained for 
the DE marker CXCR4. Gates were set according to hESC. Data show results of one 
experiment that is representative of two independent experiments. 
 
          
Figure 89. qRT-PCR analyses of FSPS13.B, FPSP13.B*, FSPS13.B-derived mutant cells 
and Patient B on day 3 differentiated via PSC Definitive Endoderm Induction Kit 
from Life Technologies. RNA was extracted on day 3 and the expression of CXCR4 
was determined. Data are triplicate samples of one experiment, error bars indicate 
standard deviation. 
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3.4. GATA6 is required for differentiation into the pancreatic lineage 
To further study the effects of heterozygous and homozygous loss of GATA6 
during human pancreatic development, I continued the differentiation process with 
the mutant lines in order to characterise their later phenotypes during acquisition of 
pancreatic identity (pancreatic endoderm; PE on day 12) and allocation to the 
endocrine lineage (endocrine progenitors; EP on day 24). 
 
3.4.1. Homozygous GATA6 mutants fail to enter the pancreatic lineage 
To characterise the phenotype of homozygous loss of GATA6 using our in 
vitro model system, I differentiated H9 TALEN-derived GATA6 Δ4/Δ4 and GATA6 GFP/GFP 
mutant cells toward the EP stage. Expectedly, ICC analyses of GATA6 Δ4/Δ4 cells 
showed the absence of key markers PDX1 at day 12 (Figure 90), NGN3 at day 15 
(Figure 91) and C-PEPTIDE, SST and GCG at day 24 (Figure 92), indicating that the 




Figure 90. PDX1 is not activated in GATA6 Δ4/Δ4 cells by day 12 of differentiation. 
Cells were grown in culture conditions that specified them toward the pancreatic 
progenitor lineage and analysed via immunofluorescence. Cells were fixed on day 12 
and were stained for the pancreatic marker PDX1. Scale bar, 100 µm. 
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Figure 91. NGN3 is not activated in GATA6 Δ4/Δ4 cells by day 15 of differentiation. 
Cells were grown in culture conditions that specified them toward the endocrine 
lineage and analysed via immunofluorescence. Cells were fixed on day 15 and were 




Figure 92. C-PEPTIDE, SST and GCG expression are not activated in GATA6 Δ4/Δ4 cells 
by day 24 of differentiation. Cells were grown in culture conditions that mature into 
endocrine progenitors and analysed via immunofluorescence. Cells were fixed on 
day 24 and were stained for key markers C-PEPTIDE, SST and GCG. Scale bar, 100 µm. 
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FACS analyses of GATA6 Δ4/Δ4 and GATA6 GFP/GFP mutant cells on day 12 
showed a 90-100% loss of PDX1+ cells compared to H9 wild-type and H9* cells 
(Figure 93 and Figure 94). On day 24, C-PEPTIDE levels in GATA6 GFP/GFP cells were 
almost negligible (Figure 95 and Figure 96). In some experiments, GATA6 Δ4/Δ4 cells 
did not survive up to day 24 and died around day 18 (Figure 95). 
 
 
Figure 93. Summary of PDX1 levels via FACS for H9 homozygous mutant cells on 
day 12. Wild-type H9 cells are normalised to 100% and the relative PDX1 levels of 
H9*, H9-derived GATA6 Δ4/Δ4 and GATA6 GFP/GFP mutant cells are shown. Data show 
results of two independent experiments and error bars indicate standard deviation. 
           
Figure 94. Summary of PDX1 levels via FACS for all H9-derived mutants cells on day 
12. Wild-type H9 cells are normalised to 100% and the relative PDX1 levels of H9* or 
mutant cells are shown. Data show results of two experiments and error bars 
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Figure 95. Summary of C-PEPTIDE levels via FACS for H9 homozygous mutant cells 
on day 24. Absolute percentage of C-PEPTIDE-positive cells in H9 wild-type, H9* and 
H9-derived GATA6 Δ4/Δ4 and GATA6 GFP/GFP mutant cells are shown. Each bar 
represents one biological sample, and the graph was taken from one experiment, 
which is representative of two independent experiments. 
 
                     
Figure 96. Summary of PDX1 (day 12) and C-PEPTIDE (day 24) expression via FACS 
for H9 and FSPS13.B selected heterozygous mutant cells, and Patients A and B. For 
PDX1, H9 and FSPS13.B cells are normalised to 100% and the relative PDX1 levels of 
their respective mutant cell lines are shown. Data show results of three independent 
experiments and error bars indicate standard deviation. For C-PEPTIDE, absolute 
percentages of C-PEPTIDE-positive cells in all cell lines are shown. Each bar 
represents one biological sample, and the graph was taken from one experiment, 
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3.4.2. Heterozygous GATA6 mutants elicit a pancreatic defect in all 
protocols 
 
Next, to characterise the phenotype of heterozygous loss of GATA6 using our 
in vitro model system, I first differentiated H9 TALEN-derived GATA6 4ins/+ and clones 
1 and 2 of GATA6 GFP/+ mutant cells via the lab-derived protocol toward the EP stage. 
FACS analyses of key PE marker PDX1 at day 12 for GATA6 4ins/+ and clones 1 and 2 of 
GATA6 GFP/+ mutant cells indicate a decrease in PDX1+ cells by about 50% in both 
lines (Figure 94 and Figure 96), even though GATA6 GFP/+ seemed to have lower levels 
of PDX1 (Figure 97). In contrast, ICC analyses of GATA6 4ins/+ cells did not show an 
observable difference in PDX1 expression levels compared to H9* cells (Figure 90). 
This observation could be due to the fact that the cells analysed by ICC are grown 
very densely, resulting in overlapping growth that may mask PDX1-negative cells.  
 
On day 24, C-PEPTIDE levels by FACS were almost negligible in both GATA6 
4ins/+ and GATA6 GFP/+ mutant lines (Figure 96). Similar to PDX1, GATA6 GFP/+ have 
lower levels of Insulin mRNA compared to GATA6 4ins/+ (Figure 97). qRT-PCR analyses 
of key genes showed a similar down-regulation of HNF4A and GATA4 in both GATA6 
4ins/+ and GATA6 GFP/+ mutant lines at day 24 (Figure 97). HLXB9, on the other hand, 
was strongly decreased in GATA6 4ins/+ mutant cells but not in GATA6 GFP/+ mutant 
cells at day 24 (Figure 97). 
 
In addition, I performed C-peptide ELISA on H9*, GATA6 4ins/+ and GATA6 Δ4/Δ4 
mutant cells. Similar to the H9 wild-type cells that was described earlier in Chapter 
3.1.1, H9* elicited an inverse C-peptide release response upon glucose stimulation 
(Figure 98). The levels of C-Peptide stimulation and down-regulation in H9*is very 
similar to H9 wild-type, suggesting the lack of off target effects from the TALEN 
targeting, if any. In contrast, GATA6 4ins/+ and GATA6 Δ4/Δ4 mutant lines did not elicit 
any glucose-stimulated C-peptide release, and the basal C-Peptide levels these lines 
are much lower than H9 wild-type and H9* (Figure 98). 
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Figure 97. qRT-PCR analyses of H9*, GATA6 4ins/+ and GATA6 Δ4/Δ4 cells on days 3, 6, 
12 and 24. RNA was extracted at specific stages and the expression patterns of key 
markers were determined. Data are triplicate samples of one experiment and 




















Figure 98. C-peptide secretion of TALEN-derived H9 mutants upon glucose 
stimulation on day 24. Cells were differentiated using the lab-derived protocol and 
assayed on day 24. Data are presented as the average of 3 biological replicates of 
one experiment and representative of two independent experiments. Error bars 
indicate standard deviation. LG1 is first incubation of low glucose; HG1 is first 
incubation of high glucose; LG2 is second incubation of low glucose; HG2 is second 
incubation of high glucose. 
 
 
In FSPS13.B TALEN-derived GATA6 Δ14/+ and GATA6 GFP/+ mutant cells, PDX1 
levels were also strongly down-regulated on days 12 and 24 by qRT-PCR (Figure 99). 
FACS analyses showed an approximately 80-90% decrease of PDX1+ cells in GATA6 
Δ14/+ mutant cells and 50% decrease of PDX1+ cells in GATA6 GFP/+ mutant cells on day 
12 (Figure 96). PDX1 FACS analyses for all the other heterozygous mutant lines are 
shown in Figure 100. qRT-PCR analyses of key genes showed down-regulation of 
HNF4A and Insulin on days 12 and 24, but no change for HLXB9 (Figure 99). GATA4 
expression was down-regulated in GATA6 Δ14/+ mutant cells at all time points but 
remained relatively unchanged in GATA6 GFP/+ mutant cells (Figure 99). On day 24, C-
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Figure 99. qRT-PCR analyses of FSPS13.B*, GATA6 Δ14/+ and GATA6 GFP/+ cells on 
days 3, 12 and 24. RNA was extracted at specific stages and the expression patterns 
of key markers were determined. Data are triplicate samples of one experiment and 




Figure 100. Summary of CXCR4 levels via FACS for all FPSP13.B-derived mutant cells 
on day 12. Wild-type FSPS13.B cells are normalised to 100% and the relative CXCR4 
levels of FSPS13.B* or mutant cells are shown. Data show results of two experiments 
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In Patients A and B, PDX1 levels were also strongly down-regulated on days 
12 and 24, as shown by qRT-PCR (Figure 101). FACS analyses showed an 
approximately 70-80% decrease of PDX1+ cells in both Patients A and B lines on day 
12 (Figure 96). qRT-PCR analyses of key genes showed down-regulation of GATA4, 
FOXA2, HNF4A, HLXB9 and Insulin on days 12 and 24 (Figure 101). On day 24, FACS of 
C-PEPTIDE+ cells were near zero in both Patient A and B lines (Figure 96). 
 
 
Figure 101. qRT-PCR analyses of FSPS13.B, Patient A and Patient B cells on days 3, 
12 and 24. RNA was extracted at specific stages and the expression patterns of key 
markers were determined. Data are triplicate samples of one experiment and 
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Using the STEMdiff pancreatic progenitor kit from SCT, I differentiated H9*, 
H9-derived GATA6 4ins/+ and GATA6 Δ4/Δ4 lines toward the PE lineage. A similar 
pancreatic defect was observed in the H9-derived GATA6 4ins/+ and GATA6 Δ4/Δ4 cells 
using this protocol as compared to the lab protocol. FACS analyses on day 12 showed 
that PDX1+ cells were decreased by approximately 50% in GATA6 4ins/+ cells and 
absent in GATA6 Δ4/Δ4 cells (Figure 102). This was consistently seen in qRT-PCR 
analyses where key markers such as GATA4, HNF4A, PDX1 and NKX6-1 were strongly 
down-regulated in GATA6 4ins/+ mutant cells and absent in GATA6 Δ4/Δ4 cells (Figure 
103). These results complement the results derived from the lab protocol. 
 
Using the PSC Definitive Endoderm Induction Kit from Life Technologies, I 
differentiated FSPS13.B* and FSPS13.B-derived mutants GATA6 Δ14/+, GATA6 GFP/+ and 
GATA6 Δ14/ Δ11 mutant cell lines and Patient B toward the PE lineage. Interestingly, 
despite the heterozygous mutants showing no impairment of DE formation 
(described in Chapter 3.3.5), a very similar pancreatic defect was observed in the 
heterozygous mutants using this protocol as compared to the lab protocol. FACS 
analyses on day 12 showed that PDX1+ cells were decreased by approximately 80-
90% in GATA6 Δ14/+cells and Patient B cells, 60% in GATA6 GFP/+ cells and is almost 
completely absent in GATA6 Δ14/ Δ11 cells (Figure 104). qRT-PCR analysis focusing on 
PDX1 on day 12 confirms the FACS data (Figure 105). 
 
Taken together, these finding confirm that complete loss of GATA6 in TALEN-
edited hPSCs results in failure of pancreatic development, which is most likely 
explained by the disruption of the GRN required for earlier DE specification. 
Heterozygous loss of GATA6 seems to impair pancreatic formation (day 12) by 50-
90%, which is a smaller variation in phenotype penetrance across all heterozygous 
mutants as compared to DE. By day 24, all heterozygous mutants fail to differentiate 
into endocrine cells at similar rates, thereby reducing the variation in phenotype 
penetrance further. The similarity of phenotypes between the lab-derived, SCT and 
Life Technologies protocols suggest that the pancreatic phenotypes observed in the 
heterozygous mutants are not a consequence of the differentiation protocol used, 
and are true effects of heterozygous loss of GATA6. 
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Figure 102. The number of PDX1+ cells is decreased in GATA6 4ins/+ cells and is 
almost completely zero in GATA6 Δ4/ Δ4 H9 cells differentiated via STEMCELL 
Technologies kit. Cells were fixed on day 12 and were stained for PDX1. Data show 




Figure 103. qRT-PCR analyses of H9*, GATA6 4ins/+ and GATA6 Δ4/Δ4 cells on days 3, 
6, 9 and 14 differentiated via STEMCELL Technologies kit. RNA was extracted at 
specific stages and the expression patterns of key markers were determined. Data 
are triplicate samples of one experiment and representative of three independent 






























            IgG                   hiPSC                   PDX1 
Figure 104. The number of PDX1+ cells is decreased in GATA6 heterozygous 
FSPS13.B mutant cells and Patient B differentiated via PSC Definitive Endoderm 
Induction Kit from Life Technologies. Cells were fixed on day 12 and were stained 




Figure 105. qRT-PCR analyses of FPSP13.B*, FSPS13.B-derived mutant cells and 
Patient B on day 12 differentiated via PSC Definitive Endoderm Induction Kit from 
Life Technologies. RNA was extracted on day 12 and the expression of PDX1 was 
determined. Data are triplicate samples of one experiment, error bars indicate 
standard deviation. 
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3.5. GATA6 is a key regulator of DE and pancreatic specification 
Next, to investigate if GATA6 is a master regulator of the DE and pancreatic 
transcriptional networks, I conducted RNA-sequencing (RNA-seq) on H9*, H9-derived 
GATA6 4ins/+, GATA6 Δ4/Δ4 and Patient A (clones 1-3) mutant cells at the DE and 
pancreatic stages of the lab differentiation protocol. Specifically, I performed RNA-
seq for biologically triplicate samples on days 3 and 12 for GATA6 4ins/+ mutant cells, 
days 3 and 12 for Patient A cells, days 2 and 3 for GATA6 Δ4/Δ4 mutant cells and days 
2, 3, and 12 for H9* cells. In addition, to identify the direct interacting partners of 
GATA6, I also perform chromatin immunoprecipitation followed by high-throughput 
sequencing (ChIP-seq) for biologically duplicate samples on days 3 and 12 for H9* 
and H9-derived GATA6 4ins/+ mutant cells, and on day 12 for FSPS13.B* and FSPS13.B-
derived GATA6 Δ14/+, GATA6 GFP/+ mutant cells. Pre-processing and downstream 
analyses of the RNA- and ChIP-seq data were performed with the help of Dr. Pedro 
Madrigal. These experiments will elucidate the molecular mechanism of GATA6 and 
reveal the functional consequences and global transcriptional profiles of GATA6. 
 
3.5.1. Loss of GATA6 perturbs the DE transcriptional network and 
promotes mesoderm formation 
 
Using RNA-seq data, I first performed differential gene expression analyses 
between GATA6 Δ4/Δ4 mutant cells against H9* cells at day 2 to investigate the effect 
of biallelic loss of GATA6 on the GRN prior to DE formation. I found 4,679 
differentially expressed genes between H9* and GATA6 Δ4/Δ4 cells (Table S1) 
(adjusted p-value 0.01; fold-change ≥ 2). Of these, 3,649 were protein coding genes; 
2,239 down-regulated in GATA6 Δ4/Δ4 cells and 1,410 up-regulated in GATA6 Δ4/Δ4 
cells. Interestingly, gene ontology (GO) analysis via DAVID revealed the enrichment 
of many mesodermal developmental pathways, which were found up-regulated in 
GATA6 Δ4/Δ4 mutant cells (Figure 106). Conversely, endodermal developmental 
pathways were down-regulated in GATA6 Δ4/Δ4 mutant cells. In a heat map showing 
the top 10 most variable genes, SOX17 was amongst the most highly down-regulated 
genes, suggesting that the expression of SOX17 is regulated by GATA6 (Figure 107). 




Figure 106. Enriched GO of GATA6 Δ4/Δ4 mutant cells against H9* cells on day 2 from 
RNA-seq. GO shows fold enrichment of many mesodermal and endodermal 
developmental pathways up- and down-regulated respectively in GATA6 Δ4/Δ4 mutant 
cells. Data show results of triplicate samples in one experiment representative of 




Figure 107. Key DE marker, SOX17, is one of the most highly down-regulated genes 
in GATA6 Δ4/Δ4 mutant cells. Heat map illustrating differential gene expression of the 
top 10 most variable genes in GATA6 Δ4/Δ4 mutant cells against H9* cells.  
H9* GATA6 Δ4/Δ4 
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From RNA-seq results on day 3, I found 7,472 differentially expressed genes 
between H9* and GATA6 Δ4/Δ4 mutant cells (Table S2), 2,898 genes between H9* and 
GATA6 4ins/+ (Table S3), and 6,977 between clones 1-3 of Patient A mutant cells 
(Table S4). Of the 7,472 genes, 5,393 were protein coding genes; 2,702 down-
regulated in GATA6 Δ4/Δ4 cells and 2,691 up-regulated in GATA6 Δ4/Δ4 cells. Of the 
2,898 genes, 1,460 were protein coding genes; 729 down-regulated in GATA6 4ins/+ 
cells and 731 up-regulated in GATA6 4ins/+ cells. Of the 6,977 genes, 3,981 were 
protein coding genes; 2,154 down-regulated in Patient A cells and 1,827 up-
regulated in Patient A cells. 
 
In a heat map derived from RNA-seq results focusing on genes involved in 
ectoderm, endoderm and mesoderm development, I observed that consistent with 
my day 2 RNA-seq data, GATA6 Δ4/Δ4 mutant cells displayed a decreased endodermal 
signature, with a concomitant increase in the expression of mesodermal genes 
(Figure 108). A similar trend was observed when comparing between H9*, 
GATA64ins/+ and clones 1 to 3 of Patient A (Figure 109). 
 
Next, in order to subsequently identify the direct interacting partners of 
GATA6, I performed ChIP on H9* cells and H9-derived GATA6 4ins/+ cells which were 
differentiated to the DE stage via the lab protocol to identify those genes bound 
directly by GATA6. I validated the ChIP via qPCR using primers recognising a region 
on the human HNF4α P2 promoter as a GATA6 positive control (primer sequences 
are listed in Chapter 2.10.5). The primer sequences were kindly provided to us by our 
collaborator Dr. Santi Rodriguez. Indeed, GATA4 and GATA6 have been shown to 
bind to HNF4α (Sumi et al., 2007). Results from qPCR show a 4-fold increase in 
binding in H9* cells and only a 1-fold increase in binding in GATA6 4ins/+ mutant cells 
compared to IgG (Figure 110). To ensure that this was not a result of a decreased 
number of cells, I performed FACS on GATA6 at the DE stage and found that both 
H9* and GATA6 4ins/+ cells similarly express approximately 95% GATA6-positive cells 
(Figure 111), indicating that the decreased DNA binding observed in GATA6 4ins/+ 
mutant cells is indeed a consequence of heterozygous loss of GATA6.  




                 
 
Figure 108. Heat map illustrating differential gene expression of key germ layer 
markers via RNA-seq between H9*cells and H9-derived GATA6 4ins/+ and GATA6 
Δ4/Δ4 mutant cells at the DE stage (day 3). n = 3 biological replicates for each cell line. 
 




Figure 109. Heat map illustrating differential gene expression of key germ layer 
markers via RNA-seq between H9*cells and H9-derived GATA6 4ins/+ and clones 1-3 
of Patient A mutant cells at the DE stage (day 3). n = 3 biological replicates for each 
cell line. 
 





Figure 110. ChIP validation via qPCR using primers specific to a GATA6 positive 
binding region on day 3. Values of input samples were subtracted from the values of 
IgG or GATA6 samples and the graph shows fold over IgG (normalised to 1) of H9* 
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Figure 111. The number of GATA6+ cells is similar in H9* and H9-derived GATA6 
4ins/+ cells differentiated via the lab protocol on day 3. Cells were fixed on day 3 and 
were stained for GATA6. Data show results of one experiment that is representative 
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Now that I had validated the ChIP, I proceeded to perform ChIP-seq on these 
samples with the aim of revealing the direct binding targets of GATA6. From the 
ChIP-seq data at the DE stage, 12,098 peaks were called (IDR ≤ 0.05; median 
width=417 bp) for H9* cells, of which 10,669 were associated to genes, 4,790 of 
them protein coding (Table S5). For GATA6 4ins/+ mutant cells, 2,220 peaks were 
called, of which 1,137 of them were protein coding (Table S6).  
 
Comparing GATA6 binding at the GATA4 locus between H9* and GATA64ins/+ 
cells, I saw an enrichment of GATA6 binding in H9* cells, suggesting that GATA6 
directly regulates GATA4 during DE development (Figure 112). RNA-seq data showing 
GATA4 expression levels in GATA6 4ins/+ and GATA6 Δ4/Δ4 mutant cells (Figure 112) are 
also consistent with qRT-PCR data (Figure 68), where GATA4 is down-regulated in 
GATA6 4ins/+ cells by approximately 50% and almost completely abolished in GATA6 
Δ4/Δ4 mutant cells, thus further validating the RNA-seq results. 
 
To relate GATA6 binding to global gene expression dynamics and investigate 
genes that were not only direct interacting partners of GATA6, but also differentially 
expressed, I compared the ChIP-seq analysis to the RNA-seq data set to identify the 
subset of GATA6-bound genes that were up- or down-regulated. In GATA6 Δ4/Δ4 
mutant cells, I found that 1,120 protein coding genes were GATA6-bound and down-
regulated including DE genes such as CXCR4 and SOX17, and posterior foregut 
markers such as HNF1B and HNF4A, while 745 genes were GATA6-bound and up-
regulated (Figure 113). 337 and 607 genes were GATA6-bound and down-regulated 
in GATA6 4ins/+ and Patient A cells respectively, while 254 and 616 genes were GATA6-
bound and up-regulated in GATA6 4ins/+ and Patient A cells respectively (Figure 113). 
Overlapping the RNA-seq differentially expressed gene sets of GATA6 Δ4/Δ4, GATA6 
4ins/+ and Patient A identified 143 genes commonly down-regulated and 104 genes 
commonly up-regulated in these three separate data sets (Figure 114). Key 
endoderm markers CXCR4, SOX17, GATA4 were among the 143 genes commonly 
down-regulated, suggesting that GATA6 is a direct regulator of DE development.  




Figure 112. GATA6 binding is enriched near the GATA4 gene and GATA4 is 
decreased in H9-derived GATA6 4ins/+ and GATA6 Δ4/Δ4 mutant cells. ChIP-seq binding 
profiles of H9* and GATA6 4ins/+ and RNA-seq representation of GATA4 locus showing 
gene expression in H9*cells and H9-derived GATA6 4ins/+ and GATA6 Δ4/Δ4 mutant cells 
at the DE stage (day 3). The input control profile (IgG control) is included for 





Figure 113. Venn diagrams indicating the overlap of GATA6-bound genes from 
ChIP-seq and differentially expressed genes from RNA-seq at the DE stage (day 3). 
Diagram shows GATA6-bound down- or up-regulated genes of H9-derived GATA6 
Δ4/Δ4, GATA6 4ins/+ and Patient A mutant cells compared to H9* cells. Key bound genes 
up-or down-regulated for GATA6 Δ4/Δ4 are indicated in the table. 




Figure 114. Venn diagrams indicating the triple overlap of GATA6-bound genes at 
the DE stage (day 3). Down- or up-regulated genes of H9-derived GATA6 Δ4/Δ4, 
GATA6 4ins/+ and Patient A mutant cells are represented. Key bound genes up-or 
down-regulated common in all three mutants are indicated in the respective boxes. 
 
To infer genes that are directly targeted and regulated by GATA6 and with 
the help of Dr. Denil, I used a software package binding and expression target 
analysis (BETA) to integrate the ChIP-seq dataset of H9* with differential gene 
expression data of GATA6 Δ4/Δ4, GATA6 4ins/+ and Patient A from RNA-seq (Wang et al., 
2013). Motif analyses generated by BETA showed the GATA motif as highly enriched 
in both up- and down-regulated target genes, thus further validating the ChIP (Figure 
115). Results from activating/repressive function prediction did not show an 
activating or repressive function of GATA6 in GATA6 Δ4/Δ4, GATA6 4ins/+ and Patient A 
mutant cell lines (Figure 116). Next, I performed gene ontology (GO) analyses on the 
direct targets prediction of up- and down-regulated gene lists generated by BETA 
data set using the DAVID tool (Huang da et al., 2009b, Huang da et al., 2009a). I 
found that endoderm development is consistently up-regulated in H9* cells 
compared to GATA6 Δ4/Δ4, GATA6 4ins/+ and Patient A mutant cells, while mesoderm 
development is consistently up-regulated in all three mutant cell lines compared to 
H9* cells (Figure 117). Together, these results show a direct molecular function of 
GATA6 in driving the development of the endoderm. Loss of one or two alleles of 
GATA6 promotes mesodermal formation. 




Figure 115. Screenshot of binding motif analysis on UP and DOWN target regions of 
GATA6 ChIP-seq on day 3 derived from BETA analysis. Similar motifs are grouped 
together, and the motif logo of the most significant factor in the group is provided in 
the last column. The motif symbol, DNA-binding domain and species are shown in 
the first three columns; the t score and the P value from the t test are shown in the 
middle two columns. 
 
   
Figure 116. BETA output of activating/repressive function prediction of H9-derived 
GATA6 Δ4/Δ4, GATA6 4ins/+ and Patient A mutant cells on day 3. The red and the 
purple lines represent the up-regulated and down-regulated genes, respectively. The 
dashed black line indicates the non-differentially expressed genes as background. 
Genes are cumulated by the rank on the basis of the regulatory potential score from 
high to low. P-values that represent the significance of the UP or DOWN group 
distributions are compared with the NON group by the Kolmogorov-Smirnov test. 






Figure 117. Enriched gene ontology derived from BETA analysis showing 
developmental pathways. Tables are derived from direct target genes differentially 
expressed between H9* (WT), H9-derived GATA6 Δ4/ Δ4, GATA6 4ins/+ and Patient A 
mutant cells on day 3. P-values of the developmental pathways are indicated along 
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Based on results from integrating the RNA-seq and ChIP-seq datasets, GATA6 
seems to be a master regulator of DE development. This prompted me to investigate 
whether GATA6 interacts with other know DE regulators such as EOMES and 
SMAD2/3. With the help of Dr. Denil, I looked at the physical overlap of potential 
transcription factor binding sites from my GATA6 ChIP-seq dataset on day 3 with 
previously published EOMES (Teo et al., 2011) and SMAD2/3 ChIP data (Brown et al., 
2011) (Figure 118). The data were reprocessed as described in Chapter 2.11.2. This 
resulted in 16,303, 20,089 and 2,613 sites respectively. The overlap between GATA6 
and EOMES was 8,126/20,089 (40.5%); the overlap between GATA6 and SMAD2/3 
was 950/2,613 (36.4%). Overlap of the three data sets is found in 858 locations. Of 
those sites upstream from a gene, the mean distance to the transcription start site 
was 831bp (median 0). Results from this experiment suggests that GATA6 co-
operates with EOMES and SMAD2/3 to deploy the gene regulatory network 
governing human DE development. 
 
                            
Figure 118. Density heat maps of GATA6-binding peak intensity at DE. Figure shows 
direct overlaps with known endodermal regulators including SMAD2/3 and EOMES 
within a 10-kb window centered at the transcription start site (TSS). 
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3.5.2. GATA6 haploinsufficiency perturbs the pancreatic transcriptional 
network 
 
Next, to investigate whether GATA6 also plays a master regulator role at the 
pancreatic stage, I repeated the RNA-seq at the PE stage (day 12) for H9* cells, H9-
derived GATA6 4ins/+ and Patient A mutant cells. H9* RNA-seq data closely 
recapitulated a previously profiled transcriptome using the same protocol (Spearman 
ρ =0.77 for in vitro, ρ =0.59 for in vivo, P < 2.2e-16), which was used for the analyses 
of in vitro MPCs described in Cebola et al. (Cebola et al., 2015). 
 
I found 1,423 differentially expressed genes between H9* and GATA6 4ins/+ 
(Table S7), and 6,093 between clones 1-3 of Patient A mutant cells (Table S8). Of the 
1,423 genes, 1,230 were protein coding genes; 899 down-regulated in GATA6 4ins/+ 
cells and 331 up-regulated in GATA6 4ins/+ cells. Of the 6,093 genes, 4,148 were 
protein coding genes; 2,424 down-regulated in Patient A cells and 1,724 up-
regulated in Patient A cells. In a heat map derived from RNA-seq results at the PE 
stage focusing on genes involved in pancreatic development, I observed that 
consistent with qRT-PCR (Figure 97 and Figure 101) and FACS results (Figure 96) 
discussed earlier, GATA6 4ins/+ and Patient A mutant cells displayed decreased 
pancreatic formation (Figure 119).  
 
Figure 119. Heat map illustrating differential gene expression of key pancreatic 
markers via RNA-seq between H9*cells, H9-derived GATA6 4ins/+ and clones 1-3 of 
Patient A mutant cells at the PE stage. n = 3 biological replicates for each cell line. 
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Next, I performed ChIP on H9* cells and H9-derived GATA6 4ins/+ cells which 
were differentiated to the PE stage via the lab protocol to identify those genes 
bound directly to and interacting with GATA6 at the pancreatic stage. I validated the 
ChIP via qPCR using primers that would amplify a region on the human HNF4α P2 
promoter, which acts as a GATA6 positive control. In addition, I also used a primer 
pair that amplifies a positive PDX1 binding location, again kindly provided to us by 
our collaborator Dr. Santi Rodriguez. Results from qPCR show an approximately 10-
fold higher binding at the GATA6 positive region in H9* cells compared to GATA6 
4ins/+ mutant cells and an approximately 7-fold higher binding at the PDX1 positive 
region in H9* cells compared to GATA6 4ins/+ mutant cells (Figure 120). To ensure that 
this was not a result of a decreased number of cells, I performed FACS on GATA6 at 
the PE stage and found that both H9* and GATA6 4ins/+ cells had similar numbers of 
GATA6+ cells of approximately 75% GATA6+ cells (Figure 121), indicating that the 
decreased DNA binding observed in GATA6 4ins/+ mutant cells is indeed a 
consequence of heterozygous loss of GATA6.  
 
Unfortunately, when I proceeded to perform ChIP-seq on H9 WT cells on day 
12, the ChIP-seq data retrieved was of low quality, which resulted in only 171 peaks 
called. This was in contrast to GATA6 ChIP-seq data published by Cebola et al., where 
using the same parameters, 2,060 peaks were called (Cebola et al., 2015). The ChIP 
experiment was repeated two more times and ChIP-seq was performed on samples 









Figure 120. ChIP validation via qPCR using primers specific to a GATA6 and PDX1 
positive binding region on day 12 for H9* and H9-derived GATA6 4ins/+ mutant cells. 
Values of input samples were subtracted from the values of IgG or GATA6 samples 








                                                          hESC                   GATA6 
Figure 121. Number of GATA6+ cells is similar in H9* and H9-derived GATA6 4ins/+ 
cells differentiated via the lab protocol at day 12. Cells were fixed at day 12 and 
were stained for GATA6. Data show results of one experiment that is representative 
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As a result, I was prompted to use FSPS13.B cell line and its respective 
heterozygous mutant cell lines for ChIP and ChIP-seq experiments. I hence 
performed ChIP on FSPS13.B* cells and FSPS13.B -derived GATA6 Δ14/+ and GATA6 
GFP/+ cells which were differentiated to the PE stage via the lab protocol. Validation of 
the ChIP via qRT-PCR showed an approximately 7-fold and 4-fold higher binding at 
the GATA6 and PDX1 positive binding regions respectively in FSPS13.B* cells 
compared to GATA6 Δ14/+ mutant cells (Figure 122). On the other hand, an 
approximately 2-fold higher binding at the GATA6 and PDX1 positive binding regions 
in FSPS13.B* cells compared to GATA6 GFP/+ mutant cells was observed (Figure 122). 
From FACS data of GATA6 in FSPS13.B*, GATA6 Δ14/+ and GATA6 GFP/+ mutant cells, 
FSPS13.B* and GATA6 GFP/+ mutant cells had similar levels of GATA6+ cells at the PE 
stage, whereas GATA6 Δ14/+ mutant cells had an approximately 30% decrease of 
GATA6+ cells (Figure 123). Although a decrease was seen in the number of GATA6-
expressing cells in GATA6 Δ14/+ mutant cells, the decrease in binding was more so for 
ChIP, suggesting that the decrease in binding could be a combined consequence of 
fewer cells and the loss of one allele of GATA6. 
 
Sequencing was next performed on these ChIP samples. From the ChIP-seq 
data at the PE stage, 2,306 peaks were called for FSPS13.B* cells, of which 1,096 of 
them protein coding (Table S9). For GATA6 Δ14/+ mutant cells, 543 peaks were called, 
of which 234 of them were protein coding (Table S10). For GATA6 GFP/+ mutant cells, 
2,376 peaks were called, of which 1,157 of them were protein coding (Table S11). 
Notably, PDX1 was found to bind GATA6 in both FSPS13.B* and GATA6 GFP/+ mutant 










Figure 122. ChIP validation via qPCR using primers specific to a GATA6 and PDX1 
positive binding region on day 12 for FSPS13.B* and FSPS13.B-derived GATA6 Δ14/+ 
and GATA6 GFP/+ mutant cells. Values of input samples were subtracted from the 
values of IgG or GATA6 samples and the graph shows fold over IgG (normalised to 1) 






                                                          hESC                   GATA6 
Figure 123. The number of GATA6+ cells is similar in FSPS13.B* and FSPS13.B-
derived GATA6 GFP/+ cells but down-regulated in GATA6 Δ14/+ cells differentiated via 
the lab protocol on day 12. Cells were fixed on day 12 and were stained for GATA6. 
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Next, Dr. Denil helped to repeat the BETA analyses to integrate the ChIP-seq 
dataset of FSPS13.B* with differential gene expression data of H9-derived GATA6 
4ins/+ and Patient A mutant cells on day 12. Motif analyses generated by BETA showed 
the GATA motif as highly enriched in both up- and down-regulated target genes, thus 
further validating the ChIP (Figure 124). Results from activating/repressive function 
prediction did not show an activating or repressive function of GATA6 in GATA6 Δ14/+ 
and Patient A mutant cell lines at the PE stage (Figure 125).  
 
Next, I performed gene ontology (GO) using DAVID on the up- and down-
regulated gene lists generated by BETA and found that pancreas-related terms such 
as regulation of insulin secretion, endocrine and pancreas development are up-
regulated in FSPS13.B* cells compared to GATA6 Δ14/+ and Patient A mutant cells 
(Figure 126). Interestingly, skeletal and nervous system developments, which are of 
mesodermal and ectodermal origins respectively, were observed to be up-regulated 
in both GATA6 Δ14/+ and Patient A mutant cells (Figure 126). Together, these results 









Figure 124. Screenshot of binding motif analysis on UP and DOWN target regions of 
GATA6 ChIP-seq on day 12 derived from BETA analysis. Similar motifs are grouped 
together, and the motif logo of the most significant factor in the group is provided in 
the last column. The motif symbol, DNA-binding domain and species are shown in 
the first three columns; the t score and the P value from the t test are shown in the 
middle two columns. 
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Figure 125. BETA output of activating/repressive function prediction of H9-derived 
GATA6 4ins/+ and Patient A mutant cells on day 12. The red and the purple lines 
represent the up-regulated and down-regulated genes, respectively. The dashed 
black line indicates the non-differentially expressed genes as background. Genes are 
cumulated by the rank on the basis of the regulatory potential score from high to 
low. P-values that represent the significance of the UP or DOWN group distributions 
are compared with the NON group by the Kolmogorov-Smirnov test. 
 
      
       
Figure 126. Enriched GO derived from BETA analysis showing developmental 
pathways. Tables are derived from direct target genes differentially expressed 
between H9* (WT), H9-derived GATA6 4ins/+ and Patient A mutant cells on day 12. 





CHAPTER 4  DISCUSSION 
 
4.1. DE and pancreatic differentiation of hPSCs in vitro mimics developmental 
events during pancreatic formation in humans 
 
Human PSCs offer a unique opportunity to study disease phenotypes not 
reproduced in model organisms such as the mouse. This is particularly relevant for 
my project where a discrepancy in genetics and the subsequent disease phenotype 
has been observed between mice and human. In this aspect, efficient generation of 
pancreatic cell types in vitro using hPSCs presents the first step toward successful 
disease modelling to potentially provide insights into the molecular mechanisms 
underlying pancreatic agenesis. Indeed, my results show that hPSCs can be efficiently 
differentiated into near homogenous populations of DE and pancreatic progenitor 
cells using several established defined culture systems. Importantly, the DE and 
pancreatic progenitor cells generated across these protocols follow a normal path of 
development, with the initial down-regulation of pluripotency genes such as NANOG, 
OCT4 and SOX2 followed by the up-regulation of DE markers CXCR4 and SOX17, and 
the subsequent up-regulation of key pancreatic-specific genes such as PDX1 and 
NKX6-1. In addition, GO analyses derived from RNA-seq show endoderm (Figure 106) 
and pancreatic (Figure 126) development among the top enriched pathways, further 
reinforcing these observations.  
 
It has been well documented that hESCs and hiPSCs share many similar 
properties such as morphology, proliferation, gene expression, and the ability to 
differentiate into various cell types etc. (Takahashi et al., 2007, Takahashi and 
Yamanaka, 2006, Evans, 2011). However, variation in the efficiencies of 
differentiation has been reported between different hPSC lines (Osafune et al., 2008, 
Chin et al., 2009). Hence, it was not surprising to observe a difference in β-cell 
specification efficiency between the H9 and FSPS13.B cell lines despite their similar 
pancreatic progenitor specification efficiencies. The process of β-cell differentiation 
is controlled by a complex network involving tight regulation of genes required for 




determining the successful generation of pancreatic insulin-secreting β cells from 
hPSCs (Rostovskaya et al., 2015). Since the difference in β-cell specification efficiency 
between the H9 and FSPS13.B cell lines was observed using the same lab-derived 
protocol, variation in the efficiencies of differentiation is most likely explained by the 
different genetic backgrounds of the H9 and FSPS13.B cell lines. 
 
The goal of deriving functional β-cells from hPSCs still remains a major 
challenge. Although substantial improvement has been made to differentiate hPSCs 
toward functional pancreatic β-cells, existing protocols for in vitro differentiation 
produce immature pancreatic β-cells that are not highly responsive to glucose 
stimulation. Pancreatic β-cell maturation is characterised by the ability of the 
differentiated β-cells to perform glucose-stimulated insulin secretion (GSIS). This 
challenge presents a hindrance to the use of hPSCs in applications such as disease 
modelling, where differentiation of hPSCs into mature, glucose responsive β-cells is 
required for establishing the disease phenotypes in vitro, and to understanding the 
molecular mechanisms underlying different forms of diabetes. While previously 
published protocols have shown an improvement in producing glucose-responsive 
insulin-secreting β-cells in vivo, the GSIS of the β-cells in vitro still remains limited, 
indicating an immature nature of these cells (Maehr et al., 2009, Zhang et al., 2009, 
Jiang et al., 2007a, D'Amour et al., 2006). Furthermore, a recent study has reported 
that insulin-secreting β cells differentiated from hPSCs are highly similar to human 
fetal pancreatic β-cells and do not resemble adult β-cells (Hrvatin et al., 2014). This 
could be one of the factors responsible for the inverse GSIS response that I observed 
with the H9 cells, where the immature nature of the cells impedes the cells from 
proper function.  
 
Another factor that could have hindered the success of eliciting a GSIS 
response from β-cells in vitro is the low efficiency in producing insulin-secreting β-
cells. With only approximately 10% and 6% of insulin-secreting β-cells generated 
from H9 or FSPS13.B cells respectively, the current lab-derived protocol is most likely 
lacking critical signals required for efficient generation of insulin-secreting β cells. 




published protocols that report an increased efficiency in generating an average of 
30-50% of insulin-producing cells (Rezania et al., 2014, Pagliuca et al., 2014). 
 
4.2. GATA6 and GATA4 expression patterns during human pancreatic 
development 
 
The expression pattern of GATA6 and GATA4 during human pancreas 
development has not been well characterised to date. My work has revealed the 
precise expression kinetics of GATA6 and GATA4 during in vitro differentiation into 
the pancreatic lineage.  
 
That GATA6 is expressed from the DE stage and remains expressed 
throughout pancreatic development suggests an important role of this transcription 
factor during human pancreas development. Interestingly, the expression pattern of 
GATA4 is highly similar to that of GATA6 in that it is not expressed in pluripotent cells 
and its expression is first observed in the DE stage and remains expressed 
throughout pancreatic development. This indicates a similar and possibly redundant 
role of both transcription factors. These findings confirm previous studies where 
both GATA6 and GATA4 have been reported to be expressed in DE cells in hPSC 
differentiation cultures (McLean et al., 2007, Vallier et al., 2009b). Similarly in mice, 
Gata6 and Gata4 are both expressed in the DE and its derivatives, including the 
pancreas (Decker et al., 2006, Watt et al., 2007). 
 
My results show that GATA4 levels are consistently more highly expressed 
than GATA6 at the later stages of pancreatic development (D9 onwards), suggesting 
a critical role of GATA4 in the development of the human pancreas. This is consistent 
with a previous report describing GATA4 expression at the onset of pancreatic 
development in human embryos, although it was unknown from the study whether 
GATA4 is also expressed in DE cells prior to pancreas formation (Jennings et al., 
2013). It has also been reported that GATA4 mutations are a rare cause of NDM and 
pancreatic agenesis in five patients harbouring GATA4 mutations, confirming a role 




4.3. TALEN as a genome editing tool for disease modelling 
The successful generation of TALEN-derived GATA6 mutant hESC and hiPSC 
lines via both NHEJ and HR shows the versatility of TALENs as a genome editing tool 
for disease modelling. Interestingly, using the same TALEN cut sites, the cutting 
efficiency in H9 cells was observed to be higher than in FSPS13.B cells, possibly due 
to differences in nuclease cleavage efficiencies and/or intrinsic differences in 
activities of DNA repair pathways.  
 
In addition to generating mutant lines, TALENs can also be used to correct 
mutations via homologous recombination. In the context of my project, it would be 
useful to correct the missense GATA6 mutation in Patient A and Patient B to derive 
isogenic wild-type control cell lines as this would eliminate differences arising from 
different genetic backgrounds. However, this was not performed due to time 
constraints and was not prioritised because the patient phenotypes were similar to 
the TALEN-generated mutants which indicated the suitability of the TALEN-
generated mutants as a disease modelling platform.  
 
The similar differentiation efficiencies between the untargeted hPSCs (H9 and 
FPSP13.B) and their respective isogenic controls, which are targeted hPSCs but 
harbour no observable mutation around the target site (H9* and FPSP13.B*), 
indicated that off-target effects (if any) did not affect pancreatic specification. The 
normal karyotype displayed by all the targeted wild-type and mutant hPSC lines over 
many passages also suggested that the TALEN targeting did not introduce any gross 
chromosomal rearrangements and abnormalities such as deletions, inversions or 
translocations in addition to local mutations that can occur when imprecise repair of 
on- and off-target DNA cleavages take place (Lee et al., 2010, Lee et al., 2012, Park et 
al., 2014, Brunet et al., 2009, Cho et al., 2014). 
 
The ability of the TALEN-derived mutant hPSC lines to retain pluripotency 
similarly to wild-type and untargeted hPSCs indicate that genome editing via TALENs 




undifferentiated cells, it is unlikely that this transcription factor plays an important 
role in pluripotency, which is evident from the non-effect that loss of GATA6 has on 
pluripotency.  
 
4.4. GATA6 is required for DE specification 
Using the TALEN-generated GATA6 homozygous knockout H9 (GATA6 Δ4/Δ4 
and GATA6 GFP/GFP) and FSPS13.B (GATA6 Δ14/Δ11) mutant cell lines, I have shown that 
GATA6 is essential for the formation of the DE in humans. Although truncated 
proteins were detected in H9-GATA6 Δ4/Δ4 and FSPS13.B-GATA6 Δ14/Δ11 mutant cell 
lines, their phenotypes were indistinguishable from the H9-GATA6 GFP/GFP mutant cell 
line that had no detectable GATA6 protein. This indicates that, consistent with its 
known biochemical characteristics (Bates et al., 2008, Molkentin, 2000), the 
truncated GATA6 protein lacking the C-terminal DNA-binding zinc-finger domains is 
non-functional. Thus, it can be inferred that in the absence of functional GATA6 
proteins, a human embryo would likely fail to form the pancreas as a consequence to 
a primary defect in definitive endoderm formation. This finding, coupled with the 
rapid and strong up-regulation of GATA6 at the DE stage, as well as its co-localisation 
with key DE marker SOX17 strongly suggests that GATA6 does indeed play an 
important role in DE formation. 
 
Using the TALEN-generated GATA6 heterozygous knockout H9 (GATA6 4ins/+ 
and GATA6 GFP/+) and FSPS13.B (GATA6 1ins/+, GATA6 Δ14/+, GATA6 Δ21_8ins/+ and GATA6 
GFP/+) mutant cell lines, as well as the patient-derived GATA6 heterozygous mutant 
lines Patient A and Patient B, an impairment in DE formation was observed using the 
lab-derived protocol and STEMdiff pancreatic progenitor kit from SCT, with 
FSPS13.B-GATA6 GFP/+ mutant cells being the exception. However, a discrepancy was 
observed in cells differentiated via the PSC Definitive Endoderm Induction Kit from 
Life Technologies, where the DE formed as efficiently as the wild-type controls. 
Hence, it is possible that the DE phenotypes observed in the heterozygous mutants 
differentiated via the lab-derived protocol and STEMdiff pancreatic progenitor kit 




am unable to verify this hypothesis through detailed comparison of the protocols by 
eliminating/adding certain growth factors due to the restrictions imposed by Life 
Technologies, where I was unable to obtain more information on the media 
formulation. 
 
Furthermore, the fundamental differences in the differentiation protocols 
may underlie (or contribute to) the results I obtained and those recently published 
by Shi et al. and Tiyaboonchai et al. (Shi et al., 2017, Tiyaboonchai et al., 2017). For 
example, the growth factor and small molecule components as well as medium 
formulations differ substantially for the first three days of DE differentiation among 
the three studies. This was further evidenced in the study led by Tiyaboonchai where 
the group showed that a GATA6 heterozygous iPSC line derived from an agenesis 
patient unexpectedly produced beta-like cells in vitro by simply reducing the 
concentration of retinoic acid 80-fold (Tiyaboonchai et al., 2017). This change led to 
statistically significantly fewer PDX1+ cells from the patient line when compared to a 
wild-type iPSC line that showed negligible sensitivity to the same culture regime.  
 
Comparing across the patient-derived and TALEN-derived H9 and FSPS13.B 
heterozygous mutants, a spectrum of DE phenotypes was observed using the lab-
derived and SCT protocols; FSPS13.B-GATA6 GFP/+ mutant cells displayed no defect in 
DE formation, and FSPS13.B NHEJ-generated mutants as well as Patients A and B 
displayed a similar but a slightly more severe DE defected compared to H9-GATA6 
4ins/+ and GATA6 GFP/+ mutant cells. This observation, however, was unsurprising as 
recent studies have reported that GATA6 mutations can cause diverse diabetic 
phenotypes, ranging from pancreatic agenesis to adult-onset diabetes where most, 
but not all, patients display exocrine insufficiency requiring insulin treatment and 
enzyme replacement therapy, and other extrapancreatic features (De Franco et al., 







In the report by Bonnefond et al., two French sisters were described with the 
same GATA6 allele (c.1504_1505del; p.Lys502Aspfs*5) but presented strikingly 
different clinical manifestations—one with permanent neonatal diabetes and the 
other without (Bonnefond et al., 2012). Similarly, Shi et al. (2017) engineered using 
CRISPR/Cas9 the common GATA6 agenesis mutation c.1366C>T (p.Arg456Cys) in 
HUES8 cells—the same allele present in the patient A-derived iPSC line 
(GATA6R456C/+)—and observe no heterozygous phenotype at the DE or pancreatic 
progenitor (PDX1+) stages (Shi et al., 2017), whereas I do, both at the DE stage and 
beyond. A more recent publication by Yau et al. (2017) describes the inheritance of a 
novel GATA6 frame-shift mutation (c.635_660del; p.Pro212fs) in three children from 
a GATA6 mosaic mother, and each child (one is an abortus) presents a different 
phenotype (Yau et al., 2017). 
 
By analogy, it is entirely possible that hiPSC derived from the patients in the 
Yau et al. (2017) and Bonnefond et al. (2012) studies would each behave entirely 
differently when differentiated in vitro. The simplest explanation for the existence of 
such “resilient individuals” who are not impacted by deleterious GATA6 alleles is the 
influence of modifier genes and rare variants attributable to individual genetic 
backgrounds (Lek et al., 2016, Chen et al., 2016). GATA4 is an obvious choice for a 
genetic modifier, given its expression in the DE, genetic interaction with Gata6 in 
mice, the identification of rare GATA4 heterozygous patients with pancreatic 
agenesis as well as our finding that GATA4 is bound and regulated by GATA6 in vitro 
(Figure 113) (Morrisey et al., 1996b, Freyer et al., 2015, Shaw-Smith et al., 2014, 
D'Amato et al., 2010). Indeed, Shi et al. (2017) elegantly show dosage-dependent 
effects of GATA4 alleles on phenotypes associated with GATA6 heterozygosity during 









The observation of extrapancreatic abnormalities in GATA6 patients, which 
include malformations in endodermal-derived organs such as congenital heart 
defects (Kodo et al., 2009, Lin et al., 2010), hepatobiliary malformations, gall bladder 
agenesis, and gut herniation (Allen et al., 2012), further provide evidence that 
GATA6 plays an important role in the development of the DE. In addition, the two 
patients in the family studied in Yau et al. (2017) present defects in a number of 
endoderm-derived organs, further supporting that diminished GATA6 levels during 
DE formation underlie a constellation of clinical endodermal phenotypes (Yau et al., 
2017). Indeed, when I ran pilot differentiations to specify H9* and H9-GATA6 4ins/+ 
mutant cells into the hepatic lineage, I observed decreased differentiation 
efficiencies for H9-GATA6 4ins/+ mutant cells to differentiate into hepatic progenitors, 
the precursors of hepatic cells (data not shown). Unfortunately, I was unable to 
successfully differentiate the wild-type H9 cells into mature hepatocytes as the 
hepatic differentiation protocol was still being optimised in the lab when the 
experiments were performed. As such, I was unable to perform phenotypic 







4.5. GATA6 is required for pancreatic progenitor specification 
My work has demonstrated that GATA6 is required for pancreatic 
specification. Surprisingly, despite the broad spectrum of phenotypes observed at 
the DE stage, a less variable phenotype of 50-80% down-regulation of PDX1 across all 
heterozygous mutants was seen at the pancreatic stage and this was consistently 
observed using all three DE specification protocols. This finding strongly indicates 
that the pancreatic phenotype seen in the GATA6 heterozygous mutant cell lines is 
most likely a true effect of GATA6 haploinsufficiency, thus establishing a human in 
vitro hPSC model system to study the role of GATA6 in the development of the 
human pancreas. However, this present system has its limitations. As heterozygous 
GATA6 mutations have been reported to have incomplete penetrance as displayed 
by different phenotypes in family members having identical mutations (Bonnefond 
et al., 2012), it is possible that my in vitro PSC model system is lacking intrinsic 
signalling pathways or factors present in vivo that may mitigate the negative effects 
of GATA6 haploinsufficiency, thus driving a more severe phenotype.  
 
The discordant phenotypes between mice and human models, especially for 
haploinsufficient disease genes, have been observed and widely discussed (Seidman 
and Seidman, 2002). In my hPSC model system, deleting one allele of GATA6 
impaired pancreatic formation as seen from the reduction of PDX1+ cells across all 
genetic backgrounds of the hPSCs used in this study. This finding demonstrates 
phenotypes not previously reported in mice (Morrisey et al., 1998, Carrasco et al., 
2012, Xuan et al., 2012). For instance, pancreatic defects were not observed in 
Gata6-/+ or Gata4-/+ mouse embryos or adults. This suggests distinct gene dosage 
sensitivities between both species. Furthermore, the genetic background of GATA6 
patients is much more diverse than the inbred mouse strains. Thus, extreme 
phenotypes such as pancreatic agenesis may be seen in some, but not all, GATA6 
heterozygous patients. Lastly, the different timing where GATA6 is deleted between 
the mice and human model systems could also contribute toward the discordant 
phenotypes between both systems. Due to early embryonic lethality of Gata6 and 




necessary for Gata6/4 to be conditionally inactivated using the Cre-LoxP system in 
the early pancreatic progenitors or the gut endoderm stages prior to pancreatic 
specification (Carrasco et al., 2012, Xuan et al., 2012). In contrast, in my in vitro hPSC 
model system, GATA6 is deleted in pluripotent cells, before the initiation of 
differentiation. An inducible knockout system, such as a tetracycline-inducible shRNA 
or doxycycline-inducible CRISPR interference system, where GATA6 can be 
inactivated at specific stages such as the gut endoderm could be a suitable method 
to replicate the mice model more closely (Bertero et al., 2016, Mandegar et al., 
2016). Despite these differences, GATA6/4 interactions are observed in both mice 
and hPSC model systems, supporting the use of both systems for investigating 








4.6. GATA6 is a key regulator of DE and pancreatic progenitor specification 
The molecular mechanism by which GATA6 controls DE and pancreatic 
specification in humans was not known prior to my study. My results using genome-
wide transcriptional analyses from RNA-seq revealed that GATA6 transcriptionally 
activates the expression of endoderm markers in human. Interestingly, loss of both 
alleles of GATA6 leads to an increase in mesoderm development. This suggests a 
possible role of GATA6 not only to enable endoderm formation, but also to suppress 
mesoderm formation. 
 
For the first time, results from ChIP-seq data suggest a direct molecular 
mechanism whereby GATA6 directly controls the gene expression of endoderm 
markers such as SOX17 and CXCR4, placing it centrally in the regulation of endoderm 
specification. The direct binding of GATA6 to GATA4 at both the DE and pancreatic 
progenitor stages also indicates that GATA6 and GATA4 are interacting partners, a 
finding that has also been previously reported in the developing and postnatal 
myocardium (Charron et al., 1999). Thus, the down-regulation of GATA4 expression 
in the GATA6 mutants suggests that GATA6 is directly responsible for this 
observation. Interestingly, results from my ChIP-seq data also shows PDX1 as a 
binding partner of GATA6 (data not shown), a finding that was previously not shown 
in an earlier study (Cebola et al., 2015). This suggests that GATA6 also plays a direct 
role in pancreatic specification.  
 
Performing ChIP and ChIP-seq on Patients A and B could further identify 
important direct binding partners of GATA6. Since GATA6 mutations in Patients A 
and B did not lead to nonsense-mediated decay of the GATA6 protein (Figure 52), it 
would be possible to perform ChIP on these samples. Thus, subsequent 
bioinformatics analyses comparing Patient A and B ChIP-seq datasets to their 
respective isogenic corrected wild-type control cell lines could further elucidate the 






Overlapping the GATA6, EOMES and SMAD2/3 ChIP-seq datasets at the DE 
level suggests a fundamental role of GATA6 at the DE stage, and that EOMES is 
required in the interaction of GATA6-SMAD2/3. Thus, as EOMES limits the expression 
of mesodermal markers, it can be speculated that GATA6 mutations may impede 
DNA binding of EOMES-SMAD2/3 linked to endoderm formation (Figure 127). 
 
        
 
Figure 127. Model depicting the molecular mechanism of action for GATA6 in the 
formation of the DE. EOMES, SMAD2/3 and GATA6 interacts to initiate DE 
differentiation while repressing mesoderm genes. Illustration adapted and modified 




CHAPTER 5  FUTURE EXPERIMENTS 
 
5.1. Unknown effects on penetrance of GATA6 heterozygous mutants using 
various DE or pancreatic specification protocols 
 
The discrepancy observed at the DE stage between different protocols 
suggests that the specification protocols used to differentiate the cells can have a 
significant impact on the DE phenotype observed. Hence, future work involving the 
identification of growth factors and/or signalling pathways that cause this 
discrepancy can be useful in further investigating the role of GATA6 in the formation 
of the DE. 
 
Moreover, it must be acknowledged that adherent differentiation fails to 
achieve the 3D complexity of human endoderm formation in vivo. Thus, future 
studies involving specification of pancreatic progenitors into functional and mature 
β-cells will likely benefit from 3D organoid systems which will more closely represent 
the in vivo environment of developing organs in humans, enabling the interactions 
between different pancreatic cell types and the interplay with possible niche signals.  
 
With the availability of robust commercially available DE and pancreatic 
progenitor differentiation kits, perhaps studies of early pancreatic lineage 
commitment can be standardized intra- and inter-laboratory in an effort to minimize 
line-to-line and protocol-to-protocol differences. 
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5.2. Unexplored role of GATA6 in other endoderm-derived organs 
Although my work is focused on the pancreatic lineage, it is likely that GATA6 
haploinsufficiency plays a role in the development of other endoderm-derived 
organs such as the gall bladder, intestine and liver given that results from my study 
have established a critical role of GATA6 in early endoderm formation. Indeed, 
preliminary results from my study where GATA6 heterozygous mutants were 
specified toward the liver lineage have indicated that GATA6 haploinsufficiency gives 
rise to defects in liver formation. The role of GATA6 in these organs can be studied 
more closely using an inducible knockout system, such as a tetracycline-inducible 
system, where gene knockdown in hPSCs and even in differentiated cells can be 
rapid and tightly controlled, thus providing a unique opportunity for functional 
analyses in multiple cell types relevant for the study of human development. 
 
5.3. Other possible roles of GATA6 
Additional roles of GATA6 such as whether GATA6 haploinsufficiency can 
impair the proliferation and maintenance of pancreatic progenitors during their 
maturation into β-cells, or whether GATA6 dosage may influence β-cell mass and 
function remain to be investigated. Utilising xenograft models such as grafting or 
transplanting β-like cells under the kidney capsules of mice can be used to further 








 The transcription factor GATA6 has recently been identified as the most 
common cause of pancreatic agenesis in humans. My work has revealed dosage-
dependent requirements for GATA6 in lineage specification leading to the formation 
of pancreatic progenitors and immature β-cells using hPSCs as an in vitro system for 
disease modelling. The similarities in DE and pancreatic phenotypes observed 
between TALEN-derived lines and patient-derived lines indicate the success in 
disease modelling using genome editing tools coupled with hPSCs, and establish the 
suitability of using genome editing tools such as TALENs in the study of human 
diseases. On the molecular level, GATA6 directly regulates the development of the 
DE and pancreatic progenitors. Thus, this work provides evidence that GATA6 is 
involved in the development of the human definitive endoderm and pancreas as well 
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